The genetics of potential albendazole and ivermectin resistance in lymphatic filariae / by Schwab, Anne Elisabeth.
.~. 
The Genetics of Potential Albendazole and Ivermectin 
Resistance in Lymphatic Filariae 
Anne Elisabeth Schwab 
Doctor of Philosophy 
Institute of Parasitology 
McGill University 
Montreal, Quebec, Canada 
February 2007 
A thesis submitted to the Faculty of Graduate Studies and Research in partial 
fulfillment of the requirements of the degree of Doctor of Philosophy 
©Anne Schwab, 2007. 
1+1 Library and Archives Canada Bibliothèque et Archives Canada 
Published Heritage 
Branch 
Direction du 
Patrimoine de l'édition 
395 Wellington Street 
Ottawa ON K1A ON4 
Canada 
395, rue Wellington 
Ottawa ON K1A ON4 
Canada 
NOTICE: 
The author has granted a non-
exclusive license allowing Library 
and Archives Canada to reproduce, 
publish, archive, preserve, conserve, 
communicate to the public by 
telecommunication or on the Internet, 
loan, distribute and sell th es es 
worldwide, for commercial or non-
commercial purposes, in microform, 
paper, electronic and/or any other 
formats. 
The author retains copyright 
ownership and moral rights in 
this thesis. Neither the thesis 
nor substantial extracts from it 
may be printed or otherwise 
reproduced without the author's 
permission. 
ln compliance with the Canadian 
Privacy Act some supporting 
forms may have been removed 
from this thesis. 
While these forms may be included 
in the document page count, 
their removal does not represent 
any loss of content from the 
thesis. 
• •• 
Canada 
AVIS: 
Your file Votre référence 
ISBN: 978-0-494-32238-3 
Our file Notre référence 
ISBN: 978-0-494-32238-3 
L'auteur a accordé une licence non exclusive 
permettant à la Bibliothèque et Archives 
Canada de reproduire, publier, archiver, 
sauvegarder, conserver, transmettre au public 
par télécommunication ou par l'Internet, prêter, 
distribuer et vendre des thèses partout dans 
le monde, à des fins commerciales ou autres, 
sur support microforme, papier, électronique 
et/ou autres formats. 
L'auteur conserve la propriété du droit d'auteur 
et des droits moraux qui protège cette thèse. 
Ni la thèse ni des extraits substantiels de 
celle-ci ne doivent être imprimés ou autrement 
reproduits sans son autorisation. 
Conformément à la loi canadienne 
sur la protection de la vie privée, 
quelques formulaires secondaires 
ont été enlevés de cette thèse. 
Bien que ces formulaires 
aient inclus dans la pagination, 
il n'y aura aucun contenu manquant. 
This thesis is dedicated to my parents, Rosemarie and Andreas. 
ii 
Abstract 
A CUITent initiative to eliminate lymphatic filariasis (LF), headed by the World 
Health Organization, aims to interrupt transmission of the disease through yearly 
community-wide treatment with the broad spectrum anthelmintic albendazole (ABZ), in 
combination with ivermectin (IVM) or diethylcarbamazine (DEC). Over the years, the 
use of both ABZ and IVM in the treatment of veterinary parasites has led to widespread 
anthelmintic resistance against these drugs. In this study, we genotyped microfilaria of 
Wuchereria bancrofti, a causative agent of LF, in order to detect the presence of 
mutations which confer ABZ resistance in other parasites, and we identified such 
mutations in worms obtained from untreated patients in Ghana and Burkina Faso, West 
Africa. Microfilaria from patients who had been treated with ABZ + IVM, had a 
significantly higher frequency of the resistant genotype, and this frequency was even 
higher in worms from patients that had received two rounds of treatment. In addition, the 
untreated population of microfilaria had an excess of homozygotes in the population. 
This excess homozygosity was equivalent to a Wright's Inbreeding Statistic of FIT = 0.44, 
and we found that the population was significantly subdivided between patients. In order 
to better understand the mechanisms and factors involved in the potential spread of ABZ 
resistance, caused by such mutations, through a population of Culex-transmitted W 
bancrofti, we developed a deterministic model that incorporates genotype structure into 
the epidemiological model EPIFIL. This model predicts that the combination of ABZ + 
DEC leads to stronger selection for the resistant genotype than ABZ + IVM, and that 
drug efficacy assumptions are an important factor affecting the spread of drug resistance. 
Treatment coverage, non-random mating, initial allele frequency and number of 
treatments also had substantial impact on the speed aild magnitude of the spread of ABZ 
resistance. When we expanded this model to inc1ude potential IVM-resistance alle1es we 
found that, under ABZ + IVM treatment, selection for resistance to either drug is 
enhanced by the presence of resistance against the second drug. Similarly, excess 
homozygosity caused by parasite non-random mating may increase selection for a 
dominant IVM resistance allele through enhancing the spread of a recessive ABZ 
resistance allele. Resistence developed more slowly when it was inherited as a polygenic 
trait. ResuIts from this study suggest that resistance monitoring is crucial, as resistance 
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may not be apparent until treatment is stopped, recrudescence occurs and treatment is 
reapplied. 
iv 
Abrégé 
Une initiative actuellement menée par l'Organisation mondiale de la santé a pour 
but d'éliminer la filariose lymphatique (LF) par l'interruption de la transmission de cette 
maladie, en traitant annuellement des communautés complètes avec l'antihelminthique à 
spectre large albendazole (ABZ),' combiné avec l'ivermectin (IVM) ou la 
diethylcarbamazine (DEC). Avec les années, l'usage de l'ABZ et le l'IVM comme 
traitement contre les parasites vétérinaires a résulté en une pharmacorésistance répandue 
contre ces deux médicaments. Dans cette étude, nous avons déterminé le génotype de 
plusieurs micro filaires de Wuchereria bancrofti, l'agent causal de la LF, afin de détecter 
la présence· de certaines mutations reconnues pour conférer une résistance à l' ABZ chez 
d'autres parasites du même type. Ces mutations ont été trouvées chez des vers obtenus 
de patients non traités provenant du Ghana et du Burkina Faso, en Afrique de l'Ouest. 
Les vers des patients du Burkina Faso qui avaient été traités avec de l'ABZ + IVM ont 
démontré une fréquence significativement accrue du génotype résistant, et cette fréquence 
était encore plus élevée chez les patients qui avaient été traités deux fois. De plus, la 
population non-traitée de micro filaires contenait un excès d'homozygotes, équivalent à 
une statistique de consanguinité de Wright FIT = 0.44, et nous avons trouvé que cette 
population était subdivisée de façon significative entre les patients. Nous avons 
développé un modèle déterministe qui incorpore les structures de génotypes au modèle 
épidémiologique EPIFIL afin de mieux comprendre les mécanismes et les facteurs 
impliqués dans la dispersion potentielle de la résistance à l'ABZ dans une population de 
W bancrofti transmise par le moustique Culex. Ce modèle prédit que la combinaison 
ABZ + DEC mène à une sélection pour le génotype résistant plus forte que l'ABZ + 
IVM, et que les suppositions sur les efficacités des médicaments sont des facteurs 
importants qui influencent la dispersion de la pharmacorésistance. La couverture des 
traitements, l'accouplement non-aléatoire des vers, les fréquences initiales des allèles 
ainsi que le nombre de traitements administrés influençaient aussi fortement la vitesse et 
1'ampleur de la dispersion de la résistance à l'ABZ. L'inclusion dans ce modèle d'allèles 
potentiels conférant une résistance à l'IVM a mené à la conclusion que, sous traitement 
avec l' ABZ + IVM, la sélection pour la pharmacorésistance à un des médicaments est 
accrue par la présence de pharmacorésistance à l'autre médicament. De même, un excès 
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d'homozygosité causé par un accouplement non-aléatoire des parasites peut augmenter la 
sélection pour l'allèle dominant de la pharmacorésistance à l'IVM, par l'accroissement de 
la dispersion de l'allèle récessif de la pharmacorésistance à l' ABZ. La résistance se 
développait plus lentement si elle était causée par plusieurs gènes. Les résultats de cette 
étude suggèrent que la surveillance pour la résistance est de grande importance, car celle 
ne sera pas apparente avant la fin du traitement, la recrudescence des parasites est le 
recommencement du traitement. 
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GENERAL INTRODUCTION 
Many ofthe world's most debilitating diseases are caused by parasites. The 
filarial worms Wuchereria bancrofti, Brugia malayi and Brugia timori are the causative 
agents of lymphatic filariasis, a disease which may lead to disability and has a severe 
impact on endemic countries. Recognizing this, the World Health Organization is 
currently implementing a global program to eliminate lymphatic filariasis (Maher and 
Ottesen, 2000). This program is designed to disrupt transmission ofthe disease using 
chemotherapy. The benzimidazole drug albendazole is used in combination with 
diethylcarbamazine or the macrocyclic lactone, ivermectin, in sorne geographical areas 
(WHO, 1999). However, like manY ofthe current anthelmintics used to treat nematode 
parasites, resistance to both albendazole and ivermectin has occurred in sorne species, 
although in human populations, this has not been unequivocally confirmed despite sorne 
reports suggesting resistance (De Clercq et al., 1997). 
Resistance against these broad-spectrum anthe1mintics has been a concem in 
veterinary science for many years (Prichard, 1990). Though resistance against 
anthelmintics has not yet impeded the treatment ofhuman helminth infections (Coles, 
1999), the development of drug resistance has had an adverse impact on the control of 
other parasites, such as Plasmodiumfalciparum (Krogstad et al., 1987). Recently, there 
have been several reports of a poor response to ivermectin in a related filarial worm 
Onchocerca volvulus, the causative agent of River Blindness, after many years of 
exposure to the drug, possibly due to drug resistance (Awadzi et al., 2004a; Awadzi et al., 
2004b). While there are no reports ofresistant strains of Wuchereria, our current 
knowledge of the development of resistance suggests that it is likely that resistance to 
albendazole (ABZ) and ivermectin (IVM) will occur. Development of resistance against 
both ABZ and IVM would be a major threat to the elimination program, since 
chemotherapy is the primary strategy employed. 
The overall objective ofthis thesis was to explore the risk ofpotential 
anthelmintic resistance developing in lymphatic filariasis. Specifically this thesis 
examines the genetics of potential drug resistance in W bancrofti, frOID a practical, as 
weIl as a theoretical perspective. The first chapter reviews the current knowledge of 
lymphatic filariasis and the parasites causing it, as well as the drugs used to treat the 
disease. A summary of advances made in the mathematical biology of LF and of drug 
resistance in parasites is also inc1uded. Chapter 2 presents evidence that ABZ resistance-
associated mutations are present in populations of W bancrofti from West Africa and 
explores the frequencies of these mutations in patients with different treatment histories. 
The third chapter of this thesis introduces a deterministic mathematical model, which 
incorporates population genetics with epidemiology, in order to better understand the 
mechanisms and key factors involved in the potential spread of ABZ resistance through a 
population of W bancrofti. This mathematical model is extended in the fourth chapter, to 
inc1ude IVM-resistance genes, and thus explores important factors in the spread of 
polygenic multi-drug resistance in W bancrofti. The fifth chapter ofthis thesis consists 
of a detailed discussion of the implications of the findings on our CUITent thinking of 
potential drug resistance in filarial parasites. The manuscript in Appendix 1 explores the 
population genetics of the W bancrofti population in Burkina Faso. Evidence ofnon-
random mating in this population is presented and examined, in order to develop more 
appropriate sampling strategies. The second Appendix contains supplemental figures to 
Chapters 3 and 4. 
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CHAPTER 1: LITERATURE REVIEW 
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1.1 Endemicity And Impact Of Lymphatic Filariasis 
Lymphatic fi1ariasis (LF) is endemic to over 90 countries (Fig. 1.1). It has been 
estimated that approximate1y 128 million people are current1y infected or afflicted with 
the disease. The global preva1ence ofLF is thought to be 3.39% in the exposed 
population (Michael, 2000; Michael and Bundy, 1997; Michael et al., 1996). Wuchereria 
bancrofti is associated with 91 % of all cases, with Brugia malayi causing most of the 
remaining cases (WHO, 1992). A third species, Brugia timori, replaces B. malayi in the 
eastem is1ands ofthe 1esser Sunda archipe1ago (Nusa Tenggara Timur) (Fischer et al., 
2004). Bancroftian fi1ariasis is endemic throughout the tropics and subtropics, whi1e 
brugian fi1ariasis is confined to South and Southeast Asia (Michael, 2000). Though India 
accounts for the 1argest number of cases for a single country (Michael et al., 1996), 
disease prevalences are higher in Africa and the Pacific islands where mean regional 
preva1ences are estimated at 10.3% and 29% of positive countries respective1y compared 
to 2.4% for positive countries in Asia and 0.2% in South America (Michael and Bundy, 
1997). 
.' 
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Figure 1.1: Geographica1 distribution of Lymphatic fi1ariasis. Grey are as indicate 
countries endemic to LF. This map is reproduced from WHO (2002) 
L ymphatic fi1ariasis imposes a devastating socioeconomic burden on affected 
communities. It is estimated that in 1990, 560 000 Disability Adjusted Life Years 
/". (DALYs) and 290000 DALYs were 10st worldwide due to the disease for men and 
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women, respectively (World Bank:, 1993). It is believed that in India, LF is responsible 
for a one billion US dollar loss in productivity (Ramai ah et al., 2000). Studies in Ghana 
have also indicated that the disease greatly contributes tohousehold poverty (Gyapong et 
al., 1996). A recent study showed that LF is endemic in 89% of the 46 countries 
classified as the least developed (Durrheim et al., 2004). In addition, there is a severe 
psychosocial impact on individuals infected with the disease. Severe cases lead to 
stigmatization and in turn social isolation (Krishna Kumari et al., 2005). 
1.2 Biology and Life Cycle of Lymphatic Filaria 
A summary of the life-cycle oflymphatic filarial is shown in Fig. 1.2. Lymphatic 
filariae are nematodes, belonging to the order Spirurida and the family Onchocercidae. 
The Spirurida is most close1y re1ated to the Ascaridida and the Oxyurida (Scott 2000). 
Most nematode parasites pass through five life stages after hatching from the egg, 
separated by four moults. The first four stages are larval stages termed LI, L2, L3 and 
L4 and the fifth stage is the adult worm or macrofilaria. In parasitic nematodes of 
vertebrates, the infective stage is almost always at the beginning of the third stage, 
immediately or shortly after the second moult. 
1.2.1 Development in The Human Host 
In LF, the infective L3 stage enters the host upon a bite of an infected mosquito 
vector. Mature L3 are deposited onto the host's skin and enter the host via the puncture 
site (Scott, 2000). Studies in monk:eys have shown that L3 develop into L4s in 14-38 
days and into adults 42-103 days post infection (Cross et al., 1979). The pre-patent 
period has been found to be 2-3 months for B. malayi and 7-8 months for Wuchereria 
( 
(WHO, 1984; WHO, 1992), after which each female releases thousands ofmicrofilariae 
every day. Calculations have shown that an adult female worm may produce as many as 
l.32 xIO? microfilariae during her lifetime (Hairston and Jachowski Jr., 1968). 
AIl species of lymphatic filaria are dioecious. Males are approximately 4 cm in 
length and 50 mm in diameter, while females are 200 !lm in diameter and range from 8-
10 cm in length (Scott, 2000). Brugia worms ar~ slightly smaller than Wuchereria, 
ranging from 4-5.5 cm and 130-170 !lm diameter in females and l.5-2.3 cm in males 
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(Rao, 2005). Estimates for the lifespan of W bancrofti adults vary greatly, and are based 
on blood microfilariallevels. Tablel.l (Dreyer et al., 2005) summarizes sorne ofthese 
estimates. It has also been shown that the life-span of adult worms may be reduced in 
areas ofhigh transmission, likely due to sorne form of density dependence (Dreyer et al., 
2005). Estimates for the reproductive lifespan of B. malayi females range from 3.4 years 
(Sabesan et al., 1991) to 8-9 years (Wang et al., 1994). 
InfC'ctive l<wvail releasli!d (rom mosqulto IMuthparls 
du ring blood ffleal 
IngtstiOn 
by mosquito during 
bloodmeal 
Oewlopme:l'\t .... ~ .......... . 
.of ." 
mlcrofilariae 
tnto il'lfectlw 
Figure 1.2: Life Cycle of lymphatic filaria 
Reproduced from http://www .mectizan.org/lifecycle2. asp 
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Table 1.1: Estimates of W bancrofti adult lifespan (Dreyer et al., 2005). 
Author Location(s) Estimated Sample 
lifespan Slze 
(years) 
Carme and Laigret, 1979 TahitilFrance 40 1 
Leeuwin, 1962 Surname/ Amsterdam ~8 28 
Jachowski et al., 1951 American Samoa/Hawaii ~6 11 
WHO/WPRO, 2003 China ~8 model 
Vanamail et al., 1990 Pondicherry, India 10.2 877 
Vanamail et al., 1996 Pondicherry, India 5 7525 
Vanamail et al., 1989 Pondicherry, India 5.4 633 
Subramanian et al., 2004 Pondicherry, India 10.2, 11.8 model 
Guptavanij and Harinasuta, 1971 Thailand 5 1 
Conn and Greenslit, 1952 Pacific/United States 7.5 1 
Mahoney and Patrick, 1970 Samoa/Hawaii/Califomia ~8 25 
Webber, 1977 Solomon Islands 8 model 
Within the host, adult worms live in the lumen of dilated lymphatics (Amaral et 
al., 1994). Worms are found in nests containing several individuals, and the location of 
nests remains stable over time in untreated patients (Dreyer et al., 1994). In men, W 
bancrofti worm nests are often found in the lymphatic vessels ofthe epididymis, 
spermatie cord and paratesticular region (Noroes et al., 1996a; Reddy et al., 2004). In 
women, worm nests have been found in lymphatic vessels in the uterus, the groin and 
between the muscular fibers ofthe thighs (Mand et al., 2004). Lymphatic filaria are 
oviviparous (Scott 2000), or they lay motile vermiform eggs or very young larvae in 
diapause, known as microfilariae or LI (Bain and Babayan, 2003). These sheathed 
microfilariae migrate to the peripheral circulation. The presence of microfilariae in the 
blood was first observed by Thomas Manson (1893-1958). Microfilaraemia is usually 
nocturnally periodic, and thus microfi1ariae appear in the blood between 10 PM and 2 
AM, coinciding with the peak biting times for many night-biting Culex and Anopheles 
mosquito species. In sorne parts of Asia and the Pacifie, lymphatic filaria display 
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subperiodic behaviour. Thus, they are present continuously, but peak at specific times of 
the day (McCarthy, 2000). This periodicity is a product of circadian migration of the 
microfilariae from the peripheral circulation to the lungs (Hawking and Thurston, 1951). 
Microfilariae react to physiological signaIs from the host, since reversaI of the host's 
circadian cycle will also reverse the periodicity of microfilariae in the blood (Hawking, 
1965). It has been shown that periodicity behaviour of microfilariae is related to changes 
in oxygen tension between venous and arterial blood. At night arterial O2 tension may 
faU slightly, while venous O2 tension may be slightly higher than during the day, thus 
providing a signal to microfilariae (Edeson et al., 1957; Hawking et al., 1966). 
1.2.3 Development in the Vector 
Microfilariae are picked up from the peripheral blood through the bite of a 
mosquito. Over ninety species of mosquitoes are known to be competent for the 
transmission ofLF. Periodic W bancrofti is transmitted primarily by Anopheles or Culex 
mosquitoes (except for two species of Aedes in South Asia), whereas the predominant 
vector species for subperiodic W bancrofti belong to the genus Aedes. Brugia malayi is 
transmitted by both Anopheles and Mansonia species and B. timori is transmitted by 
Anopheles barbirostis (WHO, 1984). Inside the mosquito, the larvae penetrate the 
midgut and migrate to the flight muscles of the mosquito. They develop to a shorter form, 
known as the "sausage stage" in three days, and to the L2 stage in 7 days. L2 larvae molt 
to the L3 stage within 12-14 days and then migrate to the head ofthe mosquito 
(Samarawickremaet al., 1985; Scott 2000). Though most infective L3 remain in the 
head of the mosquito, sorne migrate back and forth to the thorax or abdomen of the insect 
(Paily et al., 1995). L3 are thought to be stimulated to move into the labium of the 
mosquito by the movement of the muscles of the pharyngeal pump (Zielke, 1977). 
Wuchereria bancrofti L3 were found to be alive and motile in Culex mosquitoes up to 46-
50 days after ingestion (Paily et al., 1995). 
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1.3 Pathogenesis of Lymphatic Filariasis 
The pathology of LF is complex and still poorly understood. Its clinical 
manifestations are highly variable and depend on the endemic area and the filarial species 
involved (Kumaraswami, 2000; Partono, 1987). Pathology also varies with age and 
gender (Pani et al., 1991). Traditionally, it has been assumed that the disease progresses 
from asymptomatic microfilaraemia to acute and finally chronic disease, depending on 
the patient's immunological state (Partono, 1987). This theory has been challenged 
recently, and secondary bacterial infections are now known to be strongly implicated in 
the development of chronic disease (Dreyer et al., 2000). Acute disease is characterized 
by recurrent attacks of fever and adenolymphangitis (Relm et al., 1989), often 
accompanied by retro grade lymphangitis known as acute filariallymphangitis (APL) 
(WHO, 1992). In bancroftian filariasis, the male genitalia may be affected, with 
symptoms such as funiculitis, epididymitis or orchitis (Partono, 1987). In Brugian 
filariasis, mostly lymph nodes in the inguinal region are affected. Repeated episodes of 
APL have been implicated in the progression of the disease to a chronic state (Pani et al., 
1995). Chronic manifestations oflymphatic filariasis include lymphoedema, 
elephantiasis, hydrocoele and chyluria (WHO, 1992). Bancroftian disease causes 
primarily hydroceole and swelling of the testis, followed by elephantiasis of an entire 
lower limb, and less frequently of the scrotum, the arm, vulva and breasts (Kumaraswami, 
2000). In Brugian filariasis, elephantiasis most commonly affects the leg below the knee 
and less frequently the arm below the elbow (Partono, 1987). Chyluria is the result of the 
rupture of a dilated lymphatic vessel, causing drainage of the lymph through the urinary 
tract (Dreyer et al., 2000). 
The use of ultrasound and lymphoscintigraphy has led to a re-evaluation of 
microfilaraemia that appears to be asymptomatic. It has recentIy been shown that 
virtually an patients bearing adult worms exhibit lymphangiectasia and lymphatic 
abnormalities, and thus have subclinical forms of the disease (Dissanayake et al., 1995; 
Dreyer et al., 2000; Dreyer et al., 1996c; Freedman et al., 1994; Freedman et al., 1995; 
Kumaraswami, 2000). An inflammatory response was not evident in the lymphatics near 
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the adult wonns in these asymptomatic patients. This is clearly different from patients 
with chronic pathology, who display a vigorous inflammatory reaction (Melrose, 2002). 
It is also known that APLs are strongly associated with death of adult wonns, which does 
lead to inflammation (Dreyer et al., 2000). Acute hydrocoele and lymphoedema can be 
the result of temporary blockage of lymphatics due to this inflammation in response to 
damaged or dead wonns. However, these conditions usually resolve quickly, and only 
sometimes lead to chronic hydrocoele and very rarely to chronic lymphoedema (Dreyer et 
al., 2000). It is not yet clear what usually triggers the onset of chronic disease. Recent 
evidence suggests that immunological changes in response to filaria and lymphatic 
obstruction per se may not be as important in chronic lymphoedema as previously 
suspected (Melrose, 2002). It has recently been shown that acute attacks are often 
precipitated by secondary bacterial infections (Kumaraswami, 2000), and it was 
suggested that acute episodes of APL caused by the death of adult worms can be 
c1inically differentiated from acute attacks caused by bacterial infections, acute 
dennatolymphangioadenitis or ADLA. A recent hypothesis c1aims that ADLA is a 
common cause of elephantiasis (Dreyer et al., 1999). In fact it was proposed that, though 
hydrocoele can sometimes be caused solely by the presence of worms, development of 
chronic elephantiasis always requires the presence ofbacterial infections (Dreyer et al., 
2000). 
A rare complication of LF is tropical pulmonary eosinophilia, whose symptoms 
are similar to those ofbronchial asthma (Kumaraswami, 2000). It is characterized by 
marked elevations ofimmunoglobulin E (IgE) titers and circulating eosinophils in the 
serum, thought to be caused by immunologie hyperactivityto filarial parasites or their 
antigens (O'Bryan et al., 2003). Patients do not have overt microfilaraemia, though dead 
or dying microfilariae have been found in the lung, liverand lymph nodes (Webb et al., 
1960) and adult wonns have been detected (Dreyer et al., 1996b). Lymphatic filariasis 
has also been associated with rheumatic symptoms (Adebajo, 1996). 
Endemic nonnals are individuals that live in endemic areas, thus being 
continually exposed to filariasis, but remain amicrofilaraemic (Kumaraswami, 2000). 
Many so-called endemic nonnals show the presence offilarial antigens and anti-filarial 
antibodies in the intra-venous circulation, which suggests that these individuals are likely 
11 
not immune, but bear an amicrofilaremic and asymptomatic infection (Weil et al., 1996). 
In other cases, ultrasound examination of endemic normals have revealed the presence of 
adult worms in their lymphatics (Dreyer et al., 1996c; Faris et al., 1998; Noroes et al., 
1996a; Noroes et al., 1996b). Thus, true endemic normals may be rare in the population 
(Melrose, 2002). 
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1.4 Immunological Aspects of Filarial Infections 
The host immune response to lymphatic filaria is complex and poorly understood. 
The host cornes into contact with three distinct stages of the parasite's life-cycle, in 
immunologically distinct compartments, and each stage presumably elicits its own 
specific type of immune response (O'Connor et al., 2003). In order to survive in the 
lymphatics as a multicellular organism, filarial worms must use a large number of 
adaptive strategies (Devaney and Yazdanbakhsh, 2001). It is well-documented that 
filarial infections with microfilaraemia lead to high levels of immunosuppression, as 
evidenced by a lack ofproliferative T-cell responses (King et al., 1992; Lawrence, 2001; 
Ottesen et al., 1977). Interferon (IFN)-y production has been shown to be absent 
(Sartono et al., 1997). This lack ofresponsiveness appears to be primarily directed at the 
parasite (Nutman and Kumaraswami, 2001), though recent studies have shown that 
concurrent infection with W. bancrofti can diminish responses to unrelated antigens 
(Nookala et al., 2004). In contrast, IgG4 levels and circulating eosinophils may be 
extremely high in microfilaraemic patients (Kwan-Lim et al., 1990; Wong and Guest, 
1969). Surprisingly, there is also a lowered interleukin (IL)-5 production (Sartono et al., 
1997), which complicates any assumptions of a simple suppression ofThl cytokines. It 
should be noted that in South India, induction of IL-5 was sometimes observed (Nutman 
and Kumaraswami, 2001). Interestingly, if given diethylcarbamazine (DEC) therapy, T-
cell responsiveness in microfilaraemics may be restored (Sartono et al., 1995). It has also 
been demonstrated that filarial antigens alter the function of antigen presenting cells to 
induce tolerance (Nutman and Kumaraswami, 2001; O'Connor et al., 2003). Studies in 
mice have revealed that infection with only the microfilarial stage of the parasite induces 
IFN-y production and causes elevated lymphocyte apoptosis (O'Connor et al., 2003), 
suggesting the possibility of a different immunomodulary mechanism by this lifestage in 
an artificial host. 
Protective immunity to LF in humans has been the subject ofmuch debate. To 
date, extensive studies have not been able to produce conclusive evidence of its existence 
(Maizels and Yazdanbakhsh, 2000; Ravindran et al., 2003). Mathematical modeling and 
combined data analysis have shown that the age prevalence pattern of infection can be 
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explained by exposure-driven herd immunity (Michael and Bundy, 1998). A 
mathematical model has also shown that transmission intensity has a profound effect on 
infection and disease, and that immunity against infection with new worms is likely 
modulated by adult worm experience. In addition, a separate type of immunity, which 
leads to pathology, appears to be mediated by cumulative experience of infective larvae 
(Michael et al., 2001). It has also been shown that the age of the patient has an impact on 
the cytokine profile produced, thus the length of exposure clearly affects the immune 
response (Sartono et al., 1997). Indirect evidence of the presence of density-dependent 
mechanisms such as acquired immunity is also provided in a study that showed a 
decrease in aggregation or overdispersion with age (Das et al., 1990). In Papua-New 
Guinea, in an area with constant levels of microfilaraemia, antigenaemia tended to 
increase in patients younger than 20 years, but remained stable in older patients, 
suggesting sorne resistance to superinfection (Day et al., 1991). 
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1.5 Diagnosis of Lymphatic Filariasis 
Diagnosis of LF is inherently difficult, due to several factors, such as periodicity 
of microfilariae and incidence of amicrofilaraemic patients, as well as the difficulty of 
locating adult worms. 
Traditionally, diagnosis has been achieved through the detection of microfilariae 
in the blood. This method requires a blood sample to be taken at a time ofpeak 
microfilaraemia. Thus in areas of nocturnal periodicity the sample must be taken at 
midnight, which may be unacceptable in many settings (McCarthy, 2000). A thick blood 
film stained with Giemsa stain is the simplest method (Melrose, 2002). However this test 
lacks sensitivity as it cannot detect microfilarial counts below 20 mf/ml (McCarthy, 
2000). There may be an additionalloss of microfilariae from the blood film during the 
steps of dehaemoglobinization, staining and rinsing in this procedure, further limiting the 
reliability of diagnosis (Denham et al., 1971). An alternative is to use concentration 
techniques of larger blood samples. The method developed by Knott (1939) is still 
widely used today. One ml ofblood is added to 9 ml of2% formalin solution in normal 
saline. The sample is then centrifuged and the sediment analyzed. Formalin preserves 
the microfilariae and inactivates other infectious agents. However, since the sediment is 
often difficult to analyze (McCarthy, 2000; Melrose, 2002) other concentration 
techniques, such as filtration, are more common today. The filtration ofblood through a 
polycarbonate membrane with a 5 /lM pore-size to concentrate microfilariae was first 
described by Bell (1967). Membrane filtration has been shown to be more sensitive than 
using blood films (Moulia-Pelat et al., 1992). 
The recent development of tests that detect circulating filarial antigens in the 
blood has proven revolutionary, as they are capable of diagnosing amicrofilaraemics and 
can be performed during the daytime (Melrose, 2002). It has long been known that 
patients infected with lymphatic filaria present circulating antigen (Franks, 1946). 
Early assays, which detected the W bancrofti excretory/secretory product 
phosphorylcholine (PC) with a monoclonal antibody (Gib-13) were, however, not 
~-, sensitive enough to recognize aIl patent infections (93% sensitivity) (Forsyth et al., 1985; 
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LaI et al., 1987). The first commercially available W bancrofti diagnostic test for 
circulating filarial antigen (CFA) was a capture enzyme-linked immunosorbent assay 
\ 
(ELISA) using the monoclonal antibody Og4C3, which recognizes a major PC-
containing epitope that was first characterized by Maore and Copeland (1990). It has 
proven to have high sensitivity and specificity (Chanteau et al., 1994; Lammie et al., 
1994). 
A rapid card format immunochromatographic test (ICT) using the antifilarial 
monoclonal antibody ADI2.1, which recognizes CFA in the blood, is also available. This 
test is rapid and easy to use and shows specificity and sensitivity up to 100% (Simonsen 
and Dunyo, 1999; Weil et al., 1997). No CFA tests are currently available for Brugian 
filariasis (McCarthy, 2000). Instead, diagnosis has been improved by immunodiagnostic 
tests for antifilarial IgG4 (Melrose et al., 2004; Rahmah et al., 1998a; Rahmah et al., 
2001a; Rahmah et al., 2001b). This test is specific for filaria, but does not distinguish 
between B. malayi, B. timori and W bancrofti (Rahmah et al., 1998a). 
DNA based tests for Brugian and bancroftian filariasis have also been developed. 
Such tests can detect parasites within mosquito vectors using polymerase chain reaction 
(PCR)-based assays (Dissanayake et al., 1991; Goodman et al., 2003; Hoti et al., 2001; 
Vasuki et al., 2001) or enzyme-Iabeled DNA probes (Dissanayake et al., 1991). PCR-
based tests which amplify repetitive DNA sequences capable of detecting B. malayi in 
blood samples (Lizotte et al., 1994; Rahmah et al., 1998b) and W bancrofti in sputum 
(Abbasi et al., 1999; Abbasi et al., 1996; Lucena et al., 1998; McCarthy et al., 1996) and 
urin (Lucena et al., 1998) ofhuman patients, have also been usefu1. Recently, a PCR-test 
for combined detection ofboth species has been developed (Mishra et al., 2005). 
Molecular-based tests have shown high specificity and sensitivity (Abbasi et al., 
1996; Lizotte et al., 1994; McCarthy et al., 1996), though the latter has been questioned 
by other groups (Dissanayake et al., 2000). PCR-based tests are more rapid than 
traditional methods, however they tend to be expensive and impractical in field settings 
(Melrose, 2002). 
Recently ultrasonography has been added as a diagnostic too1. Live adult worms 
pro duce a characteristic signal in lymphatics known as 'filaria dance signs'(Amaral et al., 
1994), which can be used to detect infection with macrofilaria (Amaral et al., 1994; 
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Dreyer et al., 1996b; Dreyer et al., 1996c; Faris et al., 1998; Simonsen and Dunyo, 1999). 
Ultrasonography is widely available, portable, cost effective and non-invasive (Amaral et 
al., 1994; Suresh et al., 1997). 
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1.6 Treatment of Lymphatic Filariasis 
Three drugs are currently being used for the treatment of lymphatic filariasis. 
Diethylcarbamazine (DEC), ivermectin (IVM) and albendazole (ABZ) are known to be 
effective against the parasite when administered on their own, or in combination (Tisch et 
al., 2005). The efficacy ofthese drugs is currently not firmly established. DEC has been 
used to treat the disease for the last 60 years and has been shown to c1ear microfilariae 
for up to 12 months following a 12 day regimen of 6 mg DEC /kg body weight 
administered each day (Richards et al., 1991), a dose regimen that was recommended for 
many years by WHO (WHO, 1992). Recent studies have shown that a single dose of 6 
mg/kg can reduce microfilaraemia to levels and for a time-period comparable to the 12-
day regimen (Cartel et al., 1990; Cartel et al., 1991; Kimura et al., 1985; Kimura et al., 
1992; Weerasooriya et al., 1998). A single dose of the drug also appears to exert an 
adulticidal effect (Dreyer et al., 1995; Figueredo-Silva et al., 1996). Ultrasonographic 
studies found that 41.5% ofworm nests in an infected individual were inactivated by 
DEC treatment at doses ranging from 1-12 mglkg (Noroes et al., 1997) and studies 
measuring filarial antigen found a 34% macrofilaricidal effect with a dose rate of 72 
mg/kg (Day et al., 1991). The drug may also be consumed in the form of table-salt 
fortified with 0.25% DEC, which has proven highly effective, though with some minimal 
side-effects (Freeman et al., 2001; Gelband, 1994; Panicker et al., 1997; Tisch et al., 
2005). 
A single dose of IVM at 200 Jlg has been shown to rapidly reduce blood 
microfilariallevels for up to 12 months (Brown et al., 2000; Cao et al., 1997; Kazura et 
al., 1993; Kumaraswami et al., 1988; Ottesen et al., 1990). This drug does not appear to 
have a macrofilaricidal effect on W bancrofti (Dreyer et al., 1996a; Dreyer et al., 1995), 
but does affect microfilarial production, presumably through an effect on reproduction 
(Plaisier et al., 1999; Stolk et al., 2005). 
Several studies have explored the effect of a single dose of ABZ on lymphatic 
filariasis. However, there is not enough evidence to support the efficacy of this treatment. 
Some studies have shown a reduction in microfilaraemia due to ABZ (Ismail et al., 1998; 
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Makunde et al., 2003; Pani et al., 2002), but others have found that single doses of ABZ 
have litde or no impact on microfilariae (Addiss et al., 1997; Dunyo et al., 2000a). It has, 
however, been found that high and repeated doses of ABZ cause large decreases in 
microfilariallevels and are clearly macrofilaricidal for W bancrofti in humans 
(Jachowski et al., 1993) and B. malayi and B. pahangi in laboratory animaIs (Denham et 
al., 1980; Mak et al., 1984). 
Many studies have shown that combination treatment with the various drugs is 
more efficacious than the use of any drug alone (Addiss et al., 1997; Beach et al., 1999; 
Bockarie et al., 1998; Ismail et al., 2001; Ismail et al., 1998; Moulia-Pelat et al., 1995; 
Simonsen et al., 2004), though sorne studies reported no advantage to combination 
therapy (Dunyo et al., 2000a; Dunyo et al., 2000b). Recently, meta-analysis studies have 
questioned the efficacy of ABZ in lymphatic filariasis treatment, stating that there is 
insufficient evidence to conclude that there is any benefit to adding this drug to control 
programs and that further investigation is required (Critchley et al., 2005a; Critchleyet 
al., 2005b; Tisch et al., 2005). However, this has been refuted by other groups (Sunish et 
al., 2006) and a recent ultrasonographic study found ABZ/DEC treatment to be strongly 
adulticidal (Hussein et al., 2004). 
Sorne studies have examined the potential of antibiotic treatment targeting the 
obligate filarial endosymbiont Wolbachia (Rao, 2005). Studies in animal models have 
shown that targeting Wolbachia with tetracycline has a strong effect on the development 
and reproduction of filarial nematodes (Taylor, 2002). It was found that treatment of 
Litomosoides sigmodontis with tetracYcline eliminates the bacteria and leads to growth 
retardation and infertility offilaria (Hoerauf, 2000; Hoerauf et al., 1999). In humans, 
treatment with doxycycline resulted in complete long-term blockage of embryogenesis of 
Onchocerca volvulus (Taylor and Hoerauf, 2001). It was then shown that doxycycline 
treatment led to a 96% 10ss of Wolbachia and a 99% reduction in microfilaraernia in W 
bancrofti infections (Hoerauf et al., 2003). It was recently found that doxycycline 
treatrnent displays sorne adulticidal activity in addition to high efficacy against 
microfilariae (Taylor et al., 2005). However, the long-term rnulti-dose treatment 
regirnes tested to date have proven to be irnpractical (Rao, 2005). 
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1.6.1Albendazole 
Albendazole belongs to the benzimidazole (BZ) c1ass of drugs (Townsend, 1990). 
Benzimidazoles are broad-spectrum anthe1mintics, with sorne additional activity against 
fungi and protozoans (Lacey and Gill, 1994). These drugs are composed of a bicyclic 
ring system, in which benzene is fused to the 4- and 5-position of the heterocyc1e 
(Townsend, 1990). Albendazole metabolism is characterized by oxidation of the 
nuc1eophilic heteroatom, with sulfoxide and sulfone metabolites dominating the plasma 
profile (Lacey, 1990). 
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Figure 1.3: Albendazole 
Many mechanisms of action have been proposed for benzimidazoles. An early 
report demonstrated an inhibition of the fumarase reductase reaction (Prichard, 1973), 
while another reported an inhibitory effect on protein secretion (Watts et al., 1982), and 
disruption of the parasite's energy balance, due to dissipation of the transmembrane 
proton gradient (McCracken and Stillwell, 1991). In 1975, Borgers first proposed that 
the benzimidazole mebendazole had an effect on microtubules in Ascaris suum (Borgers 
and De Nollin, 1975). Microtubules are involved in many cellular functions, thus 
providing a link between the various biochemical reactions previously associated with 
benzimidazoles (Lacey and Prichard, 1986). Binding studies confirmed the mode of 
action ofbenzimidazoles to be interference with microtubule polymerization, via tubulin 
binding (Ireland et al., 1979; Kohler and Bachmann, 1981; Lacey, 1988; Lacey, 1990; 
Lubega and Prichard, 1990). Benzimidazoles were found to compete for binding with 
the microtubule inhibitor colchicine (Friedman and Platzer, 1978; Kohler and Bachmann, 
1981). Lubega and Prichard also found that the anthelmintic potency of BZs correlates 
with their affinities for tubulin binding (Lubega and Prichard, 1991). BZs bind 
~, specifically to helminth B-tubulin, though sorne binding to mammalian tubulin does occur 
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(Lacey, 1990). In Haemonchus con tortus , BZs are lethal due to inhibition of secretory 
vesicle transport via depolymerization ofmicrotubules (Jasmer et al., 2000). There has 
been speculation on the specific binding site ofbenzimidazoles to tubulin. Photolabeling 
studies determined that the binding site of benzimidazoles on ~-tubulin isotype-1 is 
between amino acids 63 and 103 (Nare et al., 1996). In a review, Prichard proposed that 
the benzimidazole binding site includes both a and ~-tubulin and that the planar 
benzimidazole ring binds between the phenyl rings of phenylalanines at position 167 and 
200 of ~-tubulin (Prichard, 2001). However, it was suggested that this model was not in 
accordance with the crystal structure of ~-tubulin (Robinson et al., 2002). Recently, it 
was proposed that residues implicated in binding lie deeply within the microtubule, and 
that a mechanism, such as an inter-domain movement between the N-terminal and the 
intermediate region of ~-tubulin, may occur to allow binding (Robinson et al., 2004), 
though it must be noted that this work was based on modeling with albendazole-
sulphoxide, an albendazole metabolite which shows lower binding affinity to tubulin than 
does albendazole (Lubega & Prichard, 1991), while still being active as an anthelmintic. 
1.6.1.1 B-tubulin 
Microtubules are the principal structural components of meiotic and mitotic 
spindles of eukaryotic cilia and flagella, and of e10ngated processes such as those found 
in neuronal cells. They are also involved in overall cell structure, maintaining cell 
surface properties, and in intracellular transport (Cleveland and Sullivan, 1985). Most 
organelles, such as mitochondria, Golgi apparatus, ribosomes, lysozomes, cell 
membranes and the nucleus, associate with microtubules (Dustin, 1984). They are also 
directly associated with hormone and neurotransmitter secretion, as well as nutrient, 
enzyme and receptor action (Lacey, 1988). 
Microtubules are hollow tubular organelles with a diameter of about 25 nm. 
Mammalian microtubules are made up of 13 parallel aligned proto filaments (Dustin, 
1984), whereas helminth tubulin consists of Il or 15 (Chalfie and Thomson, 1979). The 
protein, which makes up microtubules is the soluble dimeric protein tubulin, which is 
composed of an a and a ~-subunit. Tubulin proteins are in dynamic equilibrium with 
microtubules, as they are added and subtracted on opposite ends of the insoluble 
( 
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microtubule, in a 'treadmilling' action (Lacey, 1988). This equilibrium may be disturbed 
by changes in temperature or in levels of endogenous co-factors, such as GTP, Mg/, Ca/, 
and microtubule associated proteins (MAPs) (Lacey and Gill, 1994). Tubulin subunits 
are acidic, have a primary structure of about 450 amino acids, a molecular weight of 
about 50 KDa (Lacey and Gill, 1994), and the genes coding for the two subunits are 36-
42% homo logo us to each other (Little and Seehaus, 1988). Different isotypes ofboth a 
and ~-tubulin have been identified, and may be distinguished using isoelectric focusing 
on gels (Cleveland and Sullivan, 1985). It has been found that sorne specificity in 
function of different isotypes exists, yet generally, communal association in the 
microtubule matrix occurs (Lopata and Cleveland, 1987). 
Using a monoclonal antibody shown to bind microfilariae, Helm (1989) loca1ized 
~-tubulin in B. malayi and B. pahangi microfilariae. Screening of an adult B. pahangi 
cDNA library with this antibody allowed the identification of a small, 40 amino acid 
segment, which showed great similarity to the C-terminus ofvertebrate ~-tubulin. In B. 
malayi, ~- tubulin was found to be abundant in somatic tissues (Helm et al., 1989). Tang 
and Prichard (1989) found 4-5 ~-tubulin isotypes in B. malayi and 5 in B. pahangi 
through Western blotting with anti-chicken ~-tubulin monoclonal antibodies. The 
isoelectric point ofthese isoforms ranged from pH 4.7-5.4. Tubulin accounted for 2.8% 
and 2.9% of soluble protein in B. malayi and B. pahangi, respectively. AB. pahangi B-
tubulin gene (b 1) was sequenced and found to span 3.8 kb, contained 9 exons, and 1.8 kb 
of coding region. It coded for a 448 aa protein, which showed over 85 % similarity with 
chicken and Caenorhabditis elegans B-tubulins (Guenette et al., 1991). The b-l tubulin 
a1so contains a 22 nucleotide trans spliced leader sequence, which is homo10gous to SLI 
of C. elegans (Guenette et al., 1992). A partial sequence for a second ~-tubulin gene (b2), 
which is developmentally regulated to be expressed primari1y in adult males, has a1so 
been identified (Guenette et al., 1992). At 1east three different genes of ~-tubulin have 
been cloned and sequenced from the sheep parasite Haemonchus contortus, including the 
high1y simi1arbl2-16 and b12-164 (thought to belong to the same isotype group), and b8-
9 (Geary et al., 1992). These genes were 1ater determined to code for isotype 1 and 
isotype 2 ~-tubulin (Kwa et al., 1993b). The H. contortus genome project indicates that 
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there may be 3 p-tubulin genes in this nematode (R.K. Prichard, personal 
communication). B-tubulins have also been c10ned from the filarial worms Onchocerca 
volvulus and Dirofilaria immitis, and have high similarity to the b-l of B. pahangi 
(Geary et al., 1998). 
1.6.1.2 Resistance to Albendazole 
Resistance to BZs in livestock was reported as early as the 1960s (Drudge et al., 
1964). Thereafter, there have been many reports ofresistance (Le Jambre et al., 1979; 
Woistenhoime et al., 2004). Early on it was shown that differential expression ofp-
tubulin isotypes may be involved in benzimidazole resistance in protozoa. Ofthree 
known isotypes of P-tubulin expressed in Physarium, a mutation in only one gene, known 
as benD, was sufficient to cause resistance (Burland et al., 1984). This mutant isotype 
was equally incorporated into microtubules and was expressed in constant proportion to 
wild-type benD with increasing drug concentrations (Foster et al., 1987). Later it was 
found that the resistance mechanism to BZs in Trichostrongylus colubriformis involves a 
change in binding affinity ofBZs to tubulin (Sangster et al., 1985), which is dependent 
on the BZ structure (Lacey and Prichard, 1986). In addition, there is reduced stability in 
the BZ-tubulin complex in resistant strains (Lacey et al., 1987; Russell and Lacey, 1992). 
This change in binding has been attributed to a reduction in high affinity receptors, and 
does not appear to be linked to low-affinity binding (Lubega and Prichard, 1990; Lubega 
and Prichard, 1991). Studies involving the free-living nematode C. elegans found that a 
mutation in, or complete deletion of, the ben-l P-tubulin gene conferred BZ resistance. 
This appeared to be the only locus susceptible to BZs in C. elegans, and other P-tubulin 
isotypes in this nematode, such as mec-7 and tub-l, were not sensitive to BZs. Worms 
lacking the ben-l isotype were shown to be completely viable in the presence ofBZs, 
supporting the hypothesis that p-tubulin isotypes may be homologous in function 
(Driscoll et al., 1989). BenzimÎdazole-resÎstant populations of H con tortus show a 
decrease in polymorphism in at least two p-tubulin genes (Beech et al., 1994; Lubega et 
al., 1994; Roos et al., 1990) and T. colubriformis (Grant and Mascord, 1996). 
Kwa (1993 a,b) then showed that lower levels ofBZ resistance in H con tortus 
,~, were associated with selection of the isotype 1 p-tubulin gene (Kwa et al., 1993a). 
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Resistance was due to a mutation at amino acid position 200, changing from a 
phenylalanine to a tyrosine (Kwa et al., 1993a). It was also found that resistance could be 
enhanced by a deletion ofthe ~-tubulin isotype 2 gene, although this occurred only at 
very high levels ofresistance (Kwa et al., 1993a; Roos, 1995). However, Beech et al. 
(1992) found selection associated with BZ resistance in both isotype 1 and isotype 2 
genes, and hypothesized that resistant alleles are not novel, but were present in the 
population at low levels before selection pressure occurred, explaining the relatively 
rapid emergence of BZ resistance. Upon drug exposure, the above mentioned mutation at 
codon 200 in ~-tubulin isotype 1 was also found in resistant strains of Teleadorsagia 
circumcincta (Elard et al., 1996) and appeared to be recessive (Elard and Humbert, 1999). 
In addition, the Tyr 200 genotype has been observed in Cooperia oncophera (Njue and 
Prichard, 2003; Winterrowd et al., 2003) as well as in equine cyathostomes (Drogemuller 
et al., 2004a; Pape et al., 2003). Vertebrate ~-tubulin possesses a Tyr200, and this may 
be the reason why vertebrate cells are relatively insensitive to BZs (Li et al., 1996b; 
Sullivan, 1988). This has led to the conclusion that the nature of the amino acid at 
position 200 is fundamental for the development ofBZ resistance or susceptibility (Elard 
et al., 1999). As a result, a simple diagnostic PCR test detecting BZ resistance, which 
may replace egg hatch or microlarval development assays, was developed (Elard and 
Humbert, 1996). 
ABZ resistance in the protozoan Giardia was, however, not linked to the amino 
acid 200 mutation (Upcroft et al., 1996). In the fungus Rynchosporidium secalis, a 
mutation at codon 198, changing from glutamic acid to glycine, was associated with BZ 
resistance (Wheeler et al., 1995). The same mutation also caused decreased binding of 
BZs to a a fungal ~-tubulin expressed as a fusion protein (Hollomon et al., 1998). A 
study in R. secalis by Butters and Hollomon (1999) detected BZ resistance in ~-tubulin 
isoforms that have wild-type amino acids between codons 196-202, thus involving 
neither the mutations at residue 198 or 200. A mutation at codon 241 from arginine to 
histidine in Sacchromyces cerevisiae, (Thomas et al., 1985) and at position 240 from 
leucine to phenylalanine in Tapesia, appeared to confer BZ-resistance as weIl. Residue 
200 was found to be associated with benomyl resistance in Aspergillus nidulans (Jung et 
al., 1992) and Botrytis cinerea (Yarden and Katan, 1993) . 
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An important mutation in p-tubulin at residue 167, from phenylalanine to tyrosine, 
conferred resistance in S. cerevisiae and was confirmed with studies involving site-
directed mutagenesis (Li et al., 1996a). Similar results were found in Neospora crassa 
(Orbach et al., 1986), trichostrongylids (Silvestre and Cabaret, 2002) and in equine 
cyathostomes (Drogemuller et al., 2004b). 
Studies in the human nematode parasite W bancrofti using sequence analysis of 
bulk samples (Hoti et al., 2003) and in the human hookworms Ancylostoma duodenale 
and Necator americanus (Albonico et al., 2004), have failed to find the position 200 
mutation in worm populations exposed to BZ drugs. 
Hall et al. (1982) found BZ resistance to persist for many generations after 
removal of anthelmintic selection pressure. Lack of reversion of BZ resistance after 
prolonged use of levamisole has also been observed in H con tortus and Ostertagia spp. 
(Borgsteede and Duyn, 1989; Martin et al., 1988). Elard et al. (1998) examined the 
relative fitness of BZ-resistant and sensitive strains of T circumcincta and found no 
significant difference. This suggests that there is no selection against the resistant 
phenotype, and thus supports the hypothesis that BZ-resistance is unlikely to revert back 
to the susceptible form, once the drug is removed. 
In 1977, Coles and Simpkin proposed the use of a test based on the ovicidal action 
ofBZs to detect BZ resistance (Hall et al., 1978). Hubert and Kerboeuf(1992) proposed 
a microlarval development assay to detect BZ resistence. However, discrepancies 
between faecal egg count reduction and the lethal dose 50% in the egg-hatch assay and 
larval development assay have been found (Maingi et al., 1998). Furthermore, these tests 
have low sensitivity, and it is unlikely that resistance can be detected before it has 
become a problem in the treatment of parasites (prichard, 1990). PCR diagnostic tests for 
resistance, such as the one developed by Elard and Humbert (1999), are thus very useful 
and necessary in order to detect selection for resistance as soon as it appears. 
1.6.2 Ivermectin 
Ivermectin became commercially available in 1980 (Campbell et al., 1983; 
Chabala et al., 1980). This drug, which is an avermectin, belongs to the class of 
anthelmintics known as macrocyclic lactones, which were first developed during the 
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1970s (Burg et al., 1979). Ivennectin is derived from the fennentation products ofthe 
soil organism Streptomyces avermitilis, which was first isolated in Japan in 1975 (Burg et 
al., 1979). Avennectins are broad-spectrum compounds, which display activity against a 
wide variety ofhelminths and arthropods (Shoop, 1993). 
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Figure 1.4: Ivennectin 
The mode of action of avennectins was initially found to involve y-aminobutyric 
acid (GABA) receptors (Holden-Dye et al., 1989; Holden-Dye and Walker, 1990; Pong et 
al., 1981; Pong and Wang, 1980; Pong and Wang, 1982; Wang and Pong, 1982). It was 
initially suggested that ivennectin binds to GABA-associated chloride channe1s (Fritz et 
al., 1979), leading to flaccid paralysis (Kass et al., 1984). However, studies by Martin 
and Pennington (1989) and Arena et al., (1991) demonstrated that avennectins potently 
affect chloride channels not sensitive to GABA , and it was shown that there was 
interaction between ivennectin and glutamate-gated chloride channels (Scott and Duce, 
1985; Zufall et al., 1989). Two glutamate-gated chloride channel subunits (GluCla and 
GluClP) were c10ned from C. elegans. GluCla displayed sensitivity to ivennectin when 
expressed inXenopus oocytes (Cully et al., 1994). Two additional GluCla genes, Avr 15 
(Dent et al., 1997; Vassilatis et al., 1997) and A vr 14 (Laughton et al., 1997) were 
isolated from C. elegans, and were shown to bind glutamate reversibly, and ivennectin 
irreversibly, leading to channel activation (Dent et al., 2000). Activation of GluCl by 
ivennectin was found to be correlated with its nematocidal activity (Arena et al., 1995). 
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Glutamate binds GluCI reversibly, leading to an influx of Cl" into the target 
neuromuscular ceIl, which inhibits muscle contraction. As ivermectin binds the a-subunÏt 
irreversibly, the chloride channel remains in the open conformation, leading to 
hyperpolarization of the ceIl, causing flaccid paralysis (Dent et al., 2000). A similar 
GluCla was c10ned from Drosophila melanogaster, though ivermectin binding led to an 
inhibition of glutamate binding in this channel at high concentrations of the drug (Cully 
et al., 1996b). GluCI homologues have also been c10ned from H con tortus and Ascaris 
suum (Delaney et al., 1998; Jagannathan et al., 1999; Hejmadi et al., 2000). GluCls from 
C. oncophera have also been c10ned (Njue and Prichard, 2004). Partial GluCI sequences 
have been obtained from 0. volvulus and D. immitis (Cully et al., 1996a), and recently an 
ivermectin-sensitive GluCla was c10ned from D. immitis (Yates and Woistenholme, 
2004). Glutamate-gated chloride channels are not present in vertebrates, accounting for 
part of the relatively small effect ofthe avermectins on mammals (Laughton et al., 1997; 
Vassilatis et al., 1997). However, since avermectins are known to interact with 
mammalian GABA receptors, a7 nicotinic acety1choline receptors and P2X4 receptors 
(Yates et al., 2003) this do es not solely explain host selectivity (Geary, 2005). Recent 
studies have shown that disruption of the P-glycoprotein gene mdr-l in Collie dogs and 
mice leads to ivermectin hypersensitivity and toxicity (Mealey et al., 2001; Schinkel et 
al., 1994), implicating this protein in protection against IVM in mammals. 
GluCls were found to be largely restricted to the pharynx in C. elegans (Laughton 
et al., 1997; Vassilatis et al., 1997) and inA. suum (Martin et al., 1996). Ivermectin is 
thought to act on C. elegans by causing paralysis ofthe pharynx (Cleland, 1996; Cully et 
al., 1996a; Dent et al., 1997; Dent et al., 2000; Pemberton et al., 2001). Gill and Lacey 
(1998) found that avermectin affects the motility of H contortus and T. colubriformis, 
and speculated that this may lead to their expulsion from the host. It has been shown that 
ivermectin acts by causing paralysis ofthe pharynx in H contortus (Geary et al., 1993). 
However the presence of GluCI in the pharynx of this parasite has not yet been confirmed. 
In H contortus, GluCls were initially found only in the systemic musculature (Delany et 
al., 1998; Jagannathan et al., 1999), but micreoinjection of the H contortus GluCI-a 
subunit gene HcGluCla into C. elegans led to expression ofthis gene in phanryngeal 
neurons (Liu et al., 2004). A recent study did not find an effect ofivermectin on feeding 
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(Sheriff et al., 2005). Dent et al., ( 1997; 2000) found that Avr 15 is also expressed in 
the peripheral nervous system, and that Avr 14 is found in the somatic musculature of C. 
elegans. Glutamate binding sites are found in both a and p subunits of GluCI, whereas 
ivermectin appears to have a binding site solely on the a subunit (Dent et al., 2000 ). 
Studies suggest that ivermectin and glutamate binding sites are separate on the a-subunit, 
and that ivermectin exerts an allosteric effect on glutamate binding (Forrester et al., 2002; 
Paiement et al., 1999a). 
1.6.2.1 Resistance to Ivermectin in Parasites 
The mechanism of resistance against macrocyc1ic lactones has not been 
completely elucidated. However, several genes have been shown to exhibit selection 
associated with resistance. Using single-stranded conformational polymorphism analysis, 
it was shown that there was selection for one allele of a glutamate-gated chloride channel 
a-subunit in ivermectin-resistant strains of H. con tortus (Blackhall et al., 1998b). 
Selection in such strains was also shown at a P-glycoprotein (P-gp) gene, which is usually 
highly polymorphic in nematodes (Blackhall et al., 1998a; Xu et al., 1998). Le J ambre et 
al. (1999) found selection at a second P-gp gene. The ivermectin-selected strains also 
showed an increase in mRNA levels of a P-gp in resistant strains (Xu et al., 1998). 
Selection for an allele in a different P-glycoprotein gene was also found to be associated 
with ivermectin resistance in field strains (Sangster et al., 1999). Ivermectin has been 
shown to bind these membrane transport proteins in humans (Didier and Loor, 1996), 
which may explain their involvement in ivermectin resistance. Kwa et al. (1998) in a 
limited restriction fragment length polymorphism (RFLP) analysis using only a single 
restriction enzyme and gene probes failed to detect an involvement ofP-gp in ivermectin 
resistance. However, Le Jambre et al. (1999) conducted a more thorough genetic 
analysis and found that this same P-gp gene was associated with ivermectin resistance. 
There was also significant selection at a p-tubulin gene in ivermectin-resistant H. 
contortus strains (Blackhall et al., 1999; Eng and Prichard, 2005a). 
Resistance of H. con tortus to macrocyc1ic lactones may be measured by the extent 
of pharynge al pumping (Kotze, 1998). The effect of ivermectin on pharynge al pumping 
was significantly different in susceptible and resistant strains. There was an 8-fold 
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decrease in the efficacy of ivennectin to inhibit pharyngeal pumping in resistant strains 
(Paiement et a!., 1999b). However, Gill et al. (1998) suggested that there may be more 
. than one mechanism of resistance against ivennectin. Since avennectins may act either 
on pharyngeal pumping or through paralysis of the somatic musculature, different 
resistance mechanisms may develop depending on the mode of action (Gill and Lacey, 
1998). Furthennore, the development of resistance may be affected by additional factors. 
Dent et al. ( 2000 ) found that a deleterious mutation in pharynge al GluCla did not cause 
high levels ofresistance in C. elegans. They speculated that ivennectin, acting on 
somatic GluCla, may cause a Cl influx, which is transferred to the pharynge al 
musculature via gap junctions. 
It was discovered that glutamate binding kinetics were altered in resistant H. 
con tortus strains, with increased maximum binding (Bmax) and lowering dissociation 
1 
constant (Kd) values, suggesting that changes in a glutamate binding site are directly 
related to ivennectin resistance (Paiement et a!., 1999b). Hejmadi et al. (2000) noted no 
difference in ivennectin binding between sensitive and resistant strains of H. contortus, 
though they did find an increase in low-affinity glutamate binding sites in resistant strains. 
AIso, a study in C. oncophera showed that mutations in a GluCla subunit found in 
resistant strains led to a decrease in IVM sensitivity (Njue and Prichard, 2004). 
Recently it has been documented that some females of 0. volvulus in endemic 
foci in Ghana showed decreased sensitivity to ivennectin, possibly due to drug resistance 
(Awadzi et al., 2004a; Awadzi et al., 2004b). There is also some genetic evidence that 
selection by ivennectin is occurring in 0. volvulus. Significant differences in alle1e 
frequencies between untreated and ivennectin treated wonn populations were found for 
~-tubulin and P-glycoprotein (Eng and Prichard, 2005; Ardel1i et al., 2006 a,b ; Ardelli et 
a!., 2005; Ardelli and Prichard, 2004). This suggests that, at least in filarial nematodes, 
IVM is likely selecting on more than one gene (Prichard, 2005), contrary to an earlier 
c1aim that IVM resistance is a monogenic trait (Le Jambre et al., 2000). Little is known 
about the inheritance ofivennectin resistance, however it has been speculated that it is a 
completely dominant trait (Bames et al., 2001; Le Jambre et al., 2000). Other studies 
have shown that the mode of inheritance of macrocyc1ic lactone resistance in 
T. circumcincta may vary (Sutherland et al., 2003; Sutherland et al., 2002). Resistance to 
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abermectin in the Colorado potato beetle and the housefly is inherited as a polygenic, 
autosomal recessive trait (Clark et al., 1995). The mode of inheritance of drug resistance 
will have a large impact on its selection, with dominant traits being selected more quickly 
(Barnes et al., 1995; Dobson and Barnes, 1995). 
1.6.3 Diethylcarbamazine 
Despite its wide-spread use against lymphatic filariasis for over 50 years, the 
mode of action ofDEC against filarial still remains poorly understood (Alves et al., 
2005). For many years, it was understood that the drug had no direct effect on the 
parasite in vitro at therapeutic concentrations (Hawking et al., 1950; Johnson et al., 1988; 
Jordan, 1958). This has led to the belief of an indirect mode of action of the drug. It was 
suggested that DEC acts as an anti-inflammatory drug, as it has an antagonistic effect on 
arachidonic acid metabolism. This could lead to vasoconstriction and enhanced 
microfilarial adherence to endothelial cells, which immobilizes the parasites as well as 
increased adherence and cytotoxic activity by host platelets and granulocytes (Maize1s 
and Denham, 1992). Specifically, DEC has been shown to inhibit leukotriene synthases 
(Bach and Brashler, 1986) and to inhibit products ofthe cyc100xygenase (COX) pathway 
(Kanesa-thasan et al., 1991; McGarry et al., 2005). An augmentation ofhuman 
neutrophil and eosinophil adherence due to DEC has been shown in vitro (King et al., 
1983). 
Sorne recent studies have suggested that DEC may have a direct effect on W 
bancrofti in vitro (Peixoto, 2005). It was found that diethylcarbamazine induced a loss of 
the microfilarial sheath of W bancrofti (Florencio and Peixoto, 2003; Peixoto et al., 
2003). Thereafter, it was observed that there was cytolysis and damage to organelles and 
the formation of cellular vacuoles in microfilariae treated in vitro (Florencio and Peixoto, 
2003) and in vivo (Peixoto et al., 2004). Similar observations were made in infective L3 
larvae of W bancrofti (Alves et al., 2005). Recently, it was also shown that adult females 
of W bancrofti obtained from patients treated with DEC contained few or no embryos, 
clearly indicating an effect on reproduction (Peixoto, 2005). 
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1.6.3.1 Resistance to DEC 
There have been sorne reports of lymphatic filarial worms showing tolerance to 
treatrnent with DEC (Eberhard et al., 1991; Eberhard et al., 1988) and that sorne adult 
worms appear not to be susceptible to DEC (Dreyer et al., 1995). A recent study also 
found a variable response in treatrnent efficacy ofDEC, with sorne patients showing a 
very poor response (Stolk et al., 2005). 
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1.7 The Global Alliance to Eliminate Filariasis. 
In 1993, an international task force on disease eradication named LF amongst one 
of six diseases that could be eradicated, or potentially eradicated (WHA, 1993). Several 
years later, a World Health resolution called for global efforts to eliminate LF as a public 
health problem (WHO, 1997). In January 1998, the pharmaceutical company Glaxo-
SmithKline, then SmithKline and Beecham, announced that it would donate the 
antiparasitic drug ABZ to the World Health Organization (WHO, 1998b) for as long as 
necessary to eliminate the disease. Later that year, Merck & Co., Inc., which was already 
supplying IVM free of charge to the WHO for onchocerciasis control, extended this 
donation program to include the treatment ofLF, for the purpose ofitselimination (WHO, 
1998a). Hence, the global program to eliminate LF (GPELF) was formed. This pro gram 
resolves to eliminate LF as a public health threat by the year 2020 (WHO, 2000). It aims 
to interrupt disease transmission, primarily by chemotherapy, and thereby reduce 
morbidity due to the disease. Recommended strategies of GPELF are community 
directed mass treatment programs with drug combinations of ABZ (400 mg) and DEC (6 
mglkg), or ABZ (400 mg) and IVM (200 mg/kg) for 4-6 years. The GPELF also calls for 
the use ofDEC-fortified table salt in sorne areas, vector control via insecticide treated bed 
nets and morbidity control through home-based self care of lymphoedema and 
elephantiasis as well as surgical interventions for hydrocoele (Gyapong et al., 2005). 
Patients suffering from onchocerciasis or loiasis experience severe adverse reactions to 
DEC, thus this drug cannot be administered in areas endemic for these diseases (WHO, 
1999; WHO, 2000). 
By 2004, haif of all recognized endemic countries had initiated treatment 
programs for LF, and approximately 435 million doses of drug had been administered to 
the at-risk population (Gyapong and Twum-Danso, 2006). Though results of the program 
seem very positive, with successful reductions in microfilaraemia (WHO, 2004), the 
estimate of a required 4-6 years to interrupt transmission may be overly optimistic, and 
longer treatment periods willlikely be required in many are as (Gyapong and Twum-
Danso, 2006; Michael et al., 2004). 
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1.8 Epidemiology and Mathematical Modeling of Lymphatic Filariasis 
Mathematical models can be invaluable in helping to understand the population 
dynamics of parasites and to predict the impact of chemotherapy on these populations 
(Anderson and May, 1982; Anderson and May, 1985). Models involving populations of 
animaIs must attempt to recreate the most important dynamic features of the populations 
and their interactions (May, 1976). Models ai ding in the design and implementation of 
control programs have been successfully used for the filarial nematode Onchocerca 
volvulus (Alley et al., 2001; Basanez and Ricardez-Esquinca, 2001; Habbema et al., 
1992; Hairston and Jachowski, 1968). 
1.8.1 Analytical Models 
Mathematical models to examine various aspects ofthe biology oflymphatic 
filariasis have been in existence since the 1960s (Hayashi, 1962). This model made use 
of the two stage catalytical model introduced by Muench (1959) which de scribes the rate 
of change in the infected (microfilaraemic) and uninfected (amicrifilaraemic) populations 
in a system that is atequilibrium (Michael, 2000). Hayashi's model assumed that 
individuals are initially susceptible and may become infected and recover from the 
infection. Once they have recovered, they become resistant and may no longer become 
infected. Hairston and J alowski (1968) later found that this mode1 did not accurately 
describe the data they had collected in American Samoa. Instead they applied the 
reversible catalytical model (Muench, 1959), which allows individuals that have cleared 
the infection to become microfilaraemic again. The reversible catalytic model is defined 
by the following differential equations (Vanamail et al., 1989): 
dU 
-=-aU+bI 
dt 
dl 
-=aU-bI 
dt 
1.1 
1.2 
Where U is the number of uninfected (amicrofilaraemic) and 1 of infected 
(microfilaraemic) individuals of age t, a is the per capita rate of infection and b the per 
capita loss of infection rate. 
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The solution to this equation, assuming that no one is initially infected and that a 
and b are constant with host age is: 
let) = _a_Ir _ e-(a+b)f) 
a+b~ 1.3 
Hairston and Jalowski (1968) applied this model to cross-sectional data and 
thereby estimated average life-span of adult worms and worm burden. This same 
reversib1e catalytic modei was Iater app1ied by Vanamail et al. (1989) to longitudinal data 
from Pondicherry, India. This work indicated that the 10ss of infection is independent of 
age. However, the gain of infection displays a convex age-profile, increasing in the early 
age classes unti116-20 years and then stabilizing and declining. This ana1ysis provides 
sorne evidence of acquired immunity acting against worm establishment in LF. 
Michael and Bundy (1998) applied the two stage catalytic model and found that 
observed infection patterns in India are consistent with the assumption that there is herd 
immunity, and that this immunity is stronger and occurs earlier in are as where 
transmission is higher. 
Other theoreticai models have examined the relationship between prevalence and 
microfi1aria1 intensity offilaria1 infections. Grenfell et al. (1990) modelled the 
relationship between macrofi1arial prevalence and microfilariai burdens and found that 
most amicrofi1araemics are true negatives that arise from the absence of microfilariae or 
from single sex infections. Das et al (1990) fitted a zero-truncated negative binomial 
distribution to W bancrofti microfi1aria1 counts of different age groups, and found that 
there was a significant decrease in overdispersion with age ab ove age 10, providing 
indirect evidence for density-dependence acting on microfi1aria1 intensity in the host. 
However a simi1ar study in B.malayi did not observe such an effect (Srividya et al., 
1991a). 
There have also been mathematicai modeis that investigate the dynamics of 
disease in 1ymphatic fi1ariasis, in order to determine the re1ationship between 
lymphoedema and microfilaraemia. These models indicate a progression from uninfected, 
microfilaraemia, amicrofilaraemic to irreversible Iymphatic pathology (Bundy et al., 
1991; Srividya et al., 1991b). Recently, a model examining transmission intensity, 
immunoepidemio10gy and disease indicated that the per capita rate of chronic disease 
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may increase with transmission intensity (Michael et al., 2001). 
Much attention has also been given to modeling the transmission dynamics of 
lymphatic filariasis. It has been shown through laboratory studies, that the uptake of 
microfilariae from the ho st by the mosquito vector depends on the density and 
distribution ofmicrofilariae in the host (Subramanian et al., 1998). The relationship 
between microfilaraemia and uptake has been shown to be non-linear and saturating in 
sorne studies (Bryan and Southgate, 1988; McGreevy etaI., 1982; Subramanian et al., 
1998), though linear in others (Jayasekera et al., 1991; Lowrie et al., 1989). A meta-
analysis by Snowand Michael (2002) attributes these divergent findings to differences in 
study design. These authors found that, though aIl genera of vectors displayed density 
dependence in MF uptake, the point at which saturation was reached was significantly 
higher for Culex. 
L3 development in the vector from an ingested blood meal may follow three 
possible relationships: proportionality (a constant ratio between MF and L3), limitation (a 
decrease in this ratio with increasing MF) or facilitation (an increase in this ratio with 
increasing MF) (Southgate and Bryan, 1992). Limitation has been observed in sorne 
Aedes spp. (Pichon, 2002) and in Culex that transmit W bancrofti (Southgate, 1992; 
Southgate and Bryan, 1992; Subramanian et al., 1998). Proportionality has been found to 
occur in Mansonia and Aedes, whereas facilitation was observed in Anopheles 
(Southgate and Bryan, 1992). Limitation may in part be due to parasite-induced vector 
mortality, which has been shown in a number of analyses (McGreevy et al., 1982; 
Samarawickrema and Laurence, 1978; Zielke, 1977). This process leads to a more 
efficient transmission at low microfilarial densities and thus makes interruption of 
transmission through LF control inherently more difficult (Duerr et al., 2005; Pichon, 
2002). It has been suggested that facilitation processes lead to unstable transmission due 
to the presence of "breakpoints" below which the infection can no longer persist (Duerr et 
al.,2005). However, this concept has been questioned by others (Wada et al., 1995). 
Recently, Stolk et al. (2004) argued that in mathematical models, the relationship 
between microfilarial intensity in the patient and the number of L3 developing from a 
blood meal is more accurately modeled by a hyperbolic saturating function than by a 
linearized power curve. 
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1.8.2 Simulation Models 
ln addition to the ab ove analytical models, there has also been sorne effort to 
produce simulation models. These models go beyond the previously described 
prevalence models and explore adult and larval dynamics of Culex transmitted W 
bancrofti. 
Two simulation models have been developed. L YMF ASYM is a stochastic micro 
simulation model which is individual based, and thus each individual is tracked through 
time (Plaisier et al., 1998). This model is a result of a collaboration between the Vector 
Control Research Centre in Pondicherry and the Department of Public Health, Erasmus 
University in Rotterdam (Das and Subramanian, 2002). As it is a micro-simulation 
model, L YMF ASIM may consider variations in the human population (such as age, sex, 
exposure to mosquitoes, immune responsiveness) and in the parasites (adult life-span, 
reproduction). 
L YMF ASIM has recently been quantified using data from Pondicherry, collected 
between 1981 and 1985. This work compared different assumptions about acquired 
immunityand found that the model fitted the data best when anti L3 or anti-fecundity 
immunitywas assumed. The mean life-span of the parasite was estimated to be about 10 
years using LYMFASIM (Subramanian et al., 2004). This model has also been used to 
make predictions by simulating different control programs. When a community 
representative ofPondicherry, India was used, the simulation predicted that 8 yearly 
treatments at 65% coverage gave a 99% probability of elimination (Stolk et al., 2003). It 
was also shown that the benefit of vector control in terms of a reduction in MF 
prevalence outIasts the cessation ofthe control method (Subramanian et al., 2004). 
Another prediction, based on preliminary data, was that at least 90% coverage will be 
required in order to reach the goal of elimination within 5 years using DEC-based mass 
drug administration (Das and Subramanian, 2002). 
EPIFIL is a deterministic macro-simulation model which incorporates sorne 
probabilistic elements to describe vector transmission dynamics and also incorporates 
host age structure (Chan et al., 1999; Chan et al., 1998; Norman et al., 2000). This 
model is a resuIt of a collaboration between the Vector Control Research Centre in 
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Pondicherry and the Department of Parasite Epidemiology, Oxford University, Oxford 
(Das and Subramanian, 2002). It consists of a set of differential equations and initially 
described changes by age in worm burden, intensity in microfilaraemia, immunity and 
prevalence oflymphatic damage, lymphoedema and hydrocoel. It was fitted to 
epidemiological data collected in Pondicherry. It predicts that both hydrocoel and 
lymphoedema are irreversible and develop due to lymphatic damage produced by adult 
worms (Chan et al., 1998). The EPIFIL model was then extended to explicitly 
incorporate host age structure and vector transmission dynamics (Norman et al., 2000). 
The type of framework used in this model was first proposed by Anderson and May 
(1985). It has previously been used to model schistosomiasis (Chan et al., 1995). 
EPIFIL predicts that chemotherapy has a larger short-term effect than vector control, but 
that, like predictions made with LYMFASIM, benefits ofvector control may last beyond 
the treatment period. It also predicts that DEC is the most effective drug in reducing 
community microfilarialloads (Norman et al., 2000). In a recent review, Michael et al 
(2004) stated that predictions using EPIFIL suggested that the proposed 6 year time frame 
for disease elimination is unlikely to be achieved in areas ofmoderate and high 
transmission. They suggest that the achievement of such goals would require the 
incorporation ofvector control methods. They also conc1ude that high coverage will 
have to be maintained in order for the elimination pro gram to be successful. EPIFIL is 
now available as a free resource for health workers in operational settings (Chan et al., 
1999). 
1.8.3 Mathematical Models ofDrug Resistance 
The use of computer or mathematical models to examine the evolution and 
behaviour of drug resistance is extremely useful in order to examine the interaction of 
many different factors (Bames and Dobson, 1990). Often field experiments in drug 
resistance are expensive and technically difficult to carry out. Furthermore, a 
mathematical or computer model facilitates altering conditions and factors involved in 
producing different outcomes. 
Models that examine the development of drug resistance have been developed for 
a number ofparasites (Bames et al., 1995; Hastings and D'Alessandro, 2000). Antibiotic 
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resistance models are generally purely epidemiological models. Due to sexual 
reproduction ofhelminths, models examining anthelmintic resistance are based on 
population genetics and tend to follow individual genes (Hastings, 2001). In 1990, two 
models for anthelmintic resistance were developed. A computer model examining the 
spread of resistance, in the sheep parasite Trichostrongylus colubriformis considers 
factors such as sheep management and anthelmintic delivery in a simple model that 
allows for three anthelmintic resistance genes (Bames and Dobson, 1990). This model 
has been used to explore factors such as treatment rotations, treatment combinations and 
treatment with persistent drugs (Bames, 1995; Dobson et al., 1996). From this model, it 
was derived that resistance developed more quickly when two genes were involved than 
when a single gene conferred resistance (Barnes, 1995). Ifthis gene was dominant, 
resistance developed more quickly than if it was recessive. Interestingly, the model also 
predicted that a drug which remains in the host for a long time-period at low levels is 
more likely to lead to resistance (Dobson et al., 1996). A second general model 
applicable to direct life-cycle parasites considers one resistance gene with two alle1es and 
examines different anthelmintic treatment strategies (Smith, 1990). More complex 
deterministic and stochastic models for the evolution of anthelmintic resistance in 
trichostongylids were later developed (Smith et al., 1999). These models predict that 
host immunity, fecundity and aggregation have an important impact on the development 
of resistance. 
The impact of spatial heterogeneity and metapopulation dynamics oftransmission 
on the spread of drug resistance has been examined more recently, using stochastic 
models. These works predict that rare recessive alleles may spread through overdispersed 
parasite populations more rapidly than initially anticipated (Comell et al., 2000; Comell 
et al., 2003). 
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Abstract 
The Global Pro gram to Eliminate Lymphatic Filariasis has been implemented to reduce 
human microfilaraemia to levels low enough to break the transmission of the disease, 
using single annual doses of albendazole in combination with diethylcarbamazine or 
ivermectin. Many veterinary helminth parasites have developed resistance against both 
, 
albendazole and ivermectin. Resistance to albendazole in veterinary nematodes is known 
to be caused by either of two single amino acid substitutions from phenylalanine to 
tyrosine in parasite p-tubulin at position 167 or 200. We have developed assays capable 
of detecting these single nuc1eotide polymorphisms (SNPs) in Wuchereria bancrofti, and 
have applied them to microfilariae obtained from patients in Ghana and Burkina Faso. 
One of the SNPs was found in untreated populations of worms from both locations. 
Worms from treated patients had significantly higher frequencies of these mutations. 
These findings indicate that a p-tubulin allele associated with benzimidazole resistance is 
being selected for in these populations. 
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2.1. Introduction 
The Global Alliance to Eliminate Lymphatic Filariasis relies on chemotherapy 
with the anthelmintic albendazole in combination with ivermectin or diethylcarbamazine 
to block transmission of the main causative agent oflymphatic filariasis, Wuchereria 
Bancrofti (WHO, 1999). Avermectins and benzimidazoles have been used extensively 
in veterinary medicine, and this has led to high levels of drug resistance (Prichard, 1990). 
Though resistance against anthelmintics has not yet impeded the treatment ofhuman 
helminth infections (Coles, 1999), the development of drug resistance has had an adverse 
impact on the control of other parasites, such as Plasmodium falciparum (Krogstad et al., 
1987). The development of drug resistance in the lymphatic filariae could severely 
compromise the international control pro gram, which will involve an estimated 350 
million people. 
The mode of action ofbenzimidazoles was found to be their interference with 
tubulin polymerization into microtubules, by binding to p-tubulin (Friedman and Platzer, 
1978; Kohler and Bachmann, 1981; Lubega and Prichard, 1990). Resistance against 
benzimidazoles in a number of nematode species has been shown to be caused by a 
phenylalanine (TTT/TTC) to tyrosine (TAT/TAC) substitution at either position 167 or 
200 ofnematode P-tubulin (Driscoll et al., 1989; Elard et al., 1996, Elard and Humbert, 
1999; Kwa et al., 1993a; Kwa et al., 1993b; Pape et al., 1999; Prichard, 2001; Silvestre 
and Cabaret, 2002; von Samson-Himme1stjerna et al., 2001). The position 200-tyrosine 
mutation appears to be more common in parasitic nematodes and was found to be 
recessive (Elard and Humbert, 1999; Silvestre and Cabaret, 2002). Resistance to 
benzimidazoles was also found to be associated with 200Tyr or 167Tyr substitutions in 
normally benzimidazole susceptible fungi (Jung et al., 1992; Koenraadt et al., 1992; 
Orbach et al., 1986; Yarden and Katan, 1993) and the 200Tyr mutation in p-tubu1in was 
also found in benzimidazole-resistant strains ofprotozoa (Edlind et al., 1994). However, 
the position 200 mutation was not found in Necator americanus hookworms from Pembla 
Island in which possible benzimidazole-resistance was suspected (Albonico et al., 2004). 
Eukaryotes which normally code for tyrosine at codon 200 appear to be uniformly 
benzimidazole tolerant. Phenylalanine at codons 167 and 200 appears to be critical for 
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the high affinity binding ofbenzimidazole anthelmintics to nematode tubulin and for 
sensitivity to these anthelmintics (Prichard, 1990). 
In a study carried out in India (Hoti et al., 2003), pooled W bancrofti 
microfilariae from 14 patients from 5 geographical regions were sequenced in order to 
detect the codon 200 resistance mutation. The consensus sequences of the 14 pooled 
samples failed to show the codon 200 resistance mutation. However, sequencing the 
pooled samples would not have shown the mutation unless it was abundant, since 
sequencing pooled DNA samples is not a sensitive tool for the detection of rare SNPs. 
The sequencing result of a pooled sample will show the most abundant sequence. 
The objectives ofthis study were to assess whether mutations associated with 
benzimidazole-resistance, in other nematodes, are present in W bancrofti, to examine 
their frequency in untreated populations from Ghana and Burkina Faso and to determine 
their frequency in microfilariae obtained from patients treated with albendazole and 
ivermectin. 
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2.2. Materials and Methods 
The study and microfilarial collections were approved by the McGill University, 
Faculty of Medicine Institutional Review Board, the Noguchi Memorial Institute for 
Medical Research Insitutional Review Board, Ghana and the Ministry of Health, Burkina 
Faso. Informed consent was obtained from all human participants. 
2.2.1 Amplification of B. malayi and W. bancrofti /3-tubulin. 
Primers were designed, based on the Brugia pahangi /3-tubulin sequence -
Accession No. M36380, in order to amplify the fulliength B-tubulin cDNA from B. 
malayi. Total RNA was extracted from bulk adult worms (obtained from NIAID, NIH, 
Bethesda Maryland), using TRIzol reagent and methods described by the manufacturer 
(Invitrogen, Ontario, Canada). Total RNA was reverse transcribed with the adaptor 
primer (5'-3')GGC CAC GCG TCG ACT AGT AC(T)17 and 200 U ofmurine moloney 
leukemia virus reverse transciptase (M -ML V, Invitrogen) according to the manufacturers 
instructions. cDNA was used to amplify a fragment of B -tubulin, using a reaction 
containing 2.5 /-LI10x PCR Buffer (200 rnMTris-HCl pH 8.4,500 mM KCI), 1 /-LI of 
MgClz [50 /-LM], 0.5 /-LI each ofprimers, sense (5'-3') GGT ACC ATG GAT TCT ATT 
CG (A Y705382 position 211-230) and antisense (5' -3 ') GAT CGG CGT TCA ACT 
GTC CA (position 729-748) at a concentration of 12.5 /-LM, lU Taq polyrnerase, 1 /-LI 
dNTP (10 /-LM), and sterile HzO up to 25 /-LI. The amplification conditions were 2 min at 
94°C, followed by 30 cycles at 94°C for 55 sec, 55°C for 55 sec and 72°C for 55 sec and 
a final extension at 72°C for 10 min. The fulliength sequence was obtained using a 3' 
RACE (rapid amplification of cDNA ends) procedure. Briefly,5 /-LI of cDNA was 
arnplified in a nested reaction containing 2.5 /-LI10x PCR Buffer (200 rnMTris-HCI pH 
8.4,500 mM KCI), 1.5 /-LI ofMgClz [50 /-LM], 0.5 /-LI each ofthe sense primers (5'-3') 
GGC AAA TAT GTG CCA CGA GC (position 169-188) and (5'-3') GGT ACC ATG 
GAT TCT ATT CG (position 211-230) at a concentration of 20 /-LM, 1 U Taq polyrnerase, 
1 /-LI dNTP [10 /-LM], and sterile HzO up to 25 /-LI. The amplification conditions for both 
steps were 2 min at 94°C, followed by 40 cycles at 94°C for 30 sec, 56°C for 30 sec and 
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72°C for 1 min 15 sec and a final extension at 72°C for 10 min. The 5'end of the gene 
was amplified using the same conditions as the 3 'RACE, however with different primers: 
the sense primer, which corresponded to the nematode splice leader sequence SL1 (5'-3') 
GGT TTA ATT ACC AAG TTT GAG, and the antisense primers (5'-3') AGG GCT 
CGA TAA GCA GCA GC (position 832-851) and (5'-3') GAT CGG CGT TCA ACT 
GTC CA (position 729-748). The resulting fragments were cloned into a pCR 2.1 vector 
using a TA-cloning kit (Invitrogen), as per the manufacturer's instructions and sequenced 
with a Beckman CEQ DNA Sequencer. 
Primers to amplify genomic DNA from W. bancroftiwere designed based on the 
fulliength B. malayi 0- tubulin cDNA, in order to PCR amplify a region surrounding the 
mutations to be diagnosed from W. bancrofti microfilariae, in a reaction containing 2.5 /-LI 
10x PCRBuffer, 1 /-LI ofMgClz [50 /-LM], 0.5 /-LI each of the primers, sense (5'-3') GGC 
AAA TAT GTG CCA CGA GC (AY705382 position 169-188) and (5'-3') AGG GCT 
CGA TAA GCA GCA GC (AY705382 position 832-851) at a concentration of 12.5 /-LM, 
1 U Taq polymerase, 1 /-LI dNTP [1 O/-LM)), and sterile H20 to make 25 /-LI. The 
amplification conditions were 2 min at 94°C, followed by 30 cycles at 94°C for 55s, 55°C 
for 55s and 72°C for 55s and a final extension at 72°C for 10 min. AlI reactions were 
carried out on an MJ-Research Inc. PTC-200 Thermal Cycler. Resulting fragments were 
cloned and sequenced as above. 
2.2.2 Diagnosis of Resistance Associated Mutations in W. bancrofti. 
Blood samples (10 ml) containing microfilariae were transferred to centrifuge 
tubes and centrifuged at 4°C and 1100 rpm (300 x g) for 10 minutes. The pellet was re-
suspended in 25 ml red blood celllysis solution, incubated on ice for 10 minutes, and 
centrifuged again as above. The final pellet was re-suspended in 1.5 ml 70% isopropyl 
alcohol. To separate individual worms, a small amount of the sample was transferred to a 
small Petri dish. Single microfilariae were washed in 70% ethano1, separated into 
individu al PCR-microcentrifuge tubes using a micropipette, under an inverted 
microscope and identified visually as W. bancrofti. DNA extraction was carried out 
directly in the PCR tube using the Qiagen® DNeasy tissue kit at one quarter the 
recommended volume and following the manufacturer's instructions. 
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In order to detect mutations using a pyrosequencer, a smaller fragment 
surrounding the SNPs was amplified using microfilarial DNA or, when DNA content was 
small, the product of the PCR-amplification above was used as a template. The reaction 
contained 5 !l110x PCR Buffer, 2 !lI ofMgCb [50 !lM], 0.5 !lI each ofprimers, sense (5'-
3') GGG AAC ATT GCT GAT CTC GAA (AY705383 position 308-328) and antisense 
(5'-3') GGA AGC AGA TGT CAT ACA AAG CC (AY705383 position 672-694) at a 
concentration of20 !lM, lU Taq polymerase, 2 !lI dNTP [lO!lM], and sterile H20 to 
make 50 !lI. The second primer had biotin attached to its 3' end, in order to generate 
single stranded template using streptavidin beads. The amplification conditions were 2 
min at 94°C, followed by 40 cycles at 94°C for 15 s,55°C for 30s and 72°C for 30s and a 
final extension at 72°C for 10 min. The sequencing primers used for SNP analysis in the 
Pyrosequencer® were (5'-3') CGG ATC GAA TTA TGA GCT CT (position 346-365) 
for position 167 and (5'-3') GAA AAC ACT GAC GAA ACT T (position 637-655) for 
position 200. 
Real time diagnosis of mutations at position 200 and 167 was done in a single 
reaction in a Roche Light Cycler®. The reaction contained 1.6 !lI MgCb [25 !lM], OA!ll 
each of the primers, sense (5'-3') GGT ACC ATG GAT TCT ATT CG (AY705383 
position 1-20) and antisense (5'-3') GAT CGG CGT TCA ACT GTC CA (position 907-
926) at a concentration of 12.5 !lM, 0.2!l1 each of the probes 5'-CCGTGAGGAGTATCC 
GGATCGAATTATG (fluorescine)-3' (position 332-359) and 5'-(LC Red 640 )CTC 
TTT TTC GGT TGT GCC GTC G (phosphate)-3'(position 362-382) for position 167 and 
S'-ACT TTC TGC ATT GAT AAC GAG GC (fluorescine)-3' (position 652-674) and 5'-
(LC Red 705) TGT ATG ACA TCT GCT TCC GAA CGT (phosphate)-3' (position 677-
700) for position 200 at a concentration of20 !lM. The conditions were 20 s at 95°C and 
20 °CI s, followed by 40 cycles at 95°C for 10 sand 20 °CI s,55°C for 10 s and 20 °CI s 
and 72°C for 40 sand 20 °CI s, a melting step from 50°C to 80°C at 20 °CI s and a final 
cooling step to 40°C. Melting temperatures for the position 200 probes are 67 oC for the 
wild type gene and 63 oC for the mutant. Melting temperatures for the position 167 
probes are 63°C for the wild type gene and 58. 5°C for the mutant. 
Both diagnostic tests were optimized with a plasmid containing the wild type gene 
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and plasmids containing the mutation(s), generated by site-directed mutagenesis, using 
the QuickChange kit (Stratagene, LaJolla, USA) and the following mutagenesis primers: 
sense (5'-3') ATG AGC TCT TAT TCG GTT GTG CCG TCG (AY705383 position 
357-383 and antisense (5'-3') ACA ACC GAA TAA GAG CTC ATA ATT CG 
(position 351-377) for the mutation at codon 167, and sense (5'-3') CGA AAC TTA CTG 
CATT GAT AAC G (position 648-670) and antisense (5'-3) CGT TAT CAA TGC AGT 
AAG TTT CG (position 648-670) for the mutation at codon 200, following the 
manufacturer' s instructions. 
2.2.3 Experimental Design and Statistical Analyses. 
Microfilariae from patients infected with W bancrofti were collected from 
Burkina Faso and Ghana, West Africa. Treatment programs for lymphatic filariasis have 
been instituted in communities in Ghana and Burkina Faso and records and patient 
questionnaires were available to establish the treatment histories in the individuals 
sampled. We analyzed microfilariae from patients before treatment, after one round of 
treatment and after two rounds of treatment with 400 mg albendazole and 200 I-lg/kg 
ivermectin. In the samples obtained from Burkina Faso, five to fifteen microfilariae per 
patient were genotyped. Microfilariae from Ghana were obtained as pooled samples from 
several patients. Two pooled samples were obtained that had been collected at different 
times in 2001. These two samples were treated separately, as they were sampled from 
different populations. A Chi-square test was used to detect significant differences in 
genotype frequencies and in allele frequencies between the three treatment groups within 
each country. It was determined whether genotype frequencies of the whole population 
and within each patient were in Hardy-Weinberg equilibrium using a Chi-square analysis 
to compare observed and expected values. 
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2.3. Results 
We had access to fresh Brugia malayi which permitted us to extract high quality 
RNA and generate a fulliength ~-tubulin cDNA (Accession No. AY705382). The high 
sequence homology between B. malayi and W. bancrofti allowed us to design primers, 
based on the B. malayi sequence, in order to clone and sequence a partial genomic 
sequence of W bancrofti ~-tubulin containing the regions coding for both amino acid 
167 and 200 (Accession No. AY705383). Only one isotype of ~-tubulin was detected. 
Based on these sequences, two diagnostic tests for mutations at positions 167 and 200 of 
~-tubulin of W bancrofti were developed. The first assay was developed on a 
Pyrosequencer. This technique is able to sequence short fragments ofDNA very rapidly; 
the Pyrosequencer can process 96 samples in under 1 hour and the results are reliable and 
easy to interpret. A second test made use of FRET (fluorescence resonance energy 
transfer) probes and melting point analysis for mutation detection on a Roche Light-
Cycler. This test is able to identify both mutations in a single Light Cycler reaction. 
Both assays are capable of genotyping single microfilariae. We evaluated these tests with 
the help of several plasmids. These plasmids contained either the wild-type ~-tubulin 
gene, or the ~-tubulin gene containing the position 167 or the position 200 mutations 
introduced by site-directed mutagenesis. Absence/presence of the mutations was verified 
by sequencing. Though the FRET assay is not as quick and easy to perform as the 
Pyroquencer assay, it is more accessible for large-sc ale use, since real-time PCR 
technology is now available in many research facilities. 
We obtained several hundred microfilariae from Ghana and Burkina Faso. The 
Ghanaian samples consisted of LF microfilariae from patients that had not been treated 
with albendazole and ivermectin as part of the Global Alliance to Eliminate Lymphatic 
Filariasis. The blood samples containing Wuchereria bancrofti collected in Burkina Faso, 
came from either untreated patients or patients treated once or twice with albendazole and 
ivermectin. Samples were taken at least seven days after the last anthelmintic treatment. 
Microfilaraemia was low in the treated patients, although the patients were still 
microfilaria positive despite recent treatment. The first two batches of microfilariae from 
Ghana were analyzed using the FRET assay. We were able to identify several 
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microfilariae that had the position 200 tyrosine genotype. The frequency ofthe mutant 
allele in the first group of 130 microfilariae was 2.7%. The frequency of the mutant 
allele in the second group of 300 microfilariae was 0.33% (Table 2.1). Because of a lack 
of information regarding the size of the human population from which the microfilariae 
were pooled, we cannot make a reliable estimate of the frequency of these resistance 
associated mutations in the entire parasite population. However, these findings indicate 
that the allele, which potentially causes albendazole resistance, is present in the 
population prior ta treatment with albendazole. This suggests that with the advent of the 
mass treatment pro gram in Ghana, selection for this allele in the population could occur. 
Table 2.1: Frequencies of Codon 200 genotypes in ~-tubulin in two populations of W 
bancrofti from Ghana. F = phenylalanine, Y = tyrosine. Homozygous FF and 
heterozygous YF have been associated with a benzimidazole-susceptibility phenotype 
and homozygous YY has been associated with a benzimidazole-resistance phenotype. 
Total Y is the allele frequency of the resistance-associated allele in the population. 
Group 1 , n= 130, Group 2, n = 300. 
FF (%) FY(%) YY(%) Total Y (%) 
Group 1 96.15 1.54 2.31 2.69 
Group 2 99.67 o 0.33 0.33 
We have also analyzed a total of 400 microfilariae from 48 patients residing in the 
villages of Gara, Perigban, Bandongo and Tangonko, Burkina Faso. Thirty of these 
patients had not received any treatment for lymphatic filariasis, 14 had received one 
round of treatment with 400 mg of albendazole in combination with 200 Ilg/kg ivermectin. 
Four patients had received two yearly doses of the same treatment combination. 
Microfilarial counts obtained from these villages are found in Table 2.2. The 
microfilarial counts from the patients treated twice were taken 7 days after treatment. 
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Table 2.2: Microfilariallevels in patients from four villages in Burkina Faso. 
"n" is the sample size, MF is microfilariae , and range is the difference between the 
highest and lowest counts. 
Village Treatment history n Geometric Mean Range 
MF/ml 
Tangonko Untreated 16 15091 27050 
Bandongo Untreated 14 7674 39250 
Gora Treated once 1 9300 0 
Treated twice 4 964 350 
Perigban Treated once 13 1608 262 
U sing the Pyrosequencer, we found the resistance associated mutation at position 
200 at an allele frequency of26.2% in the untreated population. In the microfilariae 
from patients treated once, the allele frequency ofthis mutation was 60.2%; and in worms 
from patients treated twice, the allele frequency was 86.2 %. These allele frequencies 
were significantly different using Chi-square analysis (Che = 139.8). The genotype 
frequencies for all three groups from Burkina Faso were as follows (Fig. 2.1). Worms 
from untreated patients were 63% homozygous wild type (200pheI200phe), 21.5% 
heterozygous (200pheI200tyr) and 15.5% homozygous for the resistance mutation 
(200tyrI200tyr). Microfilariae from patients treated once were 26.3% homozygous wild 
type, 27.1 % heterozygous and 46.6% homozygous for the resistance mutation. 
Microfilariae from patients treated twice were 0% homozygous wild type, 13.8% 
heterozygous and 86.2% homozygous for the resistance mutation. AlI genotype 
frequencies were significantly different using Chi-square analysis (Fig. 2.1). A resistance 
mutation was not detected at codon 167. 
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Figure 2.1: Genotype frequencies of ~-tubulin codon 200 of W bancrofti Burkina Faso, 
before and after treatment with albendazolelivermectin. 
Genotype frequencies (YY = homozygous 200tyr; YF = heterozygous 
200tyr/200phe; FF = homozygous 200phe) for different treatment groups were 
significantly different from each other at p = 0.001 (Chi2 = 106.5). YY is 
associated with a resistance phenotype, YF and FF code for the susceptibility 
phenotype. Untreated, n = 246, treated once, n = 118, treated twice, n = 36. 
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2.4. Discussion 
These results of this study indicate that the resistance associated mutation at 
codon 200 was present in the populations of W bancrofti sampled, especially those from 
Burkina Faso, at a reasonably high frequency even before the mass treatment pro gram 
had been initiated. It has been found that alle1es associated with benzimidazole resistance 
in Haemonchus contortus were found in an unselected population at an alle1e frequency 
of 46% (Beèch et al., 1994), indicating that such resistance alle1es may commonly be in 
the population prior to drug treatment at re1ative1y high frequencies. However, it must be 
taken into consideration that benzimidazole resistance is recessive and that albendazole or 
mebendazole are common treatments for intestinal helminths, and yearly deworming of 
schoolchildren is common in many parts of West Africa (Hall et al., 1996). Thus, 
parasites may have been exposed to benzimidazoles in the past, and sorne selection for 
the 200 tyrosine mutation may have occurred prior to the onset of the mass treatment 
program. 
We show here that there was a significantly higher alle1e frequency of the 200 
tyrosine genotype in worms collected from patients that had been treated with 
albendazole in combination with ivermectin. This indicates that this mutation may be 
selected for with drug treatment. The total allele frequency was 31.6% higher in the 
treated versus the non-treated worm population. In worms collected from patients that 
had been exposed to two rounds of albendazole/ivermectin treatment, the allele frequency 
was an additionaI25.9% higher. Such selection is a strong indication ofthe development 
of drug resistance. Because pre-treatment microfilarial counts were not taken, we cannot 
make conclusions about the success oftreatment. However, it was only those 
microfilariae that were still present in the treated patients after treatment which were 
genotyped. In the case ofthe patients treated twice, the microfilariae were harvested 
seven days after their last treatment and could therefore represent a population of 
microfilarial survivors of treatment or progeny of adult worms which were able to 
maintain microfilarial production despite treatment. 
In sorne parasitic nematodes a second p-tubulin gene appears to be present 
(Geary et al., 1992; Guenette et al., 1992), which may contribute to benzimidazole 
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sensitivity and resistance (Beech et al., 1994). We did not detect a second p-tubu1in 
isotype in W bancrofti. However, ifpresent, it cou1d contribute to maintaining 
susceptibility to albendazole. 
It must also be noted that this was not a prospective study, but that parasites from 
different treatment groups were collected from different patients residing in separate 
villages. We can therefore not mIe out natural genetic variation, which may occur 
between populations, being responsible for the differences in polyrnorphism between the 
treated and untreated populations. 
We tested whether alleles of this gene were in Hardy-Weinberg equilibrium. 
When considering aIl worms in a treatment group (including untreated patients) as part of 
one population, the frequencies were not in balance, but showed an excess of 
homozygotes. When considering aIl worms sarnpled from an individual patient as being 
one population, the sum of the resulting allele frequencies. from aIl patients was in Hardy-
Weinberg equilibrium. The resistant-associated allele appeared to be aggregated within 
certain patients, rather than evenly distributed throughout the population. This result may 
be due to the fact that random mating does not occur between worms in different hosts. 
An excess of homozygotes may strongly accelerate selection for resistance, since it is 
believed to be a completely recessive trait (Elard et al., 1996), thus a larger proportion of 
the 200tyr as homozygotes could lead to a greater proportion of treatment failures. 
Combination treatment with ivermectin and albendazole could be expected to 
reduce the rate of selection for resistance to either of these anthelmintics, provided that 
the resistance mechanisms involve different genes. However, it has recently been found 
that ivermectin selects on p-tubulin in the filarial nematode Onchocerca volvulus (Eng 
and Prichard, 2005). Although ivermectin selection is not associated with the phe200tyr 
SNP examined here, selection by the two anthelmintics can involve the same gene, thus 
there could be linkage between the region implicated in ivermectin selection and possible 
albendazole selection for the phe200tyr SNP which could modify the rate of selection for 
albendazole resistance. The implications of combination treatment on genetic selection 
need to be examined in future studies. 
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Based on these findings, it is imperative to continue monitoring for the presence 
of this mutation, in other treatment zones, in order to detect early evidence of possible 
resistance selection and to correlate this with responses to treatment. 
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CONNECTING STATEMENT 1: 
In Chapter 2 of this thesis we present evidence that mutations known to cause 
benzimidazole resistance were present in microfilariae of W bancrofti, and that the 
frequency of these mutations was higher in worms obtained from patients that had been 
treated with ABZ and IVM. This suggests that resistance may be developing and could 
pose a threat to the CUITent international control pro gram. The GPELF is implementing 
large-scale treatment programs that have the potential to exert strong selection pressure 
for resistance alleles. However it is not known how resistance alleles may spread through 
populations of W bancrofti and how epidemiological factors, as well as CUITent treatment 
strategies, will impact selection for resistance. In the following chapter we present a 
mathematical model that incorporates population genetics into an epidemiological model 
of W bancrofti in order to further analyze the mechanisms and relative importance of 
factors involved in the spread of drug-resistance through populations of lymphatic filaria, 
due to the CUITent combination treatment strategies applied by the GPELF. Due to the 
differences in initial allele frequencies for the putative ABZ resistance mutation, between 
populations sampled in Burkina Faso (26%) and Ghana (2.6%,0.33%), for the purpose of 
the model, we have assumed that initial resistance-allele frequencies to be 5%. 
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CHAPTER3: 
AN ANALYSIS OF THE POPULATION GENETICS OF 
POTENTIAL ALBENDAZOLE RESISTANCE IN LYMPHATIC 
FILARIASIS DUE TO COMBINATION CHEMOTHERAPY 
Schwab A.E., ChurcherT.S., Schwab A.l, Basanez, M-G., Prichard R.K. 
Parasitology (2006), 133(5):589-601 
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Abstract 
The Global Program for the Elimination of Lymphatic Filariasis (GPELF) intends to 
achieve its aims through yearly mass treatments with albendazole (ABZ) combined with 
ivermectin (IVM) or diethy1carbamazine (DEC). The use of ABZ and IVM separately to 
combat parasites of veterinary importance has, on many occasions, resulted in widespread 
drug resistance. In order to help predict the spread of potential ABZ resistance alleles 
through a population of Wuchereria bancrofti, we have developed a mathematical model 
that incorporates population genetics into EPIFIL, a model which examines the 
transmission dynamics of the parasite. Our model considers the effect of the combined 
treatments on the frequency of a recessive allele, which conf ers ABZ resistance. The 
model predicts that after 10 yearly treatments with ABZ and DEC, 85% coverage and an 
initial resistance allele frequency of 5%, the frequency of the resistance genotype will 
increase from 0.25 to 12.7%. If non-random mating is assumed, the initial genotype 
frequency will be 2.34% and will increase to 62.7 %. ABZ and IVM combination 
treatment may lead to weaker selection for this genotype. Treatment coverage, initial 
allele frequencies and number of treatments also affect the rate of selection. 
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3.1. Introduction 
Lymphatic filariasis (LF) is a disease caused by a group oflymphatics-dwelling 
filarial nematodes transmitted by mosquito vectors which infect approximately 120 
million people in over 90 countries, and whose disease sequelae impose a severe 
economic and social burden on affected communities and individuals (Michael & Bundy, 
1997; Ramaiah et al., 1999; Zagaria & Savioli, 2002). Currently, a global public-private 
partnership, under the auspices ofthe World Health Organization (the Global Alliance for 
the Elimination of Lymphatic Filariasis), aims to e1iminate this disease as a public health 
problem within the next twenty years. It is hoped that this will be achieved by 
community-wide yearly mass treatment with the broad spectrum anthelmintic 
albendazole (ABZ) in combination with the well-known microfilaricide 
diethy1carbamazine (DEC) or ivermectin (IVM) (Dean, 2002; Maher & Ottesen, 2000; 
Ottesen, 2000, 2002; Zagaria & Savioli, 2002). Benzimidazoles and avermectins have 
been used extensively in veterinary medicine for over two decades, and this has led to the 
development of drug resistance to both types of compounds by many he1minth parasites 
affecting livestock (prichard, 1990; Prichard et al., 1980; Wolstenholme et al, 2004). 
Consequently, there is concem that lymphatic filarial nematodes in humans may also 
develop such drug resistance, as this could severely hamper the control programmes. 
There have already been sorne reports oftolerance to DEC by filarial parasites (Eberhard 
et al., 1988, 1991). Recently, we have shown that a mutation at position 200 of the f3-
tubulin gene, from phenylalanine to tyrosine (TYR200), known to cause benzimidazole 
resistance in veterinary parasites is present in populations of Wuchereria bancrofti from 
West Africa, and is significantly higher in treated than in non-treated populations 
(Schwab et al., 2005). Thus, selection for albendazole resistance may already be 
occurnng. 
Mathematical models can be invaluable in helping to understand parasite 
population dynamicsand predict the impact of chemotherapy on these dynamics 
(Anderson & May, 1982, 1985). Models aiding in the design and implementation of 
control programmes have been successfully used for the filarial nematode Onchocerca 
volvulus (Alley et al., 2001; Basanez & Ricardez-Esquinca, 2001; Habbema et al., 1992). 
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Simple analytical models have examined various aspects of LF transmission and 
disease dynamics (Grenfell et al., 1990; Grenfell & Michael, 1992; Hayashi, 1962; 
Michael & Bundy, 1998; Subramanian et al., 1989) by assuming equilibrium with respect 
to age or time and therefore exploring temporal dynamics or age infection profiles. 
EPIFIL is an age-structured, deterministic model which incorporates some probabilistic 
elements (the frequency distribution of the number ofmicrofilariae that will be 
transmitted to vectors) and describes changes in parasite population abundance with both 
age and time (Chan et al., 1998, 1999; Norman et al., 2000). Stochastic micro simulation 
models have also been developed [e.g. LYMFASIM (Plaisier et al., 1998)]. Both EPIFIL 
and L YMF ASIM models have beeli used to examine the effect of various control 
strategies based on different antiparasitic and antivectorial measures (Das & 
Subramanian, 2002; Michael et al., 2004; Stolk et al., 2003; Subramanian et al., 2004). 
In addition, EPIFIL is now available as a free resource for health workers in operational 
settings (Chan et al., 1999). However, neither ofthese models has so far been used to 
explore the spread of drug resistance, which requires incorporation of genetic structure 
into the parasite population (Anderson et al., 1989). 
One such model has been presented for the investigation of the spread of 
anthelmintic resistance in the sheep parasite Trichostrongylus colubriformes, considering 
various sheep management and anthelmintic delivery practices in a simple framework 
which includes up to three anthelmintic resistance genes, each with two alleles, 
associated with resistance to a single drug or to each of three drugs (Bames & Dobson, 
1990). A second, more general model applicable to direct life-cycle parasites, based on 
the simpler one locus-two alle1e system examines different anthelmintic treatment 
strategies (Smith, 1990). More complex, deterministic and stochastic models for the 
evolution of anthelmintic resistance in trichostrongylids (Smith et al., 1999) predict that 
host immunity, parasite fecundity and aggregation will have an important impact on the 
spread of resistance. More recently, the impact of spatial heterogeneity and 
metapopulation transmission dynamics on the spread of drug resistance has been 
examined using stochastic models (Comell et al., 2000, 2003). These models predict that 
rare recessive alle1es may spread through overdispersed parasite populations more rapidly 
than initially anticipated. 
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An excess of homozygotes for the TYR200 mutation was observed in a 
population of W bancrofti microfilariae from West Africa (Schwab et al., 2005). A 
preliminary analysis of these data indicates that excess homozygosity is equivalent to 
Wright' s hierarchical (inbreeding) F-statistic or FIT = 0.44 (measuring the degree of 
parasite inbreeding within individuals in the total host population; Churcher, 2006). 
Although the mechanisms generating this are unknown, an increased homozygosity will 
likely lead to a faster spread of recessive drug resistance. Here we describe a model that 
incorporates simple parasite population genetics into the transmission dynamics model 
EPIFIL in order to explore the consequences ofboth random and non-random parasite 
mating upon the evolution and spread of drug resistance in filarial parasites under the 
CUITent combination therapy treatment regimes. 
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3.2. Model Development 
3.2.1 Population Dynamics. 
The model described in this paper is based on EPIFIL, whose code is now 
publicly available (Chan et al., 1999; Norman et al., 2000). EPIFIL consists ofa system 
of partial differential equations which describe, with respect to time and host age, the 
rates of change of mean adult worm burden (W), mean microfilarial count per 20 III of 
. blood (M), mean numbers of L3 larvae per mosquito (L), and mean strength of acquired 
protective immunity by the human host (l). In EPIFIL, acquired immunity is assumed to 
depend solely on past experience to adult worms and to affect the establishment of L3 
larvae within the definitive host. Density dependence within the mosquito vector is 
represented by a saturating function of L3 output with increasing microfilarial input, and 
is influenced by an assumed negative binomial distribution of microfilariae in the human 
population (Norman et al., 2000). The equations ofthe EPIFIL model are reproduced in 
Appendix A. Parameters for EPIFIL are summarized in Table 3.1. 
3.2.1 Population Genetics. 
In order to model the spread of anthelmintic resistance through the parasite 
population, we have assumed that resistance to ABZ is associated with a single autosoma1 
locus with two alle1es S, r, with r, the recessive alle1e conferring resistance. Each ofthe 
EPIFIL equations, originally for homogeneous macrofilarial, microfilarial, and infective 
larvae populations, were structured into worms homozygotes and drug sensitive (with 
genotype SS), heterozygous drug-sensitive (Sr), and homozygous resistant (rr) (see 
Appendix B). We have assumed that there are no costs or trade-offs associated with 
resistance (e.g., resistant parasites may have a lower fecundity rate). Under 
chemotherapeutic pressure, the fitness of the resistant parasites is higher than that of the 
susceptible worms. 
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Table 3.1. Definition and values ofparameters used in the model. 
Parameter VaIne T and nnits Definition 
Â 10 month-1 biting rate per mosquito on human hosts 
Â(V/H) 5,760 month- I monthly biting rate per person 
g 0.37 proportion of mosquito bites made on microfilaraemic 
hosts that result in the mosquito acquiring infection 
p 0.047 initial proportion ofmicrofilariae per 20 ~l ofblood 
that once ingested bec orne infective larvae in the 
mosquito 
K 6 the maximum number of infective larvae produced 
per mosquito as microfilaraemia increases 
IP1 0.414 proportion of L3 leaving the mosquito during bite 
IP2 0.32 proportion of L3 entering ho st 
52 1.13 X 10-'1 proportion of L3 entering host that become adult 
worms 
f3 0.112 the severity of constraints on larval establishment 
effected by protective acquired immunity 
a 2 month-1 the rate of microfilarial production per worm per 20 
~l ofblood 
J1 0.0104 month-
1 per capita death rate of adult worms 
y 0.1 month-1 per capita death rate of microfilaria 
CT 5 month-1 per capita death rate of L3 larvae 
!1 0.005 month-1 rate of decay of protective immunity 
(value from Man-Suen Chan, pers. comm.) 
ka 0.0029 overdispersion parameters of the negative binomial 
k1 0.0236 microfilaria-1 distribution, with kb = ka + k!Mb as a function of 
treated (b=T) or untreated (b=U) microfilariae 
tparameter values are taken from Norman et al. (2000) for Culex-transmitted filariasis. 
We use these parameters in order to remain as close as possible to the EPIFIL model. 
However, our evidence for increased parasite homozygosity cornes from West African 
locations, where Anopheles- rather than Culex-transmitted filariasis prevails. 
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3.2.1.1 Random Mating. 
Initially, random mating was assumed and thus genotype distributions of 
microfilariae were calculated from those of adult worm populations by means of simple 
Mendelian genetics. In order to reflect treatment coverage, treated and untreated parasite 
populations were modelled separately. At the point of transmission, the respective 
contributions of each infective larval population (depending on coverage level) were 
introduced into the equations for adult worms. The model thus assumes that the same 
individuals are treated at each round. Total mean parasite loads are a combination of the 
three genotypes for the treated and untreated sections of the parasite populations, the 
latter in proportions depending on coverage. 
3.2.1.2 Non-random Mating. 
In order to examine the effect of non-random mating, we have included a 
parameter F in the equations to indicate deviation from Hardy-Weinberg equilibrium, as a 
crude way to incorporate increased homozygosity (see eqns. (B3.6) to (B3.8) of 
Appendix B). Wright's inbreeding Frr-statistic is a phenomenological rather than a 
mechanistic measure ofhomozygosity, and therefore does not explicitly describe the 
biological processes involved in producing an excess of homozygotes. By setting a fixed 
value for this parameter, the same adjustment factor for increased homozygosity is 
applied from generation to generation. The amount of excess homozygosity was 
calculated from a preliminary analysis of data obtained in Burkina Faso (Schwab et al., 
2005); a detailed description ofthis calculation and of the possible mechanisms 
generating homozygosity will be presented elsewhere. 
3.2.2 Drug Efficacy 
Assumptions on drug efficacy, measured as percentage ofworms (macro- and 
microfilariae) killed and female worms sterilized, were based on those made by Michael 
et al. (2004) and other published drug trials (Addiss et al., 1997; Dunyo et al., 2000; 
Ismail et al., 1998) and are summarized in Table 3.2. Treatment was modelled as 
instantaneous reductions in adult worms (macrofilaricidal effect), microfilarial 
populations (microfilaricidal effect), or female worm reproduction rate (sterilizing effect) 
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by the percentage efficacy following treatment. Sterilized females did not resume 
microfilarial production immediately but after a period of time specified for each drug 
(Table 3.2). (In Table 3.2 it is assumed that microfilaricidal efficacy for the ABZ + NM 
combination is higher than that of combinations containing DEC, but see Tisch et al., 
2005.) AlI model outcomes in this paper examine the effect often yearly treatments on 
the genotype distribution of the microfilariae (the stages more feasibly sampled for 
genetic analyses). 
Table 3.2. Drug efficacy assumptions (adapted from Michael et al., 2004) 
DEC alone IVM alone DEC andABZ NMandABZ 
Months without 3 9 9 9 
reproduction 
% Adults killed 30 10 55 35 
% Microfilariae 90 99 95 99 
killed 
Model code was written using the JSIM Immerical integration software from 
http://nsr.bioeng.washington.eduIPLN/Members/butterw /JSIMDOC 1.6/JSim Home.stx/v 
iew. DifferentiaI equations were solved using the Euler method. Prior to the initiation of 
control perturbations, parasite populations were assumed to be at endemic equilibrium. 
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3.3. Results 
We have examined different factors affecting the spread of anthelmintic resistance 
in W bancrofti. Two different treatment regimes are currently used in the LF control 
programme. ABZ and DEC are used in most are as of the world though in parts of Africa, 
where onchocerciasis is co-endemic, DEC cannot be used and patients are treated with 
ABZ and IVM. We have examined the effect ofboth ofthese treatment regimes on the 
spread of ABZ resistance. Results of this analysis can be seen in Fig. 3.1. Fig. 3.1 a 
shows the genotype frequency of the recessive, resistant homozygote in the microfilarial 
population, after ten yearly treatments with either drug combination. Coverage was 
assumed to be 85% of the total population, and the initial resistance allele frequency was 
taken as 5%. Fig. 3.1 b shows the mean microfilaraemia (all microfilariae genotypes 
combined) for each treatment regime. Model outcomes without the presence of ABZ 
resistance are virtually indistinguishable from those portrayed in Fig. 3.1 b, and are 
therefore not shown. This indicates that the spread of ABZ resistance is unlikely to 
impair the impact of the control programme on microfilariallevels. Treatment with ABZ 
and IVM leads to an increase of the resistant genotype by a factor of 1.74. However 
since the initial genotype frequency is 0.25%, it will only reach 0.44%, and thus will still 
be uncommon in the population. Treatment with ABZ and DEC has a much larger 
impact on the frequency of the ABZ-resistant genotype. Our model indicates that the 
genotype frequency will rise to 12.7% and thus increase by a factor of 4.8 (Fig. 3.1 a). 
In order to further examine these results, we have carried out a sensitivity analysis 
on different parameters of the model. The results ofthese analyses are displayed in Figs. 
3.2 to 3.6. It can be seen that when treating with the ABZ + DEC combination, selection 
for ABZ resistance is strongly dependent on increasing the differential microfilaricidal 
efficacy of the ABZ + DEC combination over DEC alone (Fig. 3.2a), and the assumed 
macrofilaricidal efficacy ofDEC (Fig. 3.2b) (Table 3.2). When treating with the ABZ + 
IVM combination, the spread of resistance is less affected by small changes in drug 
efficacies (see Appendix II, Fig. 7.1). 
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Figure 3.1: The effect of 10 yearly treatments with albendazole (ABZ) + 
diethylcarbamazine (DEC), or ABZ + ivermectin (IVM), with 85% coverage of 
the total population, on the spread of ABZ resistance in Wuchereria bancrofti. A) 
the average frequency (in percentage) of resistant genotype microfilariae; B) the 
mean microfilaraemia per 20 !-lI of blood in the human host population. Solid 
line: ABZ + DEC, dashed line: ABZ + IVM. 
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Figure 3.2: The effect, on the ABZ resistant genotype frequency (%) of W. bancrofti 
microfilariae, of increasing drug efficacy parameters. 
A) the differential microfilaricidal efficacy (% of microfilariae killed) due to 
adding ABZ to DEC, and B) adulticidal efficacy (% of macrofilariae killed) of 
DEC, when administering 10 annual treatments with ABZ + DEC to 85% of the 
human host population. 
Treatment coverage affects the speed at which ABZ resistance spreads, with 
increasing coverage considerably increasing selection for the resistant genotype (Fig. 
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3.3). When coverage reaches 95% with ABZ + DEC, the ABZ resistant genotype 
frequency in microfilariae will reach aimost 40% 10 years after cessation of the 10 yearly 
treatments (Fig. 3.3a). Coverage will also affect the frequency of the ABZ resistant 
genotype after treatment with ABZ + IVM. However, though the resistant genotype will 
increase by a factor of2.5 when changing treatment coverage to 95%, this frequency will 
reach only 0.64% 10 years after halting the annual treatments, and thus will only have a 
marginal effect (Fig. 3.3c). As expected, mean microfilaraemia, during the period of 
treatment, depends on treatment coverage with either ABZ + DEC or ABZ + IVM 
(respectively Figs. 3.3b and 3.3d), with lowest microfilaraemia corresponding to highest 
coverage. Therefore, very low microfilaraemia levels during control, mask strong 
selection and increased frequency of resistant genotypes once control is halted. 
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Figure 3.3: The effect on the ABZ resistant genotype frequency (%) of increasing therapeutic 
coverage of 10 yearly treatments. ABZ-resistant genotype microfilariae (A, C), and 
average microfilaraemia (B, D), for combination therapy with ABZ + DEC (A, B), and 
ABZ + IVM (C, D). 
We have also examined the effect ofnon-random mating. Inbreeding changes the 
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distribution of genotypes, increasing homozygosity and hence the number of resistant 
genotypes at a given allele frequency. Non-random mating can have a dramatic impact 
on the outcomes of selection, as shown in Fig.3.4. With a Wright' s FIT-statistic 
equivalent to parameter F= 0.44 in the model, the ABZ resistant genotype would reach a 
frequency of over 60% after ceasing 10 yearly treatments with ABZ + DEC. It may also 
be noted that even a much lower F value of 0.11 willlead to a resistant genotype 
frequency of over 50% (Fig. 3.4a). In the case of 10 yearly treatments with ABZ + IVM, 
an F value of 0.44 willlead the resistant genotype frequency to increase from 0.25% to 
just over 20%, under the assumptions of 85% coverage. The corresponding microfilarial 
intensities are shown in Figs 3.4b (ALB + DEC) and 4c (ALB + IVM). 
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Figure 3.4: The effect, on the spread of ABZ resistance in W bancrofti, of increasing 
non-random parasite mating (i.e., increased homozygosity as measured by the 
Fisher FIT statistic), following 10 yearly treatments at 85% coverage 
ABZ + DEC (A, B), and ABZ + IVM (C, D). Panels (A) and (C) represent the 
frequency (%) of resistant genotype microfilariae, and panels (B) and (D) the 
mean microfilaraemia. 
Schwab et al (2005) found initial frequencies of the ABZ resistant genotype ofup 
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to 26%. Thus we examined how quickly resistance will ri se if initial frequencies are 
higher than the 5% assumed in the other models. In Fig. 3.5, it may be observed how 
changing the initial ABZ resistance frequencies before treatment will dramatically change 
the spread ofresistance once mass drug administration is stopped (Fig. 3.5). An initial 
resistant genotype frequency of 10% wi11lead to an increase in the resistant genotype 
frequency to over 50% after 10 treatments with ABZ + DEC. However, if the initial 
frequency is further increased to 40%, the proportion of resistant microfilariae will rise to 
reach 70% (Figs. 3.5a, b). When treating with ABZ + IVM (Figs. 3.5c, d), the effect of 
increasing initial frequency of ABZ resistance is similar, but less dramatic than with ABZ 
+ DEC. These simulations assume no resistance to DEC or IVM. 
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Figure 3.5: The effect, on the spread of ABZ resistance, ofvarying the initial resistance 
allele frequency (in %) following 10 yearly treatments with 85% coverage. 
A) the frequency (%) ofresistant genotype microfilariae, and B) the mean 
microfilaraemia for ABZ + DEC; panels (C) and (D) present the corresponding 
results for ABZ + IVM. 
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lncreasing the duration of the treatrnent programme also considerably affects the 
spread of ABZ resistance. Here we consider the effect of up to 15 yearly treatments with 
ABZ + DEC. It was estimated that it will take 15 years oftreatment for the ABZ 
resistant genotype frequency to reach over 50% (Fig. 3.6a). Whentreating with ABZ + 
IVM, 15 yearly treatments are estimated to lead to an increase in the resistant genotype 
frequency from 0.25% to just under 0.6% (Fig. 3.6c). The effects ofthese treatment 
schedules on microfilarial intensityare shown in Figs. 3.6b and 3.6d. 
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Figure 3.6:. The effect ofincreasing the number of annual treatments with 85% coverage 
on the spread of ABZ resistance in W bancrofti: 
A) the frequency (%) ofresistant genotype microfilariae, and B) the mean 
microfilaraemia for ABZ + DEC; panels (C) and (D) correspond to treatment with 
ABZ+IVM. 
We have used parameters for homozygosity and initial frequency obtained from 
villages in Burkina Faso to indicate the spread of ABZ resistance in these communities 
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(Fig. 3.7). Both treatment regimes are estimated to result in the frequency of the ABZ 
resistant homozygote reaching 50% after ten yearly treatments at 85% coverage, though 
little difference will be seen in microfilarial burdens. 
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Figure 3.7: The effect, on the spread of ABZ resistance in W bancrofti, of 10 annual 
treatments at 85% coverage with ABZ + DEC (solid line), or ABZ + IVM (dashed 
line), using the initial allele frequencies and FIT values recorded in the village of 
Tangonko, Burkina Faso (Schwab et al., 2005): A) the frequency (%) of resistant 
genotype microfilariae; B) the average microfilaraemia 
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3.4. Discussion 
The development of drug resistance in lymphatic filarial parasites could represent 
a serious threat to the GPELF, which currently aims to eliminate the disease by blocking 
transmission. The model presented in this paper examines factors affecting the spread of 
ABZ resistance under current treatment strategies for W bancrofti, under a series of 
structural and parameter assumptions. Although the model provides quantitative results, 
given the uncertainties still remaining about such assumptions, the qualitative insights 
gained are more important than the actual predictions. Based on the assumptions of drug 
efficacies made here, treatment with ABZ + DEC would lead to a much quicker spread of 
ABZ resistance than that with ABZ + NM. The model indicates that treatment with 
ABZ + DEC for ten years, at 85% coverage and an initial ABZ resistant genotype 
frequency of 0.25%, would increase the resistant microfilarial genotype frequency to 
approximately 13%. Treatment with ABZ + IVM would lead to a negligible increase in 
the resistant genotype. 
Sensitivity analysis ofthe of ABZ + DEC treatment regime shows that the spread 
of ABZ resistance would be highly dependent on the additional microfilaricidal activity 
gained when adding ABZ to DEC (as compared to DEC alone), and the degree to which 
DEC alone can kill adult parasites. Sorne additional microfilaricidal activity, caused by 
ABZ, is required in order to give resistant worms enough of a selective advantage for the 
allele frequency to change after the introduction oftreatment. Increasing DEC adulticidal 
activity dramatically reduces the spread of ABZ resistance. Therefore, care must be 
taken when assumptions about drug efficacy are made, as small parameter changes can 
lead to larger changes in the outcomes predicted by the model. The ABZ + IVM 
combination treatment is much less affected by smaU changes in the microfilaricide and 
macrofilaricide efficacy parameters. An important factor in the behaviour of different 
treatment regimes is the fact that DEC sterilizes adult worms for a shorter period than 
IVM. Thus, following each IVM treatment, very little reproduction occurs for 9 months 
and selection for the ABZ resistant allele is minimal (as we have assumed no resistance to 
NM). 
The spread of ABZ resistance is strongly dependent on treatment coverage. 
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Higher levels of therapeutic coverage would lead to faster microfilarial reductions, but 
also to quicker spread of ABZ resistance. Our model indicates that increasing the 
treatment coverage by 10% (from 85% to 95%) would lead to an almost four-fold 
increase in the frequency of ABZ-resistant microfilariae in the population 10 years after 
cessation ofthe 10 yearly treatments with ABZ + DEC. This is due to the fact that 
untreated hosts act as refugia of susceptible parasites. Similar results have been observed 
for animal parasites (Coles, 2002; van Wyk, 2001). In this model it is assumed that the 
same individuals in the population are being treated at each round, as is the case for 
systematic compliers. Without using individual-based, more realistic models, our 
conclusions remain tentative. During the treatment period, little increase in the resistant 
homozygote frequency in the microfilarial population is apparent. During this time, the 
treated hosts are being continually infected by L3 larvae derived from untreated hosts. 
These larvae have the genotype distribution of the untreated group, which is similar to the 
initial overall genotype distribution. Within the treated hosts, susceptible worms are 
dying at a faster rate than resistant worms (the macrofilaricidal efficacy ofDEC + ABZ is 
assumed to be 55% whereas that ofDEC alone is 30%). Therefore, although the resistant 
genotype frequency of the adult worm population is increasing continually over time 
during treatment, this is not reflected in substantial changes in microfilarial genotype, 
partly because adult worms in treated hosts are reproducing only to a very small degree. 
Consequently, the overall genotype distribution in the microfilarial population is 
predominantly influenced by that of the microfilariae in untreated hosts, where the adult 
genotype frequency remains fairly constant. Thus, there is no considerable change in the 
genotype distribution of the microfilarial population during the course of the treatment. 
Following the end oftreatment, the adult worms in the treated individuals can reproduce 
once again. These adult worms have a high ABZ resistance allele frequency so the 
microfilariae resistant genotype frequency starts to rise until the adult worm allele 
frequency in the treated and untreated hosts reaches equilibrium. 
Though the genotype structure of the microfilarial population is clearly changing, 
there is only a small impact on microfilaraemia. This is a consequence of using 
combination treatment. While ABZ resistance may be developing, it has been assumed 
that DEC or IVM still remain effective in clearing microfilariae from the blood of 
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patients. Thus, ABZ resistance may not become immediately apparent, but it may have a 
considerable impact should DEC or IVM become no longer effective for treatment (e.g. if 
DEC or IVM resistance were to develop). 
Based on the resuIts obtained from the models, and with defauIt parameters, it 
would take 15 years oftreatment with ABZ + DEC in order for half of the microfilaria 
population to be homozygous resistant to ABZ. This exceeds the time frame intended by 
the GPELF, which proposes that duration of chemotherapy should last the time 
equivalent to the lifespan of an adult worm, estimated to vary between 4 and 6 years 
(Michael et al., 2004; Vanamail et al., 1996). However, there is considerable uncertainty 
around this estimate, and values ranging from 5 years (Vanamail et al., 1989) to ~40 
(Carme & Laigret, 1979), with a mean of ~ 10 years (Subramanian et al., 2004) for the 
L YMF ASIM model have been presented. The adult worm life span assumed by EPIFIL 
is approximately eight years (Norman et al., 2000). Michael et al (2004) believe that it 
may not be feasible to reach the goals ofthe GPELF in are as ofhigh endemicity within 
the proposed time-span of 4 - 6 years. 
Sorne areas may have high levels of initial benzimidazole resistance allele 
frequencies, as demonstrated by Schwab et al (2005). Similar observations were also 
made in trichostrongylid parasites (Beech et al., 1994). Our mode! indicates that when 
ABZ + DEC are used together, an increase of the initial resistant allele frequency from 
5% to 10%, would result in half of aIl microfilariae in the population becoming resistant 
after halting the 10 years of annual treatment. If the resistance allele frequency is initially 
26%, this proportion would increase to 63%. Initial allele frequencies may vary in 
different geographicallocations and were found to be around 26% in sorne areas of 
Burkina Faso, and less than 1 % in sorne microfilarial samples from Ghana (Schwab et al., 
2005). It is therefore advisable to develop resistance markers for monitoring purposes in 
areas where treatment is being introduced. Given that the sampling protocol will greatly 
influence the estimated values of ABZ resistance frequencies, the results above need to 
be taken with caution. We are developing population genetics models to address these 
issues and the results will be presented elsewhere (Churcher et al., unpublished-see). 
Results from this model suggest that excess homozygosity, caused by non-random 
parasite mating, would lead to a rapid increase in selection of recessive resistance alleles. 
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Inbreeding is incorporated very crudely within the modelling framework, and it had the 
aim to illustrate the serious implications that excess homozygosity would have on the 
spread of drug resistance. Our current model makes no assumptions about the 
mechanisms driving non-random mating. It has been demonstrated in the past that 
recessive alle1es may be selected far more quickly than initially anticipated, due to 
metapopulation structure and resulting inbreeding (Cornell et al., 2000, 2003). Filarial 
worm populations are subdivided in the host population, and thus random mating is 
unlikely to occur. In addition, vectors may not evenly ingest microfilariae and distribute 
infective larvae through the host populations and are more likely to take consecutive 
blood meals from people within the same household (Michael et al., 1998; 2001), which 
may lead to inbreeding. 
We show here, using parameters obtained from villages in Burkina Faso, that the 
effects investigated previously (i.e. inbreeding, high initial allele frequency), when 
combined together will have an additive affect on the final resistance allele frequency. 
This is because the relationship between alle1e frequency and homozygosity is non-linear. 
Though mathematical models are not necessarily accurate quantitative predictors 
of population dynamics in the field, because assumptions made in the models may tum 
out to be not entirely correct, they do help highlight influential factors (Cornell et al., 
2005). EPIFIL was optimized in India, particularly in the locality ofPondicherry, where 
LF prevalence is relatively low, and integrated vector management has taken place for a 
long time (Subramanian et al., 2004). Also, the operation of acquired immunity, which 
was thought to be essential for reproducing observed infection patterns in Pondicherry, 
has not been substantiated in other geographical regions (Stolk et al., 2004). 
Transmission intensity may be different in other areas, such as Africa, where there are 
different vectors (EPIFIL is parameterised for Culex-transmitted LF). In addition, this is 
a deterministic model that does not consider transmission breakpoints (e.g., no explicit 
mating probabilities for adult worms are incorporated), and is unable to take into account 
variability among individual hosts and parasites. Incorporating greater biological 
complexity into the model will be necessary for obtaining accurate quantitative 
conclusions, though we feel this is not likely to affect in great measure the qualitative 
conclusions drawn from our results. 
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3. 5. Concluding Remarks. 
We show that it is important to take into account the efficacies and mechanisms of 
drug effects when applying control strategies in order to predict the spread of drug 
resistance. Furthermore, it is important to be aware of initial resistance allele 
frequencies, as these will affect the speed at which resistance spreads, and thus 
monitoring field situations with appropriate resistance markers is advisable. The 
requirements ofhigh coverage and compliance, and the lengthy duration of 
chemotherapy-based control programmes risks anthelmintic resistance or at best, a 
decrease in the efficacy of the drugs of choice. Incorporation of vector control into 
control programmes can reduce the time required to meet control goals (Basanez et al., 
2002; Michael et al., 2004) and may thus prevent drug resistance from undermining the 
achievement ofthese goals. In addition, if aspects of the parasite's biology increase 
homozygosity in the population, the spread of resistance will be faster than if the parasite 
population is mating randomly. The results of the mode1 also indicate that if monitoring 
of alle1e frequencies is not undertaken during the control programme, and low 
W bancrofti infection levels persist by the time control is stopped, drug resistance may 
only become apparent once regular treatment has been interrupted, recrudescence occurs, 
and treatment is reapplied. 
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Appendix 3A. Brief Description of the EPIFIL Model 
Our model was based on the epidemiological model EPIFIL (Norman et al. 2000), 
which describes, with respect to time, t, and host age, a, the rate of change of the mean 
number of adult worms per host, W; the mean microfilarial count per 20~1 ofblood, M, 
and the average magnitude ofthe protective immune response, J, acquired due to 
infection experience (and assumed to be elicited by the adult worm stage, but targeted 
against establishment of incoming larvae) as follows, 
oW(a,t) oW(a,t) _ 1~ h( )L* -{JI - W( ) 
---+ - /l, cp! CP2S2 a e Ji a, t 
t3t oa H 
(A3.1) 
ôM(a, t) + Ô M(a, t) = a W(a, t) - rM(a, t) 
ôt ôa 
(A3.2) 
ô/(a,t) + ô/(a,t) = W(a,t) _ LI/(a,t) 
ôt ôa 
(A3.3) 
* Âxg fJr(a) f[M(a,t)] da 
L = ---'-------- (A3.4) 
L' is the average number of L3 larvae per mosquito, with the asterisk denoting 
equilibrium as the temporal changes in the infective larval population take place at a 
much faster rate than those in the adult worm and microfilarial stages, and therefore it has 
been assumed that ôL(a,t) + ôL(a,t) = O. The function f[M(a, t)] combines the density-
ôt ôa 
dependent relationship between microfilaraemia in the host and development of L3 larvae 
in the vector with the assumed negative binomial distribution of microfilariae among 
hosts, 
(A3.5) 
with p being the initial, linear rate of increase in L3 larvae per microfilariae in 
20~1 ofblood, pl Kthe severity of density-dependent constraints upon larval uptake and/or 
development; Kthe level at which the function saturates (the maximum number ofL3 
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produced per mosquito as microfilaraemia increases), and k the overdispersion parameter 
of the negative binomial; g is the proportion of bites which result in infection of 
mosquitoes, and 7r(a) is the proportion of the host population surviving to age a, based on 
a population in Pondicherry, India, with equation, 
exp(-alm) 
7r(a) = [l-exp(-nlm)] 
m 
(A3.6) 
with m = 29 and n = 65. 
Since Â is the biting rate per mosquito on humans, and V/H is the vector to human 
ratio, Â(V/H) is the mosquito biting rate as measured in the field by human landing 
catches; 1f'1 is the proportion ofL3 larvae that leave the mosquito's proboscis at the time 
ofbiting and are deposited onto human's skin, 1f'2 is the proportion of the latter which 
enter the host through the wound caused by the mosquto bite, S2 is the proportion of 
larvae that, having entered the host, will develop into adult worms; h(a) is the proportion 
ofhosts of age a that are bitten, thereby making the biting rate on humans age-dependent 
(it is assumed to increase linearly until the age of 9 years and then to become unit y); fJ 
measures the severity by which larval establishment is decreased by acquired immunity, 1 
(which is assumed to increase with accumulated worm burden or worm experience); Il, r 
and (J are, respectively, the per capita death rates of adult worms, microfilariae and L3 
larvae; D. is the rate of decay of the immune response, and a is the per capita 
reproductive rate of adult worms (the rate at which fertilized females pro duce 
microfilariae per 20 /lI of blood). 
Prevalence of microfilaraemia is estimated from microfilarial density using the 
negative binomial distribution and is given by 
pM(a,t) = 1- (1 + M~,t) J-k (A3.7) 
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Appendix 3B. Incorporation of Parasite Population Genetics into 
EPIFIL 
We now extend the EPIFIL model by incorporating genetic structure into the 
worm population in order to examine the spread ofbenzimidazole resistance. We track 
the number of worms of each ofthree genotypes (homozygote susceptible (SS), 
heterozygote susceptible (Sr) and homozygote resistant (rr) (Durrheim et al.), 2004) in 
both the treated and untreated sections of the human population. The mean number of 
adult worms per person of each genotype is denoted, after dropping the age and time 
dependency, by Wb
q
, with subscript b indicating the treatment category (b=T or b=U for 
worms within, respectively, hosts treated or untreated with benzimidazoles), and 
superscript q specifying the worm genotype (q= SS, Sr, or rr). For example, W;S 
denotes the mean number of adult homozygote susceptible worms (of genotype SS) in the 
treated population. Similar notation is used to represent the mean number of 
microfilariae per 20 ,Û blood, Mg , and the mean number of L3 larvae per mosquito, Lb. 
The level of acquired immtinity in the treated and untreated human population is 
specified by, respectively, IT and lu. The modified EPIFIL equations are as follows, 
ôwq ôWq V • 
__ b_+ __ b_=Â_rp rp S h(a)L q e-P/ -.uwq 
ôt ôa H 1 2 2 b 
ôl b ôl b 
-+-=W -Lil ôt ôa b b 
(B3.1) 
(B3.2) 
(B3.3) 
(B3.4) 
(B3.5) 
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where C is the proportion of the population treated (coverage), 
M - MSS + M Sr + M rr and L - L ss + L Sr + Lrr The expression for L * q determines the b- b b b b- b b b' 
average number of L3 larvae per mosquito for each genotype that infect the treated and 
untreated sections of the population. As with EPIFIL, the L3 population is assumed to be 
at equilibrium and is calculated using equation (B3.5). 
In order to obtain microfilariae of a particular genotype, we use Mendelian 
genetics to ca1culate the probability w % that new microfilariae will belong to a particular 
genotype given the genotype frequencies of their parent adult worms, 
1 (W ss W Sr î ( wss 1 W Sr î OJ ss=-l2-b +_b )2(I-F)+l-b + __ b )F 
b 4 ~ ~ ~ 2Wb 
(B3.6) 
1 (wrr W Sr î ( W rr 1 W Sr î 
W
rr
=-l2-b +_b )2(1-F)+l-b + __ b )F 
b 4 ~ ~ ~ 2Wb 
(B3.7) 
1 (wrr W sr î (W ss W Sr î OJ!r=-l2-b +_b ) l2-b +_b ) (l-F) 
2 ~ ~ Wb Wb 
(B3.8) 
Parameter F adjusts for excess homozygosity. In the case of random mating, Fis 
set to O. In the case ofnon-random mating, Fis set to 0.44 (see main text). 
Functions that model density dependence operating within the mosquito are 
calculated separately for treated and untreated populations, 
(B3.9) 
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CONNECTING STATEMENT 2 
In the previous chapter, the potential spread of ABZ resistance through 
populations of W bancrofti due to combination treatments, currently applied by the 
GPELF, were explored. We chose to initially examine ABZ resistance, as the 
mechanisms involved in its development are weIl known. We found that factors such as 
drug efficacy, treatment coverage, mating structure and initial allele frequency of the 
resistance mutation have a considerable impact on the development of resistance. It is 
weIl known that the use of IVM in veterinary medicine has led to many cases of drug 
resistance, and we suspect that such IVM resistance could also develop in lymphatic 
filaria, in addition to ABZ resistance. The interation between selection of resistance 
against these two separate drugs wiIllikely affect how resistance develops, and how 
many individual parasites ultimately survive treatment.. In Chapter 4, we expand the 
mathematical model presented in Chapter 3, by incorporating additional genes 
responsible for potential IVM resistance. As the inheritance of such resistance has not 
been fully elucidated, we consider several possibilities of dominance and polygenicity of 
IVM resistance. We use this mathematical model to explore mechanisms and factors 
involved in the possible spread of multidrug resistance through populations of 
W bancrofti, due to combination chemotherapy. 
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CHAPTER4: 
ANALYSIS OF THE POPULATION GENETICS OF 
POTENTIAL MULTI-DRUG RESISTANCE IN LYMPHATIC 
FILARIASIS DUE TO COMBINATION CHEMOTHERAPY 
Schwab A.B., ChurcherT.S., Schwab A.l, Basàfiez, M-G., Prichard R.K. 
Parasitology, (2007), 135: (in press) 
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Abstract 
Currently, yearly mass treatments with albendazole (ABZ) plus ivermectin (lVM) 
or diethylcarbamazine (DEC) are administered under the Global Programme to Eliminate 
Lymphatic Filariasis (GPELF). Drug resistance against both ABZ and IVM is prevalent 
in veterinary nematodes, raising awareness that if anthelmintic resistance were to develop 
among Wuchereria bancrofti populations, this wouldjeopardise GPELF's goals. Genetic 
structure was incorporated into an existing LF transmission dynamics model, EPIFIL, to 
investigate the potential development of concurrent resistance to ABZ and IVM. The 
resulting models explore the impact of different inheritance modes of resistance to ABZ 
and IVM on the likely risk of treatment failure under our model assumptions. Results 
indicate that under ABZ + IVM combination, selection for resistance to one drug is 
enhanced if resistance to the other drug is already present. Excess parasite homozygosity 
may increase selection for dominant IVM resistance via enhancing the frequency of 
recessive ABZ resistance. The model suggests that if multiple resistance genes are 
associated with different efficacy properties of a drug combination, then examining 
changes at single loci may be misleading. Sampling schemes of genetic epidemiological 
surveys that investigate the frequency of an allele under selection should consider host 
age, as individuals of different ages may acquire parasites at different rates. 
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4.1 Introduction 
Lymphatic filariasis (LF) is a parasitic disease caused by the infection with one or 
several of a group of filarial nematodes dwelling in the lymph system and being 
transmitted by mosquito vectors. Recently, revised figures estimate that LF is endemic in 
83 countries and that 119 million people are infected worldwide. LF is a major cause of 
morbidity, with the loss of 4.6 million DALYs (disability-adjusted life years) (Remme et 
al. 2006), severely affecting socioeconomic development in endemic areas (Ramai ah et 
al. 1999; Zagaria and Savioli, 2002). The Global Programme to Eliminate Lymphatic 
Filariasis (GPELF), launched in 2000, involves community-wide annual treatment with 
the broad spectrum anthelmintic albendazole (ABZ) in combination with ivermectin 
(lVM) or diethylcarbamazine (DEC). The combination chosen depends on whether or not 
human onchocerciasis is co-endemic (Maher and Ottesen, 2000; Ottesen, 2000, 2002; 
Dean, 2002; Zagaria and Savioli, 2002). 
Resistance to both benzimidazoles (inc1uding ABZ) and macrocyc1ic 
lactones (MLs, to which IVM belongs), has been documented in many parasitic 
nematodes affecting livestock (Prichard et al. 1980; Prichard, 1990, Woistenhoime et al. 
2004), suggesting that the possibility ofresistance developing in lymphatic filariae of 
humans should not be dismissed. There have been some reports oftolerance to DEC by 
filarial parasites (Eberhard et al. 1988; Eberhard et al. 1991), and we have shown that a 
polymorphism, known to be associated with benzimidazole resistance in veterinary 
parasites, is present in West African populations of Wuchereria bancrofti (see Schwab et 
al. 2005). ABZ resistance is known to be associated with selection on p-tubulin and is 
thought to be recessive in most helminths of veterinary importance (Elard and Humbert, 
1999; Prichard, 2001; Silvestre and Cabaret, 2002). 
Schwab et al. (2006) incorporated population genetics into the deterministic 
mathematical model EPIFIL, which examines the population dynamics of W bancrofti 
(see Chan et al. 1998, 1999; Norman et al. 2000), with the aim ofinvestigating the 
impact ofmass drug administration (MDA) on the development of ABZ resistance in the 
absence ofresistance to either DEC or IVM. The model suggested that iften annual 
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treatments with ABZ + DEC were applied, this would lead to a five-fold increase in a 
(homozygous) ABZ resistant genotype, whereas, in the case of the ABZ + IVM 
combination, the increase in ABZ resistance would be less pronounced. 
Recently, it has been documented that in areas of Ghana endemic for the 
related filarial nematode Onchocerca volvulus, in which humans have been treated more 
than 9 times with IVM, sorne infected individuals exhibit a sub-optimal response 
phenotype and experience a faster recovery of microfilaridermia after treatment than 
normal responders (Awadzi et al. 2004a,b). Whether this phenotype is associated with 
genetic changes indicative of selection under IVM pressure has not yet been ascertained. 
However, there is genetic evidence that selection by IVM treatment may indeed be 
occurring in 0. volvulus populations. Significant differences in allele frequencies 
between worms obtained from untreated and IVM-treated human populations were found 
for p-tubulin, P-glycoprotein and other ABC transporter genes (Eng and Prichard, 2005; 
Ardelli and Prichard, 2004; Ardelli et al. 2005, 2006a,b; Eng et al. 2006). 
In Haemonchus contortus, the barber's pole worm of small ruminants, 
more than one gene appears to be under selection by repeated treatments with IVM or 
other MLs (Blackhall et al. 1998a,b; Prichard, 2005). Although previous reports had 
concluded that IVM resistance in H con tortus was a monogenic trait (Le Jambre et al. 
2000), more recent evidence, based on the responses of field isolates of resistant 
H con tortus and Trichostrongylus colubriformis to MLs, suggests that ML resistance is 
likely to be polygenic (Le Jambre et al. 2005). The results of a mathematical model 
investigating anthelmintic resistance in sheep parasites examined concurrent selection by 
more than one drug upon multiple resistance genes, and concluded that under the 
assumption of linkage equilibrium, resistance is selected more slowly when it is 
polygenic rather than monogenic (Bames et al. 1995). 
Little is known about the relative dominance of alleles conferring ML 
resistance in parasitic nematodes. Mathematical models have demonstrated how the 
mode of inheritance of drug resistance has a large impact on its selection, with dominant 
traits being selected more rapidly (Bames et al. 1995). In H contortus, in particular, it 
has been speculated that IVM resistance is a completely dominant trait (Le Jambre et al. 
2000; Bames et al. 2001), whereas Le Jambre et al. (2005) have suggested that resistance 
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to moxidectin and abamectin, also members of the ML family, are semirecessive and 
semidominant, respectively. Another study has shown that the mode of inheritance of 
ML resistance to moxidectin in Teladorsagia circumcincta may be semi-dominant or 
recessive (Sutherland et al. 2002). 
In this paper, we exp and our previous work (Schwab et al. 2006) to 
include the possibility of concurrent selection for resistance to ABZ and IVM in 
W bancrofti. We have chosen to consider resistance to IVM and not to DEC, because, 
unlike the many cases ofIVM resistance in veterinary nematodes, resistance against DEC 
has not been unequivocally demonstrated to date. 
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4.2 Model Development 
4.2.1 Population Dynamics 
The model described in this paper is based on EPIFIL (Chan et al. 1999; Norman 
et al. 2000), into which genetic structure was incorporated by Schwab et al. (2006), 
where all equations and parameters for EPIFIL may be found. Since EPIFIL was initially 
parameterized for the locality ofPondicherry, India, where age-specifie microfilarial 
infection profiles peak in young humans, the model assumes sorne degree of protective 
immunity against incoming infective larvae. This conjecture has been maintained in the 
work presented here. Parameters determining the intensity of transmission and the 
particular epidemiology in the model are such that the annual biting rate (by Culex 
quinquefasciatus) is ~ 70,000 bites per person per year, the annual transmission potential 
is 940 third-stage larvae per person per year, the mean microfilaraemia isO.85 per 20 ~l 
ofblood, and the prevalence ofmicrofilarial infection is 8% prior to the introduction of 
chemotherapy, based on the EPIFIL model (Norman et al. 2000). 
4.2.2 Population Genetics. 
Analysis ofpatients from villages in Burkina Faso, prior to the introduction of 
anti-LF chemotherapy, indicated that the P-tubulin genotype distribution of W bancrofti 
microfilariae deviates from the Hardy-Weinberg equilibrium (Schwab et al. 2005). The 
non-random mating of W bancrofti causes a deficiency in the proportion of heterozygote 
offspring, which can be described using Wright's inbreeding F-statistic (Wright, 1951). 
W bancrofti from the untreated population in Burkina Faso was shown to have an overall 
inbreeding coefficient of FIT = 0.44 (Churcher, 2006). A detailed description ofthis 
calculation and a discussion of the possible mechanisms generating homozygosity in 
W bancrofti will be presented elsewhere. Throughout this paper, and unless otherwise 
stated, the genotype distribution for microfilariae shall be altered to account for this 
degree ofnon-random mating (see Tables A4.1. and A4.2 of Appendix 4A), as was done 
in the previous study (Schwab et al. 2006). 
We have assumed that there are no costs or trade-offs associated with the 
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resistance alleles (i.e., resistant and susceptible W bancrofti have identical fitness prior to 
the introduction of chemotherapy). We have also assumed that resistance to ABZ is 
associated with a single autosomallocus with two alle1es, with the resistance alle1e being 
recessive. IVM resistance was assumed to be associated with either one autosomallocus 
with two alleles (i.e., to be monogenic), or with two autosomalloci with two alleles each 
(i.e., to be polygenic). In the default setting, IVM resistance was assumed to be 
dominant, but this assumption was later relaxed in order to explore the influence of 
different modes of inheritance, ranging from a fully dominant to a fully recessive trait. 
Unless otherwise stated, the initial frequencies of the ABZ and IVM resistance alle1es 
were (respectively) set to 0.2 (based on Schwab et al. 2005) and 0.05 (loosely based on 
polymorphlallele frequencies observed in 0. volvulus; Eng and Prichard, 2005; Eng et al. 
2006). In order to test the sensitivity of model outcomes to lower initial values, we also 
conducted simulations using 0.02 for both putative ABZ and IVM resistance allele 
frequencies. 
4.2.2.1 Monogenic IVM Resistance 
When ABZ and IVM resistances were both considered and each was assumed to 
be monogenic, each of the EPIFIL equations for adult worms, microfilariae and infective 
larvae populations, was written to represent parasites which were either: i) drug sensitive 
for both drugs; ii) ABZ-sensitive and IVM-resistant; iii) ABZ-resistant and IVM-
sensitive, or iv) resistant to both drugs. It is thought that ABZ and IVM resistance may 
both involve the ~-tubulin gene (Prichard, 2001; Eng and Prichard, 2005; Eng et al. 
2006), such that there is a chance that the loci conferring ABZ and IVM resistance may 
be completely or partially linked. Various degrees of dominance of IVM resistance and 
linkage, with recessive ABZ resistance, were considered by altering assumptions 
regarding drug efficacy and the degree of recombination between ABZ and IVM 
resistance loci (full equations are given in Appendix 4A). 
4.2.2.2 Polygenic IVM Resistance 
For the situation in which IVM resistance would be conferred by two loci, we 
assumed that one ofthese loci is completely linked to ABZ resistance (i.e., no 
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recombination between loci), as would be the case ifboth ABZ and IVM resistance were 
to involve ~-tubulin. The other IVM resistance locus was assumed to be unlinked (e.g., 
involving a P-glycoprotein or another gene), resulting in worm populations with 30 
possible genotype combinations. We considered three different scenarios: (1) one IVM 
resistance locus was responsible for IVM resistance in adult nematodes and a second 
locus for IVM resistance in microfilariae, as may be the case if adults and microfilariae 
have different resistance mechanisms, a scenario which may be consistent with the 
differences in the responses of adult worms and microfilariae to IVM; (2) neither locus 
on its own led to IVM resistance, but selection on both loci together was required for 
resistance, which will occur if genetic change at both loci is required for the resistance 
mechanism to be functional; and (3) one locus conferred resistance in aIl microfilariae 
and 70% of adults, and a second locus conferred resistance in the remaining 30% of 
adults, suggesting that one mechanism ofresistance protects aIl microfilariae and most 
adults, and that a second mechanism has developed in the adult worms that survive 
treatment. This scenario may again, in part, reflect differences in the responses of 
macrofilariae and microfilariae to IVM. Linkage equilibrium was assumed between the 
two IVM loci. 
4.2.2 Treatment Related Parameters 
Once the model is run to equilibrium, and unless otherwise stated, MDA with the 
ABZ + IVM combination starts in year 1 and proceeds annually for 10 years 
uninterruptedly. (Although the main strategy of GPELF is based on a programme 
duration of 5 years in each endemic area, doubts have been raised as to whether this 
would be enough to attain intended goals in aIl regions (Michael et al. 2004).) In order to 
reflect therapeutic coverage (set at a default level of 85% of the total population), treated 
and untreated parasite populations were modelled separately. At the point of 
transmission, the contributions of each population of infective larvae, from treated and 
untreated people, respectively (depending on coverage level), were introduced into the 
equations for adult worms. Due to the constrains imposed by a deterministic model 
which considers population averages, and to reflect that often the same individuals fail to 
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comply with treatment in successive years, the model assumes that the same section of 
the host population is treated at each round. After cessation of chemotherapy, no further 
treatments take place, but the model is run for ten more years. Model outputs regarding 
microfilarial genotype frequencies (expressed as percentages) and host microfilaraemia 
(expressed as microfilariae per 20 /-lI ofblood) are shown up to years 15 and 20, 
respectively. 
Assumptions on drug efficacy were based on those made by Michael et al. 
(2004) and other published drug trials (Addiss et al. 1997; Ismail et al. 1998; Dunyo, 
Nkrumah and Simonsen, 2000) and have been summarized in Table 4.1. Treatment was 
modelled as instantaneous reductions in adult worms (macrofilaricidal effect), 
microfilarial populations (microfilaricidal effect), or female worm reproduction rate 
(sterilizing effect) by the percentage efficacy given in Table 4.1. Following 
chemotherapy, sterilized females did not resume microfilarial production for a period of 
time specified for each drug. Model outcomes in this paper examine the effect, during 
and up to 5 years after the cessation ofMDA, often annual treatments on the genotype 
distribution ofthe microfilariae (the stage more feasibly sampled for genetic analyses), 
and up to 10 years after the cessation ofMDA on the mean microfilaraemia. 
Table 4.1. Drug efficacy assumptions (adapted from Michael et al. 2004) 
Effect ABZ-susceptible ABZ-resistant ABZ-susceptible ABZ-resistant 
IVM -susceptible IVM -susceptible IVM-resistant IVM -resistant 
Months without 9 9 9 0 
reproduction 
% Adults killed 35 10 25 0 
% Microfilariae 99 99 10 0 
killed 
An equations for the models explored are given in Appendix 4A and Tables A4.1 
and A4.2. Model code was written using the JSim numerical integration software, 
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available from 
http://nsr.bioeng.washington.eduIPLN/Membersibutterw/JSIMDOCl.6/JSim Home.stx/view. 
DifferentiaI equations were soived using the Euler method (Edwards and Penney, 1989). 
Prior to the initiation of control perturbations, W bancrofti populations were assumed to 
be at endemic equilibrium, as it has been ascertained that prevalences of infection in areas 
of Burkina Faso have remained relatively stable for at Ieast 30 years (Gyapong et al. 
2002). 
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4.3. ResuUs 
4.3.1 Influence of parasite inbreeding 
Model outputs indicate that parasite non-random mating (which results in 
increased offspring homozygosity) increases the projected rate at which ABZ and IVM 
resistant genotypes would spread throughout the genome of W bancrofti. Increased 
microfilarial homozygosity (as reflected by the value of FIT) increases the frequency of 
the dominant IVM resistant genotypes during MDA. For FIT = 0.44 (the value of 
homozygosity observed in Burkina Faso), the frequency ofIVM resistant genotypes in 
year 10 (63 %) is 8 times higher than that prior to the initiation of control (8%), whereas 
for FIT = 0 (no excess homozygosity), the frequency in year 10 is 6 times as high (Fig. 
4.1A). If initial allele frequencies are assumed to be lower (0.02 for both ABZ and IVM), 
the frequency ofIVM resistant microfilariae would increase 17 fold (from 3% to 51 %) 
when FIT = 0.44, but only about 6 fold (from 4% to 24%) ifrandom mating is assumed. 
It is important to note that this increase only occurs in the presence of ABZ resistance. 
At the cessation oftreatment, the percentage ofmicrofilarial genotypes resistantto both 
ABZ and IVM would have increased to 52% in the case of FIT = 0.44 as opposed to 8% 
when FIT = 0 and parasite mating is random (Fig. 4.1B). The higher frequency of 
resistant genotypes caused by parasite non-random mating is reflected in higher levels of 
microfilaraemia, particularly after 5 years ofMDA (Fig. 4.1C). 
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Figure 4.1: The effect of increasing levels of parasite inbreeding (i.e., increased 
homozygosity) as measured by Wright's F-statistic, FIT, on the 
development of anthelmintic resistant Wuchereria bancrofti, during 10 
annual treatments at 85% therapeutic coverage with the ABZ + IVM 
combination, and after 5 (genotype frequency) or 10 years 
(microfilaraemia) following cessation of mass drug administration 
(MDA). The initial ABZ and IVM resistance allele frequencies were set, 
respectively, at 0.2 and 0.05. IVM resistance is assumed to be a fully 
dominant trait. (A) The average frequency (expressed as percentage) of 
IVM resistant microtilarial genotypes; (B) the average frequency (%) of 
microtilarial genotypes resistant to both ABZ and IVM, and (C) the mean 
microtilaraemia per 20 III of blood in the human host population, with 
chemotherapy starting in year 1. 
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4.3.2 Concurrent development of ABZ and IVM resÎstance 
Model outputs indicate that when the initial frequencies of the ABZ and IVM 
resistance alleles is 0.2 and 0.05, respectively, MDA with ABZ + IVM would increase 
the frequency of microfilarial genotypes resistant to both drugs from under 1 % prior to 
control to 52% at its cessation (Fig. 4.2A), or to 40% when initial resistance allele 
frequency to both drugs is 0.02. The presence ofIVM resistance increases the rate of 
ABZ resistance development. In the absence of IVM resistance, the frequency of ABZ 
resistant homozygotes only increases from 12% at year 0 to 14% at year 10, and to 40% 5 
years after halting MDA (Schwab et al. 2006). Ifthe IVM resistance gene is present at an 
initial allele frequency of 0.05, the frequency of ABZ resistant homozygotes would reach 
57% and 70%, following the same treatment schedule at years 10 and 15, respectively 
(Fig. 4.2A). Ifthe initial resistance allele frequency, in relation to both drugs, is 0.02, the 
frequency ofthe ABZ resistant homozygotes would reach 39% and 54% at years 10 and 
15, respectively. The rate ofIVM resistance spread is similarly affected by the 
concurrent selection for the ABZ resistant genotype (see Appendix II). The presence of 
IVM resistance would also increase the average microfilaraemia relative to that with no 
resistance, and this is particularly marked after 5 rounds ofMDA (Fig. 4.2B). The 
frequency of resistant genotypes, following the cessation of treatment, increased with the 
number ofyears of annual MDA treatment. Fifteen years after the commencement of 
treatment, the frequencies of microfilariae resistant to both ABZ and IVM were estimated 
to be 20%, 40% and 65%, after 5, 7 and 10 years ofMDA (combination treatment), 
respectively. The same trend was observed with the lower initial allele frequencies (see 
Appendix II). 
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Figure 4.2: Estimated development of anthelmintic resistance in W bancrofti 
during 10 annual treatments with ABZ + IVM at 85% coverage and after 5 
(genotype frequency) or 10 years (microfilaraemia) following cessation of 
MDA. (A) The average frequency (%) ofmicrofilarial genotypes resistant 
to ABZ, IVM, or to both ABZ and IVM, where resistance to both ABZ 
and IVM can develop, or if only ABZ resistance occurs, and (B) the mean 
microfilaraemia per 20 III ofblood in the human host population, with 
chemotherapy starting in year 1, if there is no drug resistance, resistance to 
ABZ, but not to IVM or when resistance can develop to both ABZ and 
IVM 
4.3.3 Age-specifie profiles of ABZ and IVM resistant genotypes 
The proportion of resistant microfilariae that a host harbours will depend on the 
age of the host and the time since the start of chemotherapy. Fig. 4.3 indicates that, in a 
treatment programme of 10 years duration and following the onset ofMDA, the 
proportion of resistant genotypes will be highest in the youngest hosts, and this is 
particularly marked 5 and 10 years into the programme. The peak resistant genotype 
frequency shifts towards older ages (teenagers and young adults) 5 and 10 years after the 
cessation of treatment, whilst the frequency in children starts retuming to that in the 
overall population. Hosts which were young at the start of chemotherapy continue to 
have a higher than average number of resistant parasites for a number of years after 
treatment ceases, and this result reflects the assumption of acquired protective immunity 
as a function of established worm burden embedded in EPIFIL. The same effect was 
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observed with the lower initial alle1e frequencies. 
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Figure 4.3. Host age-specifie profiles of the proportion ofmicrofilariae which are 
resistant to ABZ and IVM, 5, 10, 15 and 20 years after commencement of 
10 annual rounds ofMDA with ABZ + IVM with 85% therapeutic 
coverage. Initial ABZ and IVM resistance alle1e frequencies, were 0.2 and 
0.05, respectively, with FIT = 0.44. 
4.3.4 Variable ivermectin resistance dominance 
The default parameters of the model assume that the IVM resistance alle1e is fully 
dominant. However, although it is generally believed that the ABZ resistance alle1e will 
be recessive (benzimidazole resistance has been found to be recessive in nematodes of 
non-human animaIs), it is still unc1ear how IVM resistance would be inherited. We 
examined the effect of varying the degree of dominance of the IVM resistance alle1e. 
Results (not shown) indicate that varying the dominance ofIVM resistance has a small 
impact on ABZ resistance. The frequency ofthe ABZ resistant genotype is marginally 
higher if the IVM resistance allele is recessive (74.5 % 5 years after the cessation of 
treatment) than ifit is dominant (71.2 %). As may be expected, the frequency of the IVM 
resistant genotype increases with the dominance ofIVM resistance. Projected host 
microfilaraemia, after 10 years of chemotherapy, would be slightly higher if the NM 
resistance gene is recessive. However, this increase is relatively minor (0.198 
microfilariae per 20 III ofblood after treatment ifIVM resistance is recessive vs. 0.184 
microfilariae per 20 III ofblood ifit is dominant). Dominance ofIVM resistance has the 
same impact at the lower initial alle1e frequencies of 0.02 for both drugs. 
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4.3.5 Dependence of Selection on Linkage 
In the monogenic IVM resistance model, the rate ofincrease in the frequency of 
resistant genotypes was relatively insensitive to whether the loci conferring ABZ and 
IVM resistance were unlinked, partially linked, or fully linked, as long as prior to the 
introduction of chemotherapy, the resistance loci were in random association within the 
parasite genome (i.e., genotypes were at linkage equilibrium, outputs not shown). 
However, ifboth loci were 100% linked (i.e., no recombination occurs between the two 
loci at meiosis), the result of selection would be affected by the number of chromosomes 
in the W bancrofti population bearing only IVM resistance or both ABZ and IVM 
resistance before the start oftreatment (initial linkage disequilibrium). Ifthe (linked) 
alleles conferring ABZ and IVM resistance were assumed to be always on the opposite 
strands of a chromosome (high initial linkage disequilibrium with discordant alleles), the 
ABZ and IVM resistant genotypes would be less frequent in the population after 
treatment than would be the case ifthey were initially at linkage equilibrium. The 
highest frequency of resistant genotypes would result from initially high linkage 
disequilibrium when both ABZ and IVM resistance alleles are located on the same 
chromosome (concordant alleles). These results are illustrated in Fig. 4.4. The effect of 
linkage was the same when the lower initial frequencies were assumed (see Appendix II, 
Fig.7.6) . 
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Figure 4.4: . The estimated effect, on the development of ABZ and IVM 
resistance, of 100% linkage between the alleles conferring these traits during 10 
annual treatments with ABZ + IVM at 85% coverage. The initial ABZ and IVM 
resistance allele frequencies, and the value of FIT are as in Fig. 3. (A) The 
average frequency (%) of ABZ resistant microfilarial genotypes; (B) the average 
frequency (%) ofIVM resistant microfilarial genotypes; (C) the average 
frequency (%) of ABZ and IVM resistant microfilarial genotypes; and (D) the 
mean microfilaraemia per 20 )..lI of blood in the human host, with chemotherapy 
starting in year 1. Linkage disequilibrium was ca1culated after Hartl and Clark 
(1997); standardized linkage disequilibrium (D') was calculated after Lewontin 
(1988). 
4.3.6 Polygenic Ivermectin Resistance 
The rate of increase of IVM resistance will be higher if it is inherited as a single 
gene rather than as a two-gene system, although the difference will depend on the initial 
all.ele frequencies and the selective advantage that the different IVM resistance genes 
confer individually. Iftwo genes are both required for complete IVM resistance and 
individually they do not confer any resistance, the development of resistance will be 
delayed if the resistance alleles are at a low initial frequency. However, the development 
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of monogenic and polygenic IVM resistance is relatively similar at higher initial alle1e 
frequencies, as a high proportion of worms will already have both IVM resistance genes 
(Fig. 4.5). Results also indicate that the deve10pment of polygenic IVM resistance will be 
influenced by the life-cycle stage of the parasite at which resistance is manifested. If one 
gene conferred IVM resistance to microfilariae (impeding microfilaricidal effects) and 
the other gene conferred resistance to all adult worms (preventing macrofilaricidal or 
anti-fecundity effects in 100% of the worms), treatment failure, under our model 
assumptions, would deve10p more rapidly than would be the case if the first gene was, for 
instance, responsible for both microfilarial resistance and resistance in 70% of adults, and 
the second gene conferred resistance to the remaining 30% ofthe macrofilariae. These 
conclusions were the same when the lower initial alle1e frequencies were assumed. 
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Figure 4.5: The estimated effect of selection on one ABZ resistance gene and two 
IVM resistance genes on the development of ABZ and IVM resistance during 10 
annual treatments with ABZ + IVM at 85% coverage. The initial ABZ and IVM 
resistét!lce allele frequencies, and the value of FIT are as in Fig. 3. (A) The 
average frequency (%) ofIVM resistant microfilarial genotypes; (B) the average 
frequency (%) ofmicrofilarial genotypes resistant to both ABZ and IVM, and (C) 
the mean microfilaraemia per 20 /lI ofblood in the human ho st, with 
chemotherapy starting in year 1. the ABZ resistance genotypes, and (C) the mean 
microfilaraemia per 20 /lI ofblood in the human host. 
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4.4. Discussion 
Combination therapy with two anthelmintics will influence the rates of 
development of single and mùlti-drug resistant parasites according to the efficacies of the 
drugs (in combination and individually) and the underlying genetics conferring 
resistance. Due to the many uncertainties regarding the population dynamics of the 
parasite (e.g., operation of acquired protective immunity) and the inheritance of IVM 
resistance (e.g., whether it is dominant), among others, the results.ofthis study provide 
qualitative insight (rather than quantitative predictions) into how assumptions regarding 
the genetics of IVM resistance may influence the development of drug resistance in 
W bancrofti under a combination treatment with ABZ + IVM. 
The models highlight a number of results which may be of interest to those 
investigating the possibility of resistance developing, following prolonged co-
administration oftwo anthelmintics. One salient prediction was the peak and subsequent 
temporary decline in the proportion of microfilariae resistant to IVM following the first 
round of chemotherapy. Results suggest that molecular epidemiological surveys 
conducted in the first three years of treatment might conclude that the genes conferring 
drug resistance had negative pleiotropic effects, therefore reducing the chance that IVM 
resistance will impede parasite elimination. However, the model indicates that the 
decline in microfilariae resistant to IVM may mask an increase in the number of adult 
worms resistant to both ABZ and IVM. The initial peak in IVM resistance is caused by 
the relative dominance of the alle1es conferring ABZ and IVM resistance, and the 
assumed efficacies of the two drugs against the different life cycle stages of the parasite. 
Microfilariae resistant to IVM prior to the start of chemotherapy survive the first round of 
treatment, but subsequently start to decrease in number as ABZ would have sterilized the 
majority oflVM resistant adult worms. The rate of decline observed in the proportion of 
microfilariae resistant to IVM is highly sensitive to the assumed life-span of 
microfilariae, a parameter particularly difficult to quantify, with estimates ranging from 6 
months to 2 years (Plaisier et al. 1999). It should be noted that if multiple genes are 
associated with different pharmacodynamic properties of a drug or drug combination, 
then examining the changes at single loci may produce misleading results. 
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Previous work had indicated that the change in proportion of ABZ 
resistant mÎcrofilariae may only become apparent after the end of the treatment period, 
due to the small amount of reproduction that occurs in the treated population while 
chemotherapy is in progress and the fact that the microfilariae population is, at that time, 
composed primarily of parasites from untreated patients (Schwab et al. 2006). However, 
the present work suggests that concurrent selection ofboth ABZ and IVM resistance may 
cause observable changes in the proportion of ABZ, IVM, and ABZ and IVM resistant 
microfilariae during the treatment period, as sorne parasites can overcome the combined 
action ofboth drugs and are able to reproduce. According to model outcomes, the 
presence of IVM resistance would enhance the rate of increase of any ABZ resistance, 
and vice versa, as a parasite resistant to both drugs has a higher probability of completing 
its life-cycle. 
There is considerable debate as to the number of years that combination 
chemotherapy should be provided under the current GPELF programmes for achieving 
the goals of elimination. The number of years of annual combination treatment 
influences the proportion of the microfilarial population with ABZ and IVM resistant 
genotypes following the cessation of treatment. The higher frequency of resistant 
genotypes that follows a longer period oftreatment indicates that for a given location, if 
transmission has not been interrupted by the programme and the parasite population has 
not been eliminated, a return to chemotherapy would be considerably less effective ifthe 
initial phase of treatment had lasted for 10 years rather than for 5 years. However, the 
present (deterministic) framework is not appropriate to explore the probability ofparasite 
elimination with duration of control. In most of the scenarios explored here, levels of 
microfilaraemia which might cause concem would not be evident until after 5 years into 
the programme. AIso, although the levels of parasite inbreeding used here are those 
estimated for W. bancrofti populations in West Africa, vector parameters derived from 
Culex (a vector for which the per microfilariae probability of completing its development 
within the mosquito increases with decreasing microfilaraemia) were used. LF in West 
Africa is transmitted by Anopheles species (for which the per-microfilaria probability of 
development may decrease markedly at low levels of microfilaraemia due to the 
increased proportion of ingested microfilariae damaged by the cibarial armatures of these 
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vectors) (Bryan and Southgate, 1988; Bryan et al. 1990). 
An interesting result is that hosts of different ages may harbour different 
proportions ofresistant microfilariae. Following the start of chemotherapy, the model 
indicates that children will, on average, acquire a higher proportion of resistant W 
bancrofti than adult hosts, because they are becoming infected with new parasites at a 
faster rate. The exact age-profile of resistance will depend on the age-dependent 
heterogeneity in exposure, the acquisition ofprotective immune responses, and the time 
since the start of chemotherapy at which genetic surveys are undertaken. The model 
outputs in this study depend on the ability of EPIFIL to represent adequately the 
processes regulating W bancrofti population abundance. EPIFIL assumes that the 
acquisition of new infections may be reduced in adult hosts due to acquired 
immunological responses protecting against incoming infection (Norman et al. 2000), but 
this has not yet been confirmed in different geographicallocations (Stolk et al. 2004). 
Regardless of the mechanisms underlying infection age-profiles, molecular 
epidemiological surveys should take into consideration that, after the start of 
chemotherapy, hosts which acquire new infections at the fastest rate will have the highest 
resistance allele frequency. This also has implications if vector control is added to annual 
chemotherapy, because vector control would reduce the acquisition of new parasites and 
thus assist in reducing the proportion of resistant genotypes in the parasite population. 
An analysis of the microfilarial data collected by Schwab et al. (2005) indicates 
that genetic differentiation in W bancrofti between hosts, and assortative parasite mating 
may cause excess homozygosity to a degree equivalent to Wright's inbreeding F-statistic 
of FIT = 0.44 (Churcher, 2006). Helminth inbreeding typically enhances the spread of 
recessive alleles but is not expected to increase selection for alleles which are dominant, 
as excess homozygosity will reduce the number of offspring with the resistance allele. 
Model outputs suggest that, under the assumed modes of inheritance of IVM and ABZ 
resistances, and in the presence of ABZ resistance, helminth inbreeding would increase 
markedly the spread of IVM and of ABZ and IVM resistant parasites (Fig. 4.1). This is 
because the selective advantage conferred by the more rapid increase in ABZ resistance 
(which is increased by parasite inbreeding) outweighs the loss ofmicrofilariae which are 
.~. heterozygous at the IVM resistance locus (thus being resistant to IVM). How the degree 
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of parasite inbreeding will influence the frequency of parasites resistant to both ABZ and 
NM will depend on the different efficacies of the two drugs and the relative dominance 
of the resistance alleles under selection. 
Based on the assumptions made here regarding inheritance, linkage 
between the genes conferring ABZ and NM resistance is unlikely to influence the 
incidence of combination treatment failure, unless the genes are completely linked and 
are at linkage disequilibrium. The model was not extended to investigate how linkage 
would influence the development of polygenic IVM resistance, so we cannot speculate on 
more complicated genetic scenarios. If the genes conferring resistance to both drugs 
were always present in the same gamete, selection for one type of resistance would also 
lead to selection for resistance against the second drug, reducing the time that it takes for 
widespread treatment failure. A recent study indicates that this may be the case for the 
two genes under consideration here, as an increase in the frequency of the Phe200Tyr 
polymorphism in the ~-tubulin gene was observed after selection of H. con tortus with 
NM and in IVM resistant worms (Eng et al. 2006). 
Model outcomes suggest, under our assumptions and parameterisation, 
that microfilarial intensity would decrease to as low as 0.04 microfilariae per 20 !lI of 
blood by the end ofMDA in our simulations. Using the calculations proposed by 
Norman et al. (2000), this would translate into a microfilarial prevalence of 1 %. There 
has been sorne debate about the threshold prevalence below which it is deemed that 
transmission can no longer occur, with the 1 % cut-off microfilaraemia stemming from the 
Chinese experience in eliminating (bancroftian and brugian) LF transmitted by Culex 
quinquefasciatus and Anopheles sinensis (see WHO, 2003). Michael et al. (2004) 
assumed the threshold prevalence to be 0.5%. In Western Samoa, transmission was not 
interrupted even after the microfilarial prevalence fell to 0.2% due to mass DEC 
administration (Esterre et al. 2001). It is thus likely that transmission would continue in 
the scenarios explored by our model and that resistance could develop. However, we 
stress that stochastic frameworks (Plaisier et al. 1998) are more suitable than 
deterministic models (Norman et al. 2000) to investigate the probability of parasite 
elimination or recrudescence ensuing the cessation ofMDA. 
Notwithstanding modelling approaches, the presence of multi-drug 
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resistance would hinder the success of combination chemotherapy control programmes 
and may prevent parasite elimination. However, it is important to note that even though 
our models have relatively high resistance alle1e frequencies pJ;Ïor to the introduction of 
chemotherapy, as default values, the presence of resistance will only become 
phenotypically manifested in the temporal trends ofhost microfilaraemia a number of 
years after the start oftreatment (in the present model, typically after 5 years). It should 
also be noted that the frequency of a potentially ABZ resistant genotype was found to be 
already high in West African populations of W bancrofti microfilariae before the 
introduction ofLF chemotherapy (Schwab et al. 2005). It is also important to recall that 
none of the anthelmintics used for LF control is very effective at eliminating the parasite 
from the ho st, because W bancrofti is re1atively tolerant to all ofthe anthelmintics used 
by the GPELF (Michael et al. 2004). If anthelmintic resistance genes were present in the 
population prior to the onset ofMDA, and assuming that they are randomly distributed 
among the worm population initially, relatively few parasites will be resistant to both 
drugs at the first round oftreatment. Successive rounds ofMDA are like1y to promote 
assortative mating within the surviving (fèrtile) worm population, thus increasing the 
number of parasites resistant to both drugs. Only after the genes have re-assorted in the 
parasite population in this way will treatment failure start to become apparent. With this 
in mind, it is advisable to implement promptly the monitoring and evaluation of possible 
changes in the parasite genome, by means of appropriate molecular markers, and to link 
this to the monitoring of responses to treatment in the host population. These actions 
may identify, before anthelmintic resistancebecomes a major public health concern, 
treatment factors that could enhance the spread of drug resistance. Although it is 
typically thought that combination therapy should delay the emergence of treatment 
failure, factors such as moderately high initial resistance alle1e frequencies to both drugs, 
dominance, genetic linkage, parasite inbreeding and high treatment coverage in MDA 
programmes may cause multi-drug resistance to hinder the achievement of GPELF's 
goals. Continued updating and improvement of transmission models, particularly those 
which merge the population dynamics and population genetics of the parasite, should be 
essential components of any epidemiological surveillance system implemented to protect 
the investments made by the Global Alliance to Eliminate Lymphatic Filariasis and its 
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donors (Dadzie et al. 2004; Michael et al. 2006; Schwab et al. 2006). 
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Appendix 4.A. Incorporation Of Parasite Population Genetics 
Into Epifil 
The EPIFIL model is extended by incorporating genetic structure into the worm 
population in order to examine the spread of ABZ, IVM, and ABZ and IVM resistances. 
The mathematical mode1s track the number ofworms, in both the treated and untreated 
sections of the human host population, of each often genotype combinations in the case 
ofthe ABZ monogenic-IVM monogenic model (2 loci with 2 alle1es each), and thirty 
genotype combinations in the case ofthe ABZ monogenic-IVM polygenic model (3 loci 
with 2 alle1es each). ABZ resistance is assumed to be recessive throughout, whilst the 
model investigates the effects of variable IVM resistance dominance, with the default 
setting assuming that IVM resistance is fully dominant. For each ofthese loci the 
different genotypes are identified using the following system: 0 corresponds to the 
susceptible homozygote, 1 to the heterozygote, and 2 to the resistant homozygote. The 
mean number of adult worms per person of each genotype is denoted, after dropping the 
age and time dependency, by w;de, with subscript b indicating the treatment category 
(b=T or b=U for worms within, respectively, hosts treated or untreated with ABZ + 
IVM), and the superscripts c, d and e specifying the worm genotype at each of the 
different loci (c = the ABZ resistance locus, d = the first, linked IVM resistance locus, 
and e = the second unlinked IVM resistance locus). If IVM resistance is conferred by a 
single locus (the IVM monogenic model) the superscript e is dropped and superscript d 
indicates resistance to macrofilaricidal/inhibition of reproduction and embryostatic 
effects of IVM. For example, Wb
oO denotes the mean number of adult worms (in the IVM 
monogenic model) which have the homozygote susceptible genotype at both the ABZ 
and IVM resistance loci; Wb
201 indicates the mean number ofworms (in the IVM 
polygenic model) which are homozygous resistant at the ABZ resistance locus, 
homozygous susceptible at the linked, IVM resistance locus, and heterozygous at the 
second, unlinked IVM resistance locus. Similar notation is used to represent the mean 
number ofmicrofilariae per 20 )lI blood, M~de, and the mean number ofL3 larvae per 
mosquito, L~de. The level of acquired immunity in the treated and untreated human 
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population is specified by, respectively, 1 T and 1 u' The modified EPIFIL equations are 
as follows, 
ôMede :JMede b U b ede ede 
-Ô-'("---- + Ô a = a Wb (ù b - r M b 
ô1b ô1b 
-+-=W -,,11 ôt ôa b b 
a=oo Mede 
Âxg f JT(a);; f(Mb)da 
L*ede _ a=O b b -
(A4,1) 
(A4.2) 
(A4.3) 
(A4.4) 
(A4.5) 
where A., is the biting rate per mosquito on humans; V/H is the vector to human 
ratio; lP} is the proportion of L3 larvae that leave the mosquito' s proboscis at the time of 
biting and are deposited onto hum an , s skin; lP2 is the proportion of the latter which enter 
the host through the wound caused by the mosquito bite; S2 is the proportion of larvae that 
having entered the host will deve10p into adult worms; h(a) is the proportion ofhosts of 
age a that are bitten, thereby making the biting rate on humans age-dependent (it is 
assumed that this proportion increases linearly until the age of 9 years and becomes Ullity 
thereafter); f3 is the severity by which larval establishment is decreased by acquired 
immunity l (which is assumed to increase with cumulative worm burden or worm 
experience and decay at a rate LI); fl, rand (J'are, respectively, the per capita death rates 
of adult worms, microfilariae and L3 larvae; a is the per capita reproductive rate of adult 
151 
worms (the rate at which fertilized females produce microfilariae per 20 ~l ofblood), 
and. OJ~de is the proportion of microfilariae with the cde genotype (calculated as 
described in Appendix B). The proportion of the total host population treated 
2 2 2 2 2 2 
(therapeutic coverage) is denoted by C; ~ = LLL~ and ~ = LLL~aie. The 
c=O d=fJ e=O c=O d=O e=O 
expression for L *cde determines the average number ofL3 laniae per mosquito for each 
genotype that infect the treated and untreated sections of the population, As with EPIFIL, 
the L3 population is assumed to be at equilibrium (denoted by the asterisk) and is 
ca1culated using equation (AS). In this equation, the function that models larval 
development within the (Culex-type) mosquito vector as dependent on the level of 
microfilaraemia, f(Mb ) , is calculated separately for treated and untreated sections of the 
host population with expression, 
(A4.6) 
where pis the initial, linear rate of increase in L3 larvae per microfilaria in 20 ~l 
ofblood, pl K the severity of density-dependent constraints upon larval uptake and/or 
development; Kthe level at which the function saturates (the maximum number ofL3 
produced per mosquito as microfilaraemia increases), and kb the overdispersion parameter 
of the negative binomial. In the remainder of equation (AS), g is the proportion of bites 
which result in infection ofmosquitoes, and 1C(a) is the proportion of the host population 
surviving to age a, based on a population in Pondicherry, India (for which EPIFIL was 
first parameterised). The equation for 1C(a) is given by, 
exp( -a / m) [ ] 7r(a) = l-exp(-n/m) (A7) 
m 
with m = 29 and n = 65. Finally, it is assumed (motivated by data), that the 
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overdispersion parameter of the negative binomial distribution of microfilariae in the host 
population is itself a density-dependent function with expression kb = ko + k1 M b' 
representing a degree of overdispersion which depends linearly on microfilaraemia and 
will therefore increase in the treated sections of the population under microfilaricidal 
therapy. AlI the parameter values of the basic EPIFIL model have been listed in Schwab 
et al. (in press). 
IVM Monogenic Model 
In the IVM monogenic model we allow the IVM resistance locus to be either 
linked or unlinked to the ABZ resistance locus. Linkage increases the number of possible 
genotype combinations a parasite Can have as helminths which are heterozygous for both 
ABZ and IVM resistance Can either have both resistance alle1es on the same chromosome 
(alle1es are concordant, denoted by superscript C), or have resistance alleles on the 
opposite, partner chromosome (alle1es are discordant, denoted by superscript D). The 
different genotype combinations for the two loci model and their associated abbreviations 
are listed in Table A.4.1. 
Table A.4.1 : The abbreviations used within the IVM monogenic (2 loci) model. 
For the linked loci it is specified on which chromosome (denoted Ch.) the alle1e occurs. 
Abbreviation ABZ locus IVM locus Equation used to calculate the genotype 
Ch. 1 Ch. 2 Ch. 1 Ch. 2 frequency of the next generation 
00 S S S S OJ ~o= (O;sy (1- F)+ (Ory 
01 s S R S (IJ~l= 2(G;RXG;sX1-F) 
02 S S R R Ci) ~= (G;R Y (1- F)+ (G;R)F 
10 R S S S (IJ~o= 2(G:sXG;sX1- F) 
lle R S R S OJ ~lC = 2(G/:)(G;s)(I- F) 
llU R S S R OJ ~lD = 2(G:s )(GtR )(I- F) 
12 S R R R (IJ~2= 2(G;RXG:RX1- F) 
20 R R S S {IJ !o= (G:Sy (1- F)+ (G:S)F 
21 R R R S (IJ~l= 2(G:RXG:sX1- F) 
22 R R R R Ci) ~2= (o~ y (1- F)+ (O~)F 
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The genotype distribution of microfilariae in the next generation is determined by 
the allele frequency of the adult worm population using simple Mendelian genetics. The 
frequency of gametes produced by the adult worm population is denoted by G:i . 
Gametes can have either the resistance or susceptibility alle1e at each of the loci under 
investigation (where h denotes the ABZ resistance locus and i denotes the IVM resistance 
locus, with resistance in both cases referring to macrofilarial resistance as described 
above). For the 2 loci model the gamete frequencies are calculated as follows, 
(A4.7) 
(A4.8) 
(A4.9) 
(A4.10) 
where w~d is the proportion of the adult worm population with the cd genotype 
wcd (given by w~d = _b -). The proportion of new microfilariae with the cd genotype, OJ~d, 
Wb 
is calculated from the different gamete frequencies; for individual equations see Table 
A4.1. Parameter r is the recombination fraction between the two loci or the proportion of 
recombinant gametes that are produced by a double heterozygote (Hartl and Clark 1997). 
Genes that are not linked have a recombination fraction r = 0.5. Genes which are linked 
have a value ofr < 0.5. When genes are 100% linked, r = 0 (i.e., no recombination 
occurs between the twO loci). Unless otherwise stated, the model assumes non-random 
parasite mating, with F (see Tables A4.1 and A4.2) set at 0.44 (the value of FIT estimated 
for untreated populations in Burkina Faso, see main text). 
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IVM Polygenic Model 
Here we model the parasite genotype frequency when there are three loci 
associated with resistance; one which determines ABZ resistance and another two loci 
that determine NM resistance. The 3 loci model assumes that one of the IVM resistance 
loci is completely linked to the ABZ locus (with no recombination occurring between the 
loci), with the other remaining loci being unlinked to either of the first two loci. The 
frequencies of parental gametes can be derived from the 2 loci case as follows, 
(A4.11) 
G:SR = w:2 + o.S(WZI2 + W~h+11{02 + w:1} o.2S(WZll+~ICl+11{OI) (A4.l2) 
GSRS = W 020 +0 S{WOIO+WllDO+WI20 + W021 \, 02S{WOll-hJ.1Dl+WI21) 
b b • \:b b b b F' \:b b b (A4.13) 
(A4.14) 
(A4.1S) 
(A4.16) 
(A4.17) 
(A4.18) 
where w;de is the frequency of the adult worm population with the cde genotype 
wcde (given by w;de = _b -). Grs denotes the frequency of the gamete Gr with the 
Wb 
susceptibility allele at the third, unlinked locus, and GrR denotes the frequency of the 
gamete Gr bearing the resistance allele at the third unlinked locus. For individual 
equations calculating the proportion ofnew microfilariae with the cde genotype see Table 
A4.2. 
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Table A.4.2 : The abbreviations used within the IVM polygenic (3 loci) model. 
F h r nk dl' . l' "fi d h' h hr (d t d Ch ) th 11 1 ort e 1· e OCI 1 IS speCI le on w lC C omo sorne eno e e a e e occurs. 
Abbreviation ABZ locus IVM locus IVM 2lld locus Equation used to calculate the geIiotype 
Ch. Ch. Ch. 1 Ch. Linkage frequency of the next generation 
1 2 2 equilibrium 
000 S S S S SS œ ~oo= (G;ssy (1- F)+ (G;SS)F 
001 S S S S RS (ù ~Ol= 2(GgSRXGgssX1- F) 
002 S S S S RR œ ~02= (GtSRy (1- F)+ (GtSR)F 
010 S S R S SS (ù ~IO= 2(GtRsXGtSSXl-F) 
011 S S R S RS (ù~I1= 2 [(GîRRXGîSS)+ (GîRsXGîSR)Jl- F) 
012 S S R S RR (ù~12= 2(GtRRXGtSRXl- F) 
020 S S R R SS OJ ~20= (GîRSy (1- F)+ (GîRS)F 
021 S S R R RS co~21=2(GtRsXGtRRX1-F) 
022 S S R R RR OJ ~22= (GtRRy (1- F)+ (GîRR)F 
100 R S S S SS co~oo= 2(G:ssXGtSSXl- F) 
101 R S S S RS (ù~ol=2[(G:SRXGîSS)+ (G:ssXGîSR)Jl- F) 
102 R S S S RR CO~02= 2(G:sRXGtSRXl-F) 
11 OC R S R S SS (ù~lcf = 2( GtssX G:RsX1- F) 
110D R S S R SS (ù~IOD =2(GtRSXG:SSXt -F) 
111c R S R S RS CO~1 r: = 2[(GJSRXC:RS)+ (GJssX~R)ll-F) 
1111J R S S R RS CO~I f = 2[( GJRRX C:SS)+ (GJRSX c:sR)ll-F) 
112c R S R S RR (ù~lf =2(GJsRXa:RRX1-F) 
112D R S S R RR (ù~12D = 2(GtRRXG:sRX1-F) 
120 S R R R SS co~2°=2(GtRSXG:RryJ - F) 
121 S R R R RS (ù~21= 2 [(GîRRXG:RS)+ (GgRsXG:RR )Jl-F) 
122 S R R R RR CO~22= 2(GtRRXG~RXl-F) 
200 R R S S SS (ù~oo= (G:ssy (1- F)+ (G:ss)F 
201 R R S S RS co~ol=2(G:sRXG:ssXI-F) 
202 R R S S RR CO;02= (G:SRj (l-F)+(GfsR)F 
210 R R R S SS (ù~12=2(GtSRXGtRRXl-F) 
211 R R R S RS (ù~11= 2 [(G:RRXG:SS)+ (G:RsXG:sR)J1-F) 
212 R R R S RR (ù;12= 2(G:RR XG:sRX1- F) 
220 R R R R SS OJ ~20= (G:RSy (1- F)+ (G:RS)F 
221 R R R R RS OJ~21= 2(G~RXG:RsXl- F) 
222 R R R R RR OJ ~22= (G~R Y (1- F)+ (G~R)F 
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CHAPTER 5: GENERAL DISCUSSION 
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The CUITent initiative to controllymphatic filariasis, implemented under the 
auspices of the World Health Organization, promises, if successful, to prevent the 
suffering of millions of people. In order to reach its goal of eliminating the disease as a 
public health problem by the year 2020, it is proposed to repetitively administer 
anthelmintic drugs to people in endemic areas. By the year 2004, approximately 435 
million doses of dl1lg had been administered to the at-risk population in half of all 
recognized LF endemic countries (Gyapong and Twum-Danso, 2006) and in 2005 a total 
of 61 0 million people were targeted with Mass Drug Administration for LF 
(www.who.int/lymphatic filariasis/disease/enl, accessed June, 8,2006). Experience, 
from the field ofveterinary parasitology, indicates that large scale, repetitive distribution 
of anthelmintic drugs will inevitably lead to the emergence of drug resistance (Kaplan, 
2004). Further examination ofthe potential for similar drug-resistance development is 
imperative in order to predict the success ofthe control program (Michael et al., 2004). 
Drug resistance to benzimidazoles (BZ) has been reported in many species of 
helminths of veterinary importance, as weIl as in protozoa and fungi and has been shown 
to be caused by SNPs in the ~-tubulin gene (Driscoll et al., 1989; Edlind et al., 1994; 
Elard et al., 1996; Jung et al., 1992; Koenraadt et al., 1992; Kwa et al., 1993; Kwa et al., 
1994; Orbach et al., 1986; Pape et al., 1999; Prichard, 2001; Silvestre and Cabaret, 2002; 
von Samson-Himmelstjema et al., 2001; Yarden and Katan, 1993). 
In the second chapter ofthis thesis we present the first evidence that such BZ 
resistance SNPs exist in Wuchereria bancrofti lymphatic filaria. Observed frequencies, 
of the ~-tubulin 200TYR resistance SNP, were variable in untreated populations, ranging 
from less than 1 % in Ghana to 26 % in Burkina Faso. High initial allele frequencies of 
BZ resistance alleles have been observed in unselected populations of other helminths 
(Beech et al., 1994). However, in the case of the parasites obtained from Burkina Faso, 
prior exposure to ABZ cannot be ruled out, as regular de-worming of school children 
using ABZ is common in many communities in West Africa (Hall et al., 1996) and a 
large number of doses of ABZ have been administered, over many years, in numerous 
countries. 
The mathematical model that is presented in the third chapter of this thesis 
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examined the effect of differing initial allele frequencies on selection for the ABZ 
resistance genotype. The output of these simulations indicates that a higher initial allele 
frequency willlead to a higher proportion of the population that will be resistant to ABZ 
after the treatment period (assumed to be ten yearly treatments at 85% coverage). A 
simplistic model proposed in a review by Michael et al (2004) draws the same conclusion. 
Thus communities with higher initial frequencies may develop high levels of resistance 
more quickly. This highlights the importance of measuring how common resistant alleles 
are in the population prior to the ons et of treatment programs. Diagnostic tests such as 
those described in Chapter 2 will be useful in setting up such monitoring systems. 
The data collected in Burkina Faso indicates that the frequency of the ABZ 
resistance allele, as well as the resistance genotype are significantly higher in populations 
treated with a combination of IVM and ABZ. The frequency was again significantly 
higher in Mf sampled from people that had been treated twice, though there was a 
considerably smaller sample size for this group. The statistical analysis in this study was 
done using a Chi-square test. These results suggest that selection for the ABZ resistance 
allele may be occurring in W bancrofti from Burkina Faso. 
In this study, we only investigated one isotype oftubulin. None of the partial 
sequences obtained suggested that they originated from different isotypes. However, only 
three clones spanning the entire co ding sequence were sequenced, thus the presence of a 
second isotype can not be excluded. A second isotype of tubulin could contribute to ABZ 
sensitivity in W bancrofti. 
The Mf from doubly treated patients in Burkina Faso, that were genotyped in 
Chapter 2, were collected only seven days after the last treatment had occurred. Thus 
adult worms affected by the anthelmintics should not have resumed reproduction, and the 
population genotyped is probably a surviving population after drug treatment. In addition, 
this time period is far too short for worms acquired since treatment to have reached 
sexual maturity, as the pre-patent period of W bancrofti is estimated to be 7-8 months 
(WHO, 1984; WHO, 1992). 
It should be noted that the genotype frequencies of Mf sampled from treated 
people exclusively, considers the proportion ofMfin treated people and not the entire Mf 
population of the community in question. The simulations carried out in the third chapter, 
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which assume that the same people are treated each year and the untreated people are also 
the same from year to year, show that, according to the mathematical model proposed, 
resistance would only become apparent in the Mf population after the cessation of the 
treatment program. This is explained by the fact that during the treatment period, very 
little parasite reproduction would occur in the treated people, and most of the Mf 
population would be from people that have not been treated. Presumably, sorne people in 
the treated villages in Burkina Faso did not undergo treatment, and, as they likely had 
higher Mf counts, their parasite load would contribute greatly to the overall population of 
Mf in the community. The predicted increase in resistant genotypes after the end of the 
treatment period raises the concern that, should the control pro gram end before 
elimination of the parasite, a newly established population oflymphatic filaria will have a 
higher proportion of resistant individuals and will thus be more difficult to control. 
The Mf samples from Burkina Faso were not in Hardy-Weinberg equilibrium at 
the p-tubulin locus. There was a significantly higher frequency of homozygotes in the 
population than expected. Parasite populations are knowri to be strongly subdivided, as 
they are distributed amongst hosts, and cannot directly mate with individuals that are not 
within the same host. Population subdivision leads to a deficit in heterozygotes, a 
phenomenon termed the Wahlund effect (Hartl and Clark, 1997). It has been previously 
noted that genetic differentiation between hosts exists in parasites (Fisher and Viney, 
1998; Lymbery et al., 1990; Vilas et al., 2003). 
A detailed analysis of genotyping data from the study carried out in Burkina Faso 
and presented in Chapter 2 (details are inc1uded as Appendix 1 to this thesis) reveals that 
the excess homozygosity observed is unlikely to be generated simply by stochastic 
processes or sampling strategies. It also indicates that there is significant genetic 
differentiation between human hosts, though no geographical subdivision between 
villages was observed. In addition, we found sorne indication of assortative rnating 
within patients, though this was not statistically significant. 
Since ABZ resistance is known to be recessive in nematode species in which this 
has been examined, increased homozygosity will, if ABZ resistance is also recessive in W. 
bancrofti, increase the number ofworms surviving chemotherapy. This willlead to a 
more rapid spread of the resistance allele. The impact of increased homozygosity on the 
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development of drug resistance was examined using the mathematical model presented in 
Chapter 3. Simulations that vary homozygosity through the use ofWright's inbreeding 
statistic FIT suggest that even very low levels ofincreased homozygosity greatly increase 
the spread of an ABZ resistance allele after selection with combination chemotherapy. A 
similar analysis was also carried out in Chapter 4, using a mathematical model which 
incorporates a recessive ABZ resistance allele as well as a dominant IVM resistance 
allele. In the case of such multi-drug resistance, our model predicts that the spread ABZ 
resistance is increased by a positive FIT value to a similar degree to that calculated for 
ABZ resistance alone. Simultaneous selection for dominant IVM resistance is also 
increased by excess homozygosity. As increased homozygosity and decreased 
heterozygosity is expected to reduce the nurnber of genotypes surviving treatment in the 
case of dominant resistance. The increase in IVM resistance genotypes, in the case of the 
non-random mating observed here, is likely to be due to the fact that fewer individuals 
would be sterilized by ABZ in this case, and more selection may occur. 
Genetic differentiation between hosts may also increase selection for resistance, 
since there is a greater chance that resistant worms co-habit the same host and mate to 
produce homozygous resistant offspring. However, density dependent constraints on 
resistant populations within a single host may slow the spread of resistance. 
In light of the findings in Appendix l, a re-analysis of the data presented in 
Chapter 2 indicates that a proportional sampling scheme may have been more appropriate 
in order to conclusively detect a difference in the underlying microfilarial allele 
frequencies from Burkina Faso. The number of Mf samp led per patient should, more 
appropriately, be proportional to the microfilarialload of each host. 
It must however be stressed that the results obtained in Appendix l are based on 
the analysis of only one gene. It will be necessary to further analyze a nurnber of 
different genes from W bancrofti microfilarial populations in order to conclude with 
certainty the cause of such excess homozygosity. Work in our laboratory on the related 
filarial parasite 0. volvulus indicates a similar level of increased homozygosity as that 
found in appendix l in P-tubulin. However such genotype distributions were not found in 
control genes, suggesting the possibility of assortative mating (Catherine Bourguinat, 
personal communication). 
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In Chapter 3, there is further analysis of the potential spread of drug resistance in 
W bancrofti, using a mathematical model. The simulations carried out in this model 
indicate that the assumptions made about drug efficacies greatly impact the speed and 
magnitude of the spread of an ABZ resistance allele due to combination chemotherapy. 
The importance of correctly estimating the effect of drugs on lymphatic filariae, in 
mathematical models designed to predict the impact of control programs, was previously 
highlighted by Michael et al (2004). Studies examining drug effects against LF show 
great variability, and it has been traditionally very problematic to predict such drug 
effects, mainly due to the difficulty in the observation of adult worms (Stolk et al., 2005; 
Tisch et al., 2005). Increasing our knowledge of the precise impact that each of the drugs, 
used in the GPELF, alone or in combination, has on the parasite is imperative in order to 
more accurately predict how quickly ABZ resistance is likely to become a problem for 
the control program. Based on the efficacy assumptions made in Chapter 3, the 
combination ofDEC and ABZ will allow a more rapid spread of ABZ resistance alleles 
than the combination of IVM and ABZ. This can be explained by the stronger 
microfilaricidal activity of, as weIl as a longer suppression of reproduction, caused by 
IVM in comparison with DEC. 
In order to achieve its goal, the GPELF will have to maintain high levels of 
therapeutic coverage (Michael et al., 2004). We examined how different levels of 
coverage affect selection for resistance in the case of an ABZ resistance allele (Chapter 3) 
or in the case of a dominant IVM resistance allele, in addition to ABZ recessive 
resistance (Appendix II). Our model predicts that higher levels of coverage will decrease 
the overall population of Mf after treatment, but that a greater proportion of the remaining 
Mfwill be resistant to ABZ. Similar observations have been made when examining the 
case of refugia in the development of anthelmintic resistance in helminths of veterinary 
importance (Coles, 2002; van Wyk, 2001). However the impact ofincreasing coverage 
in the development of dominant IVM resistance is considerably more complicated. Our 
model predicts that increasing coverage up to 85% will increase the spread of the 
resistance allele. However, ab ove this point, higher levels of coverage may actually 
decrease the spread of the resistance alleles (see Appendix II). This may be related to the 
high microfilaricidal effect of IVM, as well as adult worm longevity, in combination with 
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selection for ABZ resistance. Estimates of adult longevity are variable, ranging from 5-
40 years (Carme and Laigret, 1979; Vanamai1 et al., 1990). Thus, a better understanding 
of the length of the adult W bancrofti lifespan, as well as drug efficacy data, should be 
given considerable attention in the future in order to improve the predictive value of 
mathematical models of lymphatic filariasis. 
In Chapter 3 we also examine how the length of the treatment period affects the 
spread of selection. As in the case of increased treatment coverage, more years of yearly 
treatment reduces the average microfilarialload per patient. However, more of the 
remaining microfilariae will be resistant to ABZ. A rapid progress towards the goal of 
the GPELF with a minimum number oftreatments is thus desirable in order to prevent the 
spread of problematic ABZ resistance. 
The simulations in this thesis show a considerable increase in anthelmintic allele 
frequencies, despite a continued reduction in total Mf load throughout the treatment 
period. This is a consequence of combination treatment. Thus iftwo drugs are used 
concurrently, resistance to one drug may still be selected, although there may be few 
cases oftreatment failure during the initial treatment period. Thus, should IVM and DEC 
become unavailable for the treatment of LF, there may already be a significant amount of 
drug resistance against ABZ that had been selected during the period of combination 
therapy. 
In Chapter 4, we examined the impact of concurrent selection for IVM resistance 
on the development of ABZ resistance. Our simulations show that the presence of a 
dominant IVM resistance gene may increase selection for ABZ resistance and vice versa. 
This is due to a larger proportion of the parasite population surviving combination 
treatment when IVM resistance is present. The model presented in Chapter 4 also 
highlights the importance of dominance in the spread of resistance alleles. Our 
simulations show that higher levels of dominance of an IVM resistance gene willlead to 
a quicker and more pronounced spread of IVM resistance alleles through the parasite 
population. Dominance was shown to have a similar effect on the development of 
anthelmintic resistance in other helminths with a direct life-cyle (Bames, 1995; Dobson et 
al., 1996). 
Based on the mode1 used in Chapter 4, linkage on1y affects selection of resistance 
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alleles if genes are completely linked and not in linkage equilibrium. If resistance loci to 
both drugs lie on the same alle1e more often than expected at linkage equilibrium, 
selection for ABZ will increase selection for IVM and vice versa. We also found that if 
IVM is inherited as a polygenic trait, resistance against IVM will develop more slowly 
than in the case of a single gene, a finding which corroborates what is known about the 
development ofanthelmintic resistance in sheep nematodes (Dobson et al., 1996). More 
detailed information on the mechanism of IVM resistance will be of great value in order 
to improve the accuracy of model predictions. 
The models presented in this thesis are deterministic models, and thus are limited 
in the accuracy of their quantitative outputs. However, such models are highly useful in 
providing qualitative insight into the mechanisms and relative importance of the factors 
involved in biological systems. Stochastic simulation models provide more realistic 
outputs, however the high levels of complexity involved in such models can make it 
difficult to draw clear conclusions. Nonetheless, a stochastic model examining single and 
multidrug resistance in filarial worms could be extremely beneficial and provide further 
insight into this complex issue. We are presently developing such a stochastic model, as 
with it, we will be able to further examine sorne of the questions examined in the 
preceding chapters. 
In addition, our models were based on EPIFIL, which was parameterized for 
Culex-transmitted filariasis. We use these parameters in order to remain as close as 
possible to the EPIFIL model. However, our evidence for increased parasite 
homozygosity cornes from West African locations, where Anopheles- rather than Culex-
transmitted filariasis prevails. Sensitivity analysis (data not shown) reveals that worm 
populations in EPIFIL are controlled primarily by immunity in the definitive host, and 
differences in density dependence in the vector willlikely have been small, and would 
not affect the qualitative conclusions of this work. 
Our models assume no trade-offs for resistance. It has been shown that BZ 
resistance persists for many generations after removal of anthelmintic selection pressure 
(Hall et al., 1982). In addition, lack ofreversion ofBZ resistance after prolonged use of 
levamisole has been observed (Borgsteede and Duyn, 1989; Martin et al., 1988) and 
Elard et al. (1998) examined the relative fitness ofBZ-resistant and sensitive strains of T. 
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circumcincta and found no significant difference, which supports our assumption. We 
made similar assumptions for IVM resistance, though there is no experimental evidence 
supporting this assumption. We can therefore not comment on whether NM resistant 
phenotypes will affect fitness, in the absence of the drugs. 
In summary, this thesis provides a detailed analysis ofthe genetics of the potential 
spread of drug resistance in the lymphatic filarial worm, W. bancrofti. We have shown 
that mutations, which cause ABZ resistance in other nematodes, exist in W. bancrofti in 
West Africa, and our models predict that such resistance mutations willlikely spread if 
the current control strategy of the GPELF is continued without monitoring and the 
addition of vector control, in the event that significant frequencies of resistance alleles are 
determined. We find that the matingstructure of filarial worms may lead to a quicker 
spread of resistance than expected and highlight the fact that factors such as drug-efficacy 
assumptions, treatment coverage, number of treatments and concurrent selection for IVM 
resistance may impact how quickly resistance spreads. We aiso find that dominance and 
polygenicity of IVM resistance impacts the spread of ABZ and IVM resistance and that 
these factors must be examined in more detail in the field. 
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INTRODUCTION TO APPENDIX 1 
In Chapter 2, we identified mutations associated with ABZ resistance in W 
bancrofti. We genotyped microfilariae from untreated and treated patients in order to 
determine the presence of this mutation. Upon close examination of the data, we observed 
that the total population of microfilariae was not in Hardy-Weinberg equilibrium. This 
indicated that lymphatic filaria may not have been mating randomly, and that the 
population may be subdivided. Such a finding could have serious implications. Selection 
for recessive resistance alleles may occur faster if the population has elevated frequencies 
of homozygotes, and treatment failures may occur at lower overallieveis ofresistance 
allele frequencies. In addition, the sampling strategies employed in order to detect the 
frequencies of resistance alleles may have to take into account the levels of 
microfilaraemia of patients sampled in the case of non-random mating in the parasite 
population. The following appendix is a detailed analysis of the microfilarial population, 
from Burkina Faso, genotyped in Chapter 2, taking into account the number of 
microfilariae sampled per ho st, as well as the hosts' microfilarial counts. Inbreeding 
coefficients are calculated and implications for sampling strategies are discussed. 
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APPENDIXI: 
HELMINTH INBREEDING AND THE DETECTION OF DRUG 
RESISTANCE 
T. S. Churcher, A. E. Schwab, R. K. Prichard, M.-G. Basanez 
To be submitted 
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Abstract 
Genetic epidemiological studies ofhelminth infections ofhumans typically 
sample the worm population indirectly, through the transmission stages that gain access 
to the environment. The results of these studies should be interpreted with caution, as the 
allele frequency and genotype distribution estimates obtained may differ greatly from 
those of the underlying adult worm population. Analysis of data collected for the 
lymphatic filarial parasite Wuchereria bancrofti, investigating a single polymorphic locus 
(a genetic change at position 200 on B-tubulin, known to cause benzimidazole resistance 
in nematodes offarmed ruminants), was conducted in microfilariae obtained from West 
African patients before and after the introduction of mass drug administration with 
albendazole plus ivermectin combination therapy. An individual-based stochastic model 
was developed to show that a wide range of microfilarial alle1e and genotype frequencies 
can be sampled from a single adult worm population, suggesting that appropriate 
theoretical null models are required in order to interpret adequately the resuIts of 
genotyping solely transmission stages. Wright's hierarchical F-statistic was used to 
investigate the population structure in W bancrofti microfilariae and showed significant 
deficiency of heterozygotes compared to the Hardy-Weinberg equilibrium. Results 
indicate strong parasite genetic differentiation between hosts, and a high degree of 
he1minth assortative mating, which are unlikely to have occurred from population 
subdivision, heIminth overdispersion, parasite mating behaviour, or the sampling scheme 
employed. If the alle1e conferring drug resistance were recessive, parasite inbreeding 
would contribute to substantialloss of antheImintic efficacy, and eventually to treatment 
failure. Genetic epidemiological surveys ofhelminth populations should consider the 
parasite's biology when designing sampling schemes, in order to maximise the accuracy 
of allele frequency estimates and identify genetic changes indicative of selection under 
chemotherapeutic pressure. 
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6.1. Introduction 
In recent years there has been a dramatic increase in the use of mass drug 
administration (MDA) to reduce the morbidity associated with helminth infections of 
humans (Lammie et al., 2006), increasing the probability that anthelmintic resistance may 
become a public health concem in the future. One such annual MDA programme is the 
Global Programme to Eliminate Lymphatic Filariasis (GPELF) which, in 2005, treated 
over 145 million people with albendazole (a broad spectrum benzimidazole) in 
combination with either ivermectin or diethylcarbamazine (WHO, 2006). GPELF targets 
mainly Wuchereria bancrofti, the most widely distributed of the human filariae. 
Evidence from the spread of anthelmintic resistance in veterinary nematodes 
indicates that once resistance reaches phenotypically detectable leve1s it may be too late 
to prevent widespread treatment failure (Roos et al., 1995). Sensitive molecular assays 
are required to detect the presence of anthelmintic resistance before it becomes a major 
public health concem. Surveys ofhelminth parasites ofhumans are being conducted to 
establish whether genetic changes at certain polymorphic loci, which have been 
associated with resistance to the same or similar anthelmintic drugs in veterinary 
helminths, are present and subject to detectable selection under chemotherapeutic 
pressure (Albonico et al., 2004; Ardelli and Prichard, 2004; Ardelli et al., 2005; Eng and 
. Prichard, 2005; Schwab et al., 2005; Ardelli et al., 2006a, 2006b; Eng et al., 2006). A 
phenylalanine to tyrosine substitution at position 200 (TYR 200) on the B-tubulin isotype 
1 molecule is thought to be associated with benzimidazole (BZ) resistance, and has been 
identified in a number of helminth parasites of farmed ruminants inc1uding Haemonchus 
contortus (Kwa et al., 1993; Kwa et al., 1994), Cooperia oncophora (Njue and Prichard, 
2004), and Teladorsagia circumcincta (Elard and Humbert, 1999; Silvestre and Cabaret, 
2002), as well as, worryingly, in W bancrofti (Schwab et al., 2005). 
Parasite alle1e frequency can differ between infrapopulations (the populations of 
parasites within individual hosts) due to the ecology of the infection or through the 
random nature of infection events (all groups may have an equal probability ofhaving a 
rare alle1e, but actual numbers may vary between groups by chance). Helminth parasites 
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have a particularly subdivided population structure as adult wonns are confined to live 
within their definitive host, and are only able to mate with other wonns that belong to the 
same infrapopulation. Parasite genetic differentiation between hosts has been observed in 
a number ofhelminth species (Criscione et al., 2005). Infrapopulation genetic 
differentiation will cause a reduction in the frequency ofheterozygote offspring, a 
princip le known as the Wahl und effect (Hart1 and Clarke, 1989). Other facets of a 
species' biology may also influence parasite genotype distribution, such as parasite 
assortative mating (when mate choice is detennined by phenotype). 
Alleles conferring drug resistance, inc1uding the TYR200 genetic change, which 
confers BZ resistance, are thought to be recessive in a number of nematode species (Elard 
and Humbert, 1999; Le Jambre et al., 1999; Prichard, 2001), making heterozygote wonns 
susceptible to treatment and the resistant phenotype unstable from generation to 
generation. If an allele conferring drug resistance is partially recessive, excess parasite 
homozygosity will increase the probability that a resistance allele will survive treatment. 
The degree of parasite genetic differentiation among hosts can be quantified using FST (or 
related analogues; see Criscione et al. (2005) and references therein). 
The adult stages ofmost parasitic helminths ofhumans cannot be obtained 
routine1y for direct examination or investigation, so genetic epidemio10gica1 surveys 
resort to sampling transmission stages, i.e. those 1ife-stages that gain access to the 
environment to be transmitted to and from hosts or through vectors (Fisher and Viney 
1998; Paterson et al., 2000; Brouwer et al., 2001; Curtis et al., 2002; Schwab et al., 2005; 
Shrivastava et al., 2005). The majority of studies investigating the spread of anthelmintic 
resistance in helminth infections ofhumans will have to rely on sampling transmission 
stages as adult wonns are often difficult to obtain. The results of these surveys should be 
interpreted with caution, as the underlying allele frequency of the adult wonn population 
may in fact differ substantially from the allele frequency of the sampled transmission 
stages. Variations in transmission stage allele frequency and genotype distribution could 
be generated randomly or be a product ofthe parasite's spatial structure and life-history 
traits. For example, population subdivision will randomly cause variation in adult wonn 
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allele frequencies between hosts at low parasite densities. Filarial parasites have separate 
sexes and are thought to be highly polygamous, which may accentuate the variability in 
microfilarial allele frequency, e.g. a rare allele may be highly over-represented in the 
subsequent generation if a male worm with this allele inhabits a host harbouring females 
but no other males. In addition, the inherent randon;l sampling of gametes during sexual 
reproduction, and the overdispersed distribution of parasite numbers among hosts 
(Anderson and May, 1992) may cause variations in allele frequency and genotype 
distribution from generation to generation. 
This paper analyses population genetic data collected for a study by Schwab et al. 
(2005) who identified the presence of the TYR200 change of the jJ-tubulin gene in 
populations of W bancrofti. Firstly, the extent of parasite inbreeding is estimated from 
W bancrofti microfilarial samples taken from patients in Burkina Faso, West Africa. 
Samples were obtained from different villages, sorne ofwhich had received a single 
round ofMDA with ivermectin and albendazole, under the auspices of the GPELF. 
Secondly, an individual-based stochastic model is presented which simulates microfilarial 
genetic diversity from adult worm allele frequencies. The model generates sample allele 
and genotype frequencies using the same number ofhosts, and the same number of 
microfilariae per host as in Schwab et al. (2005). Finally, this model is used to assess the 
likely range of adult worm allele frequencies which would give rise to the observed 
microfilarial data and to identify whether observed genotype distributions are likely to be 
generated by chance. We discuss the implications of our results in terms of the 
development and detection of anthelmintic resistance. 
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6.2. Materials and Methods 
6.2.1 Sampled Data 
Table 1 summarises the data collected for the study by Schwab et al. (2005) and 
indicates the number of microfilariae and hosts sampled. In sorne hosts it was possible to 
genotype only a few microfilariae; thus their underlying infrapopulation alle1e 
frequencies are highly uncertain. Results are grouped according to parasite treatment 
history. The average resistance alle1e frequency of microfilariae from untreated and 
treated hosts was 0.26 and 0.60, respectively (Schwab et al., 2005). Parasite 
heterozygosity in each of the villages indicates a deviation from the Hardy-Weinberg 
Equilibrium (HWE), revealing a strong deficit of heterozygotes . 
. Table 6.1: Summary of the genetic survey conducted on Wuchereria bancrofti 
microfilariae from Burkina Faso of genetic changes at the f3-tubulin locus associated with 
benzimidazole resistance (in nematodes of ruminants). Results were presented by 
Schwab et al. (2005). The range ofmicrofilarial samples obtained per host is given in 
brackets. The expected microfilariae heterozygosity according to the Hardy-Weinberg 
equilibrium is given in square brackets 
Village No. Mean no. of Mean Sample Sample and 
hosts microfilariae microfilaraemia resistance allele [expected] 
sampled genotyped per host (per 20,ul blood) ~M frequency, q heterozygosity 
Untreated villages 
Tangonko 16 9.6 323 0.28 0.20 
(1, 15) (162,703) [0.40] 
Badongo 14 6.6 212 0.23 0.24 
(1, 10) (60,845) [0.35] 
Villages that had received one round of chemotherapy (albendazole + ivermectin) 
Perigban 13 8.5 35 0.62 0.27 
(3, 12) (18,86) [0.47] 
Gora 1 7 186 0.29 0.29 
rO.4ll 
This paper refers to two different types of allele frequency: (1) underlying alle1e 
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frequency, ql , the allele frequency of the entire parasite population of a given locality, 
and (2) the parasite allele frequency within the host population that is sampled, H q 1. The 
superscript 1 denotes the parasite life-stage under investigation, be it microfilariae (l = M) 
or adult worms (l = W). The sampled (observed) allele frequency, tipM , may not 
correspond to the true underlying allele frequency, ql ,(that needs to be estimated) either 
because the hosts sampled are not representative of the whole host population, or because 
the parasites genotyped do not represent adequately the allele frequency in the host. 
6.2.1 Estimating Parasite Inbreeding 
By genotyping transmission stages before they leave the definitive host prior to 
the introduction of mass chemotherapy, insight can be gained into the different causes of 
microfilarial excess homozygosity. For a single locus trait, the genotype frequency of an 
infrapopulation's offspring is dependent on the allele frequencies of the male and female 
worms reproducing within the host, and not on their genotype distribution (assuming 
male and female adult worms have the same underlying allele frequency). If it is 
assumed that the number of microfilariae produced, their survival, and their probability of 
being sampled is independent of their genotype, it can be concluded that deviation from 
the HWE is a resuIt of non-random mating. If the locus being investigated is not under 
selection, the excess microfilarial homozygosity will most likely be the result of 
infrapopulation genetic differentiation or assortative parasite mating within hosts. 
Genotyping transmission stages would allow the relative contributions of each of these 
two sources of inbreeding to be estimated, as excess microfilarial homozygosity within 
each host will result from assortative mating. Filarial parasites are unable to self-fertilise 
or reproduce asexually, both life-history traits that are thought to influence parasite 
genotype distribution (prugnolle et al., 2005). Instead, they exhibit separate sexes 
(dioecious) and are thought to be highly polygamous (Schulz-Key and Karam, 1986). 
The Wright's hierarchical F-statistic is used to investigate the correlation of 
parasite genes within and between human hosts (Fisher and Viney 1998; Paterson et al., 
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1998; Brouwer et al., 2001; Curtis et al., 2002). It is assumed that the infrapopulation is 
the first hierarchical group in the parasite population, and FIS is defined as the correlation 
of genes between microfilariae within the infrapopulation; Fs~' as the correlation of 
microfilarial genes between different hosts living in the same village; F:r, as the 
correlation of microfilarial genes between different villages within the overall 
microfilarial population; and ~T' as the correlation of genes between individual 
microfilariae relative to the overall microfilarial population of the region. The different 
inbreeding terms introduced are summarised in Table 2. A value of FIS> 0 points 
towards adult worm assortative mating, Fs~ > 0 indicates variation in worm allele 
frequency between hosts, and F:r > 0 suggests differences in the worm allele frequency 
between villages. The same statistical frameworks used to estimate Wright's F-statistic 
may be employed, taking into account variable sample sizes (Weir, 1996). Estimates of 
the 95% confidence intervals for FIS' Fs~, F:r and FIT' were generated by 
bootstrapping simultaneously worms within each host and bootstrapping over hosts 
within each village (Efron and Tibshirani, 1993). The village of Gora (Table 6.1) was 
removed from the F-statistic analysis since only one host was sampled in this village, 
making the underlying allele frequency highly uncertain. 
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Table 6.2: The extension ofWright's F-statistic to represent the hierarchical 
population structure of obligatory parasites ofhumans, exemplified in this paper with 
Wuchereria bancrofti (see text) 
Symbol Definition 
F Correlation of parasite genes between- individual worms relative to the fT 
overall worm population (total inbreeding coefficient) 
~s Correlation of genes between individu al worms within the host 
infrapopulation (assortative mating) 
Fs~ Correlation of parasite genes between different infrapopulations within 
the same host population (village) (parasite genetic differentiation 
between hosts within villages) 
Correlation of parasite genes between different host populations within 
the overall parasite population (parasite genetic differentiation between 
villages) 
6.2.2 Modelling the allele frequency and genotype distribution of 
microfilariae 
A dioecious adult worm helminth population with al: 1 male to female ratio was 
randomly generated for a given mean number of worms per host and degree of parasite 
overdispersion (as determined by the k parameter of the negative binomial distribution). 
Each adult worm infrapopulation was randomly allocated an allele frequency, as 
regression analysis of pre-treatment data did not detect any significant relationship 
between the host' s putative resistance allele frequency and microfilarial burden. The 
variance in adult worm infrapopulation allele frequency can be generated using the 
probability function of the beta distribution cp, using the equation, 
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6.1 
where H q~ is the resistance alle1e frequency of adult worms in a single ho st 
infrapopulation (i.e. in host i); H Piw = Q - H q~); Fs~ quantifies the variability in alle1e 
frequency between hosts estimated from data (Table 6.2); qW is the true underlying 
resistance alle1e frequency; p W = Q - qW), and r denotes the gamma distribution 
(Wright, 1969; Porter, 2003). 
A microfilarial population was generated for each host i according to the size and 
alle1e frequency of the adult worm infrapopulation. Worms were assumed to be highly 
polygamous; implying that if only one male parasite were present within a host, all fertile 
females within that infrapopulation would be mated. The number of microfilariae 
produced by each parasite infrapopulation was assumed to be proportional to the number 
of fertilised females within that host. It was also assumed that gametes separate 
independently and re-assort according to the degree of assortative mating (FIs). The 
probability with which a microfilaria within host i, will be of genotype j is denoted 9{ , 
and is given by the equations, 
(PW) (1- FIS )+ pW FIS] 
(PW) 
2pW qW (1- FIS )] 
2p WqW 
(qW) (1- FIS )+ qW FIS] 
(qW) 
6.2 
6.3 
6.4 
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where Hf qW and fiHqW are, respectively, the resistance allele frequency in the 
mae 1 em 1 
male and female adult worms within host i, and Hf p~ = li - Hf q~) and 
mae 1 ~ mae 1 
Je:P~ = ~ - Je:q~) are the susceptible allele frequencies generated from equation (6.1). 
To allow random stochastic fluctuations in genotype distribution, we use the fact that the 
actual number of microfilariae in host i with genotype j follows a binomial distribution, 
with the number of trials being equal to the number of microfilariae produced by host i, 
and with genotype probability equal to S{ . 
Microfilarial allele frequencies and genotype distributions were generated by 
sampling a specifie number of microfilariae from the generated hypothetical population 
according to the sampling scheme used in Schwab et al. (2005). The exact numbers of 
samples taken from each ofthe 30 hosts were: Il, 10, 15,9, Il,9, 13, 10, 10, 7, 10, 10, 7, 
1, Il,9, 1, 7, 4, 1, 10,9,8,6,4,6,9, 10, 10,8, for a total of246 microfilariae. 
Regression analysis of pre-treatment data had indicated that the number of samples taken 
from each host by Schwab et al. (2005) was independent ofhost microfilaraemia and host 
allele frequency, allowing the number of microfilariae sampled per host to be randomly 
allocated. The pro gram code for the simulations implemented was written in C++ and 
run 100,000 times, with each run generating a new helminth population and genotype 
distribution. 
The model was parameterised for the village of Tangonko, Burkina Faso, which 
had an initial prevalence ofmicrofilaraemia of25%. The deterministic model EPIFIL 
(see original formulation in Norman et al. (2000)) was used to estimate mean adult worm 
burden from observed microfilarial counts, giving a mean adult worm burden of 3.5 hosf 
1. The degree of adult worm overdispersion was estimated from the recorded 
microfilarial prevalence (taken here as a proxy for the prevalence of adult worms 
producing microfilariae) and the mean adult worm burden, using the prevalence vs. 
intensity relationship that derives from assuming a negative binomial distribution of 
worms among hosts (Anderson and May, 1992), yielding a k value of 0.07. The model 
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outlined above will only be valid for comparisons against the pre-treatment data, since 
chemotherapy is known to impede microfilarial production and / or survival (Tisch et al., 
2005). 
The null model assumes that mating Îs random between male and female worms 
within each infrapopulation and that resistance alleles are randomly distributed across 
hosts, i.e. ~s = Fs~ = F; = FIT = O. Results of the inbreeding analysis can be 
incorporated into the individual-based model described in equations (6.1) to (6.4) to 
explore the range of adult worm resistance allele frequencies which can give rise to the 
observed microfilarial data. 
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6.3. Results 
The generated microfilarial genotype distribution was found to deviate from the 
HWE. The results of the Wright's hierarchical F-statistic analysis are shown in Figure 
6.1. Villages with no history of mass anthelmintic chemotherapy have an overall 
inbreeding coefficient of FIT = 0.44 (indicating strong inbreeding). Fifteen percent of the 
microfilariae were found to be homozygous for the putative resistance-associated genetic 
(TYR 200) change, an estimate 2.3 times higher than would be expected in a random 
mating parasite population. Results indicate a significant amount of genetic 
differentiation in worm allele frequency among the host population. Infrapopulation 
allele frequency, H q~ , varied from 0 to 0.77 in the villages with no history oftreatment, 
increasing microfilarial homozygosity by 60%. The results suggest a degree of 
assortative mating within hosts measured by ~s = 0.28, although the study had 
insufficient power for this to become statistically significant (95% confidence intervals 
for this estimate inc1uded zero). No difference was observed in the microfilarial allele 
frequency between the two villages at baseline (FJr ~ 0). A similar degree of parasite 
inbreeding was observed in those villages that had received one round ofMDA. 
183 
FIT • t --k-l 
Fs~ 1 • 1 !---~ 1 
FIS ~------
F;T 
-0.5 0.0 0.5 
F - value 
Figure 6.1. Estimates of Wright's F-statistics for the pre-treatment villages (black 
diamonds) and for the village ofPerigban (grey triangles), which received one 
round of chemotherapy (albendazole + ivermectin). The error bars are the 95% 
confidence intervals. ~T estimates the total degree of parasite inbreeding; ~s 
describes the level of assortative mating within the infrapopulation; Fs~ shows 
the variation in microfilarial allele frequency within the host subpopulation 
(village), and F; highlights the difference in allele frequencies between the 
villages under investigation (only one post-treatment village was investigated, so 
no F; value is given). 
Parasite inbreeding increases the range of undedying adult worm allele 
frequencies, qW , which can give rise to the observed microfilarial allele frequency of 0.26 
(Figure 6.2). Results from the null model, where mating was random and resistance 
alleles were randomly distributed amongst hosts, indicate that qW in the untreated 
villages of Tangonko and Badongo could range from 0.21 to 0.32. Ifwe use the excess 
inbreeding estimate reported in Figure 6.1, then model simulations suggest that qW could 
range from 0.18 to 0.37. The larger the infrapopulation size (i.e. the larger the parasite 
population size or the stronger the degree of parasite overdispersion), the more accurately 
the underlying microfilarial allele frequency will mirror qW . 
184 
0.6 
0.5 
0.4 
"M q 0.3 
0.2 
0.1 
0 
0 0.1 0.2 0.3 0.4 0.5 
qW 
Figure 6.2. The impact of inbreeding on the relationship between the sample microfilarial 
allele frequencies tfPM and the (inferred) underlying adult worm allele frequency, 
qW. The figure shows 95% confidence intervals for a population with no excess 
inbreeding (the null model, dark grey shaded area), and a population with the 
observed levels of inbreeding (~s = 0.28, Fs~ = 0.22, light grey shaded area). 
Simulations are based on the same sampling scheme used by Schwab et al. 
(2005). The thick black solid line indicates the mean result for both models. The 
observed pre-treatment microfilarial allele frequency (black thin, horizontal dotted 
line) was compared to simulation results to indicate the possible range of adult 
worm allele frequencies which could have given rise to the West African data. 
The null model (black vertical dotted-dashed lines) indicated values of qW 
ranging from 0.21 to 0.32 compared to the inbred model (FIS = 0.28, Fs~ = 0.22, 
black vertical dashed lines), which gave values of qW between 0.18 and 0.37. 
The microfilarial genotype diversity model indicates that the observed 
homozygosity is unlikely to be solely a result of genetic sampling, demographic 
stochasticity, population subdivision, or the sampling scheme employed. Figure 6.2 
indicates the range of likely microfilarial genotype distributions that can be generated 
from a given qW value using the null (random) model. The observed excess 
homozygosity in the untreated villages was greater than the 95% confidence interval 
estimates generated by the null model. It is interesting to note the wide range of 
microfilarial genotype distributions that can be generated by the null model. 
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Figure 6.3. De Finetti diagram (HartI and Clark, 1989) showing the genotype distribution 
of W. bancrofti microfilariae generating from a given underlying adult worm 
allele frequency, qW , taken from villages prior to the introduction of 
chemotherapy. The black diamond represents the value originating from the 
observed data (with qW =0.26, and FIT = 0.44 ), and the errorbars indicate the 
uncertainty in genotype distribution stemming from the values of qW that were 
estimated from the null (random) model in Figure 6.2. R indicates the allele 
coding for tyrosine in the position 200 of ,B-tubulin that is associated with 
(recessive) benzimidazole (BZ) resistance in nematodes of livestock, and S 
denotes the allele (co ding for phenylalanine) indicative ofBZ susceptibility. The 
solid-black curve represents the Hardy-Weinberg equilibrium (HWE). The null 
model generating microfilarial populations was used to investigate the range of 
sample microfilarial genotype distributions that could be obtained from a 
population exhibiting no excess inbreeding (i.e. assuming that the underlying 
adult parasite population would have values of ~s = Fs~ = F; = ~T = 0). 
Simulations mimic the same sampling scheme described in Schwab et al. (2005). 
The observed microfilarial genotype distribution falls outside the 95% confidence 
interval range (grey shaded area surrounding the HWE curve) generated by the 
null model, despite the uncertainty in the qW estimates, indicating strong parasite 
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inbreeding even before introduction of antifilarial combination therapy. 
High genetic differentiation between hosts reduces the prevalence of parasites 
homozygous for the putative resistance-associated genetic change (Figure 6.4). Despite 
the large increase in microfilarial homozygosity attributable to parasite inbreeding, there 
is only a modest increase in the prevalence of resistance homozygotes. High parasite 
overdispersion reduces the number ofhosts who are microfilaria-positive and 
concentrates the resistance genotypes into a smaller proportion ofhosts. High parasite 
assortative mating and infrapopulation genetic differentiation increases the number of 
hosts (and the number of samples per ho st) that needs to be sampled in order to quantify 
accurately the resistance alle1e frequency in the microfilarial population. To illustrate 
this, the model is used to investigate the minimum number ofhosts, and the overall 
number of samples necessary to detect a given resistance allele frequency (Figure 6.5). 
Results indicate that the observed level of parasite inbreeding dramatically increases the 
number ofhosts that need to be sampled to be 95% confident of detecting the rare alle1e. 
The sampling scheme used within Figure 6.5 assumes that the number ofparasites 
genotyped per host is weighted by the host's microfilariae load. 
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Figure 6.4. The impact of inbreeding on the relationship between the mean proportion of 
hosts harbouring microfilariae with one or two copies of the resistance allele and 
the (assumed) underlying adult worm allele frequency, qW. The figure shows the 
proportion ofhosts who have microfilariae with the resistance allele (solid lines), 
as well as the proportion who have microfilariae which are homozygous for 
resistance (broken lines). Model outcomes are compared for two hypothetical 
parasite populations; the first (thin grey lines) without excess inbreeding 
(generated by the null model), and the second (thick black lines) with the levels of 
inbreeding ( ~s = 0.28, Fs~ = 0.22) observed in the Burkina Faso data. 
Simulations used the same sampling scheme described in Schwab et al. (2005) 
and assume an overall microfilarial prevalence of ~25% (see text). 
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Figure 6.5. The impact ofhelminth inbreeding on the minimum number ofmicrofilaria-positive 
hosts who should be sampled and the minimum number of microfilariae that should be 
genotyped to be 95% confident of detecting at least one rare alle1e. A randomly mating 
.'--~ population (~s = Fs~ = 0, grey open squares) is compared to an inbred population (~s = 
0.28 and Fs~ =0.22, c10sed black diamonds). The underlying adult worm al1ele frequency 
ofboth populations is set at qW =0.05. Bach data point represents 100,000 runs of the 
stochastic model generating microfilarial populations. The number of microfilariae 
analysed per host is proportional to host microfilaraemia. 
The consequences of parasite assortative mating and genetic differentiation 
between hosts will depend on the allele frequency and the relative dominance of the 
resistance allele. If the resistance allele is recessive, helminth inbreeding will 
dramatically increase the probability that a parasite wil1 survive anthelmintic treatment. 
This is evident from Figure 6.6 which shows the influence of parasite inbreeding on the 
relative proportion of resistant genotypes for a given allele frequency. With a completely 
recessive resistance alle1e at a frequency of 0.05, the degree ofinbreeding within the W 
bancrofti population reported here, would on average increase the number ofworms with 
the homozygote resistance genotype nine-fold. Conversely, ifthe resistance alle1e were 
dominant, he1minth inbreeding would reduce the probability that a parasite will survive 
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chemotherapy, as fewer worms will have the resistant allele (the deficiency of 
heterozygous parasites caused by parasite inbreeding will be greater than the increase in 
resistant homozygous worms). 
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Figure 6.6. The number ofresistant genotypes in an inbred population relative to that in a 
population at HWE. Results are shown for different resistance allele frequencies. 
The resistance alle1e is either recessive (A), black hnes, or dominant (B), grey 
lines. The inbreeding coefficients are those estimated in the Wuchereria bancrofti 
microfilarial population reported in Figure 6.1: mean result (FIT = 0.44 , solid 
line); upper 95% confidence limit (FIT = 0.65, dashed line); lower 95% 
confidence hmit (FIT = 0.20, dotted hne). The relative change in the number of 
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6.4. Discussion 
The degree of W. bancrofti excess homozygosity reported in this paper falls 
outside the range of values generated by the null model, indicating a significant degree of 
parasite inbreeding, present even before any MDA was implemented. This result 
highlights the crucial importance of developing sound theoretical null models that enable 
helminth population genetics data to be interpreted adequately (Prugnolle et al., 2005). 
These models should take into account the uncertainty in result outcomes, given the 
sampling scheme employed and the life-history traits of the parasite. The null model 
described in this paper generates a wide range of microfilarial alle1e frequencies and 
genotype distributions indicating that caution should be exercised when interpreting 
results obtained by sampling transmission stages. The null model indicates that sampling 
transmission stages would cause estimates of the underlying adult worm allele frequency 
to be highly variable. This would make it harder to detect significant changes in the 
parasite genome with time after introduction of chemotherapeutic pressure. 
Producing a null model to assess the range of adult populations that could give 
rise to the microfilarial population within the treated villages is complex and beyond the 
scope of this paper. A dynamic, full transmission model would be required that takes into 
account the pharmacodynamic properties of ivermectin and that of the albendazole plus 
ivermectin drug combination, as the effects of chemotherapy will influence microfilarial 
genetic diversity for a number of years after chemotherapy. Large changes in 
microfilarial resistance allele frequency may not reflect such substantial changes in the 
adult worm genome. 
The results presented within this paper regarding the metapopulation dynamics of 
bancroftian filariasis stem from the analysis of a single nuc1eotide polymorphism in one 
gene. Further surveys, using multiple polymorphie loci, are required to confirm our 
findings of a high degree of parasite genetic differentiation between hosts (Anderson, 
2001). The accuracy of the model developed to derive microfilarial genetic diversity is 
limited by uncertainties regarding the biology of W. bancrofti. Results are dependent on 
our CUITent ability to mimic adult worm burden and its distribution among hosts. 
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Limitations inherent in the EPIFIL model, the presence of amicrofilaraemic yet 
circulating filarial antigen positive infections, and possible heterogeneity in host immune 
responses will make adult worm burden estimates highly uncertain from microfilarial 
prevalence and intensity data. The relationship between the number of adult filariae and 
the rate of microfilarial production is likely to be complex and may depend on the 
immune responses elicited during the infection. Our conclusions are based on the 
adequacy of the null model, which may be improved by the inclusion of further biological 
detail. For example, recent evidence suggests a possible association between ~-tubulin 
genotype in the related filarial parasite, Onchocerca volvulus, and female worm fertility 
(Bourguinat et al. 2006), suggesting a co st of resistance. Whilst the same gene has been 
analyzed in the CUITent study, it is not known whether a similar relationship between 
genotype and fertility applies to W bancrofti.. Although no differences were seen in 
genotype frequency between the two pre-treatment villages studied, additional baseline 
surveys would be required before firm conclusions regarding the true underlying 
frequency of the TYR200 genetic change in pre-treatment W bancrofti populations can 
be drawn. This emphasizes the importance of conducting genetic studies of appropriate 
molecular markers of selection under treatment pressure before (and during) 
implementation oflarge-scale MDA. 
Notwithstanding the fact that the F-statistic provides a phenomenological tool 
rather than a mechanistic measure of inbreeding (and therefore does not describe the 
biological processes generating excess homozygosity), we proceed to propose sorne 
likely causes for the strong degree of inbreeding identified in W bancrofti, as well as the 
implications that this may have for the development and detection of anthelmintic 
resistance. 
6.4.1. Assortative mating 
Our results suggest that adult W bancrofti do not mate randomly within the 
infrapopulation. This is in agreement with ultrasonography studies that show adult 
parasites congregating in 'worm nests' along lymphatic vessels, which remain stable over 
time (Dreyer et al., 1994). Spatial heterogeneity within the host may produce multiple 
192 
I~ 
reproducing populations within each infrapopulation, which would increase host 
microfilarial homozygosity. Prior anthelmintic treatment may also increase assortative 
mating, depending on the selective advantage the TYR200 genetic change may have on 
the adult worm following drug treatment. 
6.4.2. Parasite genetic differentiation between hosts 
The degree of genetic differentiation in the parasite infrapopulation can shed 
insight into the microepidemiology of parasite transmission (Nadler, 1995; Anderson, 
2001; Théron et al., 2004; Criscione and Blouin, 2005). The metapopulation 
transmission dynamics of W bancrofti will depend on the transmission efficiency and 
biting behaviour ofthe mosquito vector. Anopheles gambiae sensu stricto and 
An funestus are thought to be the main vectors of W bancrofti in Burkina Faso (Gyapong 
et al., 2002). Hosts can acquire multiple L3 larvae during the same bite. Although 
density-dependent processes are known to operate on the uptake and development of 
W bancrofti in An. gambiae, infected vectors will regularly transmit multiple related L3 
larvae simultaneously (Snow and Michael, 2002). Other mosquito vectors of 
W bancrofti have even greater vector competence. For example, up to 32 L3 larvae were 
recovered from an experimental host after it was bitten by a single Culex 
quinquefasciatus (Gasarasi, 2000), the vector in East Africa. Mark-recapture studies and 
bloodmeal analysis indicate that various mosquito species appear to have high site 
fidelity, regularly biting multiple members of the same household (McCall et al., 2001; 
Michael et al., 2001). These aspects of W bancrofti transmission increase the likelihood 
that a host will be infected with c10sely related parasites and will contribute to the 
observed genetic differentiation. Genetic metapopulation models have highlighted how 
the spread of rare recessive genes are promoted by hosts accumulating multiple related 
infections simultaneously (Comell et al., 2003). 
If anthelmintic treatment kills adult worms, then MDA campaigns will increase 
infrapopulation genetic homogeneity, as those parasites within treated hosts which 
survive treatment may have a higher resistance alle1e frequency than those harboured 
within untreated hosts. In Burkina Faso, lymphatic filariasis is treated with albendazole 
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and ivermectin. Evidence indicates that the albendazole plus ivermectin combination has 
sorne macrofilaricidal effect, mainly due to the addition of albendazole (Tisch et al., 
2005), suggesting that possible albendazole resistance may act to accentuate parasite 
inbreeding in villages that have been repeatedly treated. It is possible that sorne of the 
excess homozygosity observed in the untreated villages may have resulted from 
individual members of the community seeking, for instance, treatment for geohelminth 
infection prior to the introduction of GPELF. 
6.4.3. The spread of anthelmintic resistance 
Population subdivision and assortative mating will influence the outcomes of 
selection under chemotherapeutic pressure in different ways, depending on the initial 
frequency of the allele under selection and the ecology of the infection. Before the rate of 
spread of drug resistant parasites can be reliably estimated, greater knowledge regarding 
the number, the linkage, the dominance, and the possible negative pleiotropic effects of 
putative resistance allele(s), is required together with accurate information on the 
pharmacodynamic properties of the drugs administered singly and / or in combination 
(Schwab et al., in press). 
If the resistance alle1e is recessive and it has a low initial frequency, inbreeding 
will increase parasite homozygosity and as a result, the spread of drug resistant worms 
across the parasite population (Schwab et al., 2006). Parasite genetic differentiation 
between hosts will also increase the spread of resistance even when the resistance allele is 
initially present at a very low frequency, as it increases the probability that male and 
female resistant worms will inhabit the same infrapopulation. 
6.4.4. The detection of anthelmintic resistance 
The operation of a strong degree of parasite genetic differentiation between hosts 
reduces the prevalence of infection with drug resistant parasites and would therefore 
increase the number ofhosts that should be sampled to detect and quantify anthelmintic 
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resistance reliably. Even at high resistance allele frequencies sorne hosts will have no 
phenotypic signs of resistance, particularly ifthe resistance allele is recessive. With this 
in mind, genetic epidemiological surveys ofhelminth parasites should carefully consider 
the sampling scheme they employ in order to maximise the accuracy of allele frequency 
estimates. The mathematical model developed in this paper can be used to derive sample 
size calculations, taking into consideration the approximate degree of parasite inbreeding, 
the resistance allele frequency, the intensity of infection, and the degree of parasite 
overdispersion. 
6.4.5. Parasite elimination 
For human helminth infections, the importance of parasite genetic differentiation 
between hosts stretches beyond population genetics and will influence the outcomes of 
parasite elimination campaigns such as the GPELF. The ability of a parasite species to 
persist in a host population following prolonged MDA will depend in part on the 
metapopulation dynamics ofhelminth transmission and the patterns ofhost compliance 
with treatment regimes. The aggregated nature of the passage of transmission stages 
between hosts will make parasite elimination harder to achieve by lowering the 
breakpoint density (the unstable equilibrium below which the parasite population will 
tend naturally to local extinction (Macdonald, 1965)), as parasites are less likely to 
inhabit a ho st withO a single-sexed infection. 
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Figure 7.1: The effect, on the ABZ resistance genotype frequency (%) in W. bancrofti 
microfilariae, of increasing adulticidal efficacy (% of macrofilariae killed) of 
IVM, when administering 10 annual treatments of ABZ + IVM, with 85% 
coverage of the human hast population. 
This figure shows that altering the adulticidal activity ofIVM from 7.5 % ta 20 % 
changes the ABZ resistant genoptype frequency by less than 1 %. This is a smaller 
difference than that observed in a similar sensitivity analysis of the ABZ + DEC 
treatment combination. It was not possible ta examine changes in additional 
microfilaricidal activity caused by adding ABZ ta IVM, as was done for ABZ + DEC, 
since IVM alone is reported to kill 99% of microfilariae. 
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Figure 7.2: The effect of increasing the levels of non-random parasite mating 
(i.e., increased homozygosity, as measured by the Fisher FIT statistic), on the 
frequency of the ABZ resistant genotype, assuming 20 % initial frequency of 
ABZ resistance and dominant IVM resistance (with 5 % initial frequency) in W. 
bancrofti, following 10 yearly treatments, at 85% coverage, with ABZ + IVM. 
This figure shows that the spread of the ABZ resistance genotype is enhanced by 
increasing values of FIT, or increased homozygosity, in the presence of IVM resistance. 
This increase is similar to that observed in Chapter 3 when no resistance to IVM was 
considered. 
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the total population, on the spread of resistance in W. bancrofti populations, 
assuming dominant IVM resistance (5 % initial frequency) and ABZ resistance (0 
or 20% initial frequency), with FIT= 0.44. (A) The average frequency (%) ofIVM 
resistance genotypes in microfilariae. (B) The mean microfilaraemia per 20 /-lI of 
blood in the human host population. 
This figure shows that the presence of an ABZ resistance genotype increases selection 
for the IVM resistance genotype. This increase in resistance leads to higher overall 
microfilaraemia after the end of the treatment period. 
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Figure 7.4: The effect of dominance of the IVM resistance gene following 10 yearly 
treatments with ABZ + IVM, and FIT= 0.44, on the spread ofresistance 
genotypes, assuming 20 % initial frequency of ABZ resistance genotype and 5 % 
initial frequency ofIVM resistance. (A) the average frequency (%) of ABZ 
resistance genotypes in microfilariae, (B) the average frequency (%) of ABZ and 
IVM resistance genotypes in microfilariae, (C) the average frequency (%) ofIVM 
resistance genotypes in microfilariae, and (D) the mean microfilaraemia per 20 ~l 
ofblood in the human host. 
This figure shows that the IVM resistance genotype is higher after treatment if 
IVM resistance is dominant. The ABZ resistance genotype is higher if IVM resistance is 
reeessive, as is the total average Mf intensity, indicating a stronger impact on intensity of 
ABZ resistance. 
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Figure 7.5: The effect ofincreasing therapeutic coverage (the percentage ofthe total host 
population treated) of 10 yearly treatments with ABZ + IVM, and FIT= 0.44, on 
the spread of resistance, assuming 20 % initial frequency of ABZ resistance 
genotype and dominant IVM resistance (with 5 % initial frequency) in 
microfilariae. (A) the average frequency (%) of ABZ resistance genotypes in 
microfilariae, (B) the average frequency (%) ofIVM resistance genotypes in 
microfilariae, (C) the average frequency (%) of ABZ and IVM resistance 
genotypes in microfilariae, and (D) the mean microfilaraemia per 20 III ofblood 
in the human host. 
This figure shows that the spread of the ABZ resistance genotype is enhanced, in 
the presence of IVM resistance, by increasing treatment coverage. This increase is 
similar to that observed in Chapter 3 when no IVM resistance was considered. Treatment 
coverage affected the ABZ and IVM resistance genes differently. When initial resistance 
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frequencies of ABZ and dominant IVM resistance were 20% and 5%, respectively, and 
FJT=0.44, an increase in treatment coverage led to an increased spread of the ABZ 
resistance genotype after 10 yearly treatments (see Appendix II, Fig. 7.5), as was shown 
in the case of ABZ resistance alone (Schwab et al, in press). This increase was also 
observed when spread of genotypes resistant to both ABZ and IVM were considered (Fig. 
4.3A). However, in the case ofIVM resistance, the dominant resistance genotypes were 
only 10% more frequent after treatment with 85% coverage than with 60% coverage. If 
coverage was increased another 10% to 95%, the resistance genotypes were slightly less 
frequent than at 85% coverage and 10 yearly treatments (Fig. 4.3B). Varying treatment 
coverage from 60 to 95% led to a 4.75 fold reduction in the total average MF intensity 
after application of the treatment regime. 
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Figure 7.6: The effect ofvarying amounts ofrecombination between ABZ and IVM 
resistance alleles on the spread of resistance, assuming 20 % initial frequency of 
ABZ resistance genotype and dominant IVM resistance (with a 5 % initial 
frequency), after 10 yearly treatments with ABZ + IVM at 85% coverage and FIT= 
0.44 on the spread of ABZ- and IVM-resistance. (A) the average frequency (%) 
of ABZ resistance genotypes in microfilariae, (B) the average frequency (%) of 
ABZ and IVM resistance genotypes in microfilariae, (C) the average frequency 
(%) ofIVM resistance genotypes in microfilariae, and (D) the mean 
microfilaraemia per 20 JlI of blood in the human ho st. 
These panels demonstrate that linkage (decreased amount ofrecombination) between 
the ABZ and IVM resistance allele does not impact selection, if the population is at 
linkage equilibrium. This is due to the fact that alleles resistant to both drugs or to either 
drug, both exist in the population. 
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Figure 7.7: The effect of selection on one ABZ resistance gene and two IVM resistance 
genes on the spread of ABZ- and IVM- resistance at initial resistance allele 
frequencies of 20% for ABZ resistance, 5% for each IVM resistance allele and 
FIT= 0.44, (A) The average frequency (%) of ABZ resistance genotypes in 
microfilariae, (B) the average frequency (%) ofmicrofilariae with both IVM 
resistance genotypes, (C) the average frequency (%) of microfilariae with both 
IVM and the ABZ resistance genotypes, (D) the average frequency (%) of 
microfilariae with microtilarial IVM resistance genotypes, (E) the average 
frequency (%) ofmicrofilariae with adult IVM resistance genotypes and (C) the 
mean microfilaraemia per 20 III of blood in the human host. 
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In panel A of Figure 7.7 it may be noted that selection for the ABZ resistance 
genotype is stronger if microfilarial NM resistance is recessive than if it is dominant. 
This is discussed in Chapter 4. Panels Band C indicate that complete IVM resistance and 
resistance against both drugs is only noticeably higher ifboth NM resistance genes are 
inherited as dominant traits. In panel D and E, it is apparent that selection for each NM 
resistance gene is enhanced by its own dominance and diminished by the dominance of 
the other NM resistance gene, indicating the possibility of courrter selection. Finally, 
panel F shows that the total average microfilarial intensity is slightly higher after 
treatment if the microfilariai IVM resistance gene is recessive, although this may be due 
to the consequent increase in the ABZ resistance genotype frequency (see panel A). ABZ 
has a larger impact on the adult population, which may contribute to this result. 
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Figure 7.8: The effect ofincreasing the number of annual treatments with 85% coverage 
on the spread of ABZ resistance in W bancrofti, (A) The average frequency (%) 
of ABZ resistance genotypes in microfilariae, (B) the average frequency (%) of 
microfilariae with both IVM resistance genotypes, (C) the average frequency (%) 
ofmicrofilariae with both IVM and the ABZ resistance genotypes, (D) the mean 
microfilaraemia per 20 ~l of blood in the human host. 
This graph shows that fifteen years after the commencement of treatment, the 
frequencies of ABZ and IVM resistance genotypes were estimated to be 18%, 40% and 
63%, after respectively 5, 7 and 10 years of annual combination treatment It may be 
noted that the higher frequency of resistance genotypes following a longer period of 
treatment indicates that a return to chemotherapy would be initially much less effective, 
assuming continued transmission, if the initial phase of treatment had been for 10 years 
compared with 5 years. 
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